Quantitative analysis of cytokine-induced hepatocellular death in the context of hepatotoxic therapeutics by Cosgrove, Benjamin D. (Benjamin David)
 1
Quantitative Analysis of Cytokine-Induced Hepatocellular Death  
in the Context of Hepatotoxic Therapeutics 
 
by 
 
Benjamin D. Cosgrove 
 
B.Bm.E., Biomedical Engineering  
University of Minnesota, 2003 
 
Submitted to the Department of Biological Engineering  
in partial fulfillment of the requirements for the degree of 
 
Doctor of Philosophy in Bioengineering 
 
at the  
 
Massachusetts Institute of Technology 
 
February 2009 
 
© Massachusetts Institute of Technology.  All rights reserved. 
 
 
 
Signature of Author: ______________________________________________________ 
Department of Biological Engineering 
December 15, 2008 
 
 
Certified by: _____________________________________________________________ 
Linda G. Griffith 
Professor of Biological and Mechanical Engineering 
Thesis Supervisor 
 
 
Certified by: _____________________________________________________________ 
Douglas A. Lauffenburger 
Professor of Biological Engineering, Biology, and Chemical Engineering 
Thesis Supervisor 
 
 
Accepted by: ____________________________________________________________ 
Alan J. Grodzinsky 
Professor of Electrical, Mechanical, and Biological Engineering 
Graduate Program Committee Chairperson 
 2
 
 3
THESIS COMMITTEE 
 
 
 
Forest M. White 
Associate Professor, Department of Biological Engineering 
Massachusetts Institute of Technology 
Thesis Committee Chair 
 
 
Linda G. Griffith 
Professor, Departments of Biological and Mechanical Engineering 
Massachusetts Institute of Technology 
Thesis Supervisor 
 
 
Douglas A. Lauffenburger 
Professor, Departments of Biological Engineering, Biology, and Chemical Engineering 
Massachusetts Institute of Technology 
Thesis Supervisor 
 
 
Donna B. Stolz 
Associate Professor, Department of Cell Biology and Physiology 
University of Pittsburgh Medical School 
 
 4
 5
Quantitative Analysis of Cytokine-Induced Hepatocellular Death  
in the Context of Hepatotoxic Therapeutics 
 
by 
 
Benjamin D. Cosgrove 
 
Submitted to the Department of Biological Engineering on December 15, 2008,  
in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy in Bioengineering 
 
ABSTRACT 
 
Numerous therapeutics, such as viral gene therapy vectors, have unintended toxicity in 
part due to interactions with inflammatory cytokine signaling to elicit hepatocyte death, 
thus limiting their clinical use.  Although much is known about how cytokines and 
certain therapeutics individually induce hepatotoxicity, there is little understanding of 
how they jointly regulate the complex cellular signaling network governing 
hepatocellular death.  In this thesis, we explored the signaling mechanisms governing the 
cytokine-induced hepatocellular death in the context of adenoviral vector (Adv) infection 
and pharmaceutical compounds with idiosyncratic hepatotoxicity. 
Initially, we examined the role of autocrine and intracellular signaling pathways 
in governing the synergistic induction of hepatocyte apoptosis by the cytokine tumor 
necrosis factor-α (TNF) in the presence of Adv infection in a primary rat hepatocyte cell 
culture model.  We demonstrated that Adv/TNF-induced hepatocyte apoptosis is 
regulated by a coupled and self-antagonizing autocrine signaling cascade involving the 
sequential release of anti-apoptotic transforming growth factor-α (TGF-α), pro-apoptotic 
interleukin-1α/β (IL-1α/β), and anti-apoptotic IL-1 receptor antagonist (IL-1ra).  This 
three-part autocrine cascade regulates multiple intracellular signal pathways, including 
ERK and JNK, that serve to integrate TNF- and Adv-induced signals and govern the 
resultant hepatocellular death response. 
 Following this, we demonstrated that numerous idiosyncratic hepatotoxins, whose 
hepatotoxicities are not evident in standard cell preclinical screening models, elicit 
synergistic induction of hepatocellular death upon multi-cytokine co-stimulation in 
primary rat and human hepatocyte cell culture models.  We showed that this drug-
cytokine co-treatment model could be usefully scaled to the high-throughput demands of 
pharmaceutical screening while maintaining idiosyncratic hepatotoxicity prediction 
accuracy.  To identify the signaling mechanisms regulating these drug/cytokine 
hepatocellular death synergies, we collected multi-pathway signal-response data 
compendia from two human hepatocyte donors.  Through the use of partial least-squares 
regression modeling, we showed that hepatocytes integrate signals from four pathways -- 
ERK, Akt, mTOR, and p38 -- to specify their cell death responses to toxic drug/cytokine 
conditions and that accurate prediction of hepatocellular death responses can be made 
across human hepatocyte donors. 
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Together, these findings demonstrate that cytokine-induced hepatocellular death 
in the context of hepatotoxic therapeutics is governed by integrated network activity of 
multiple autocrine and intracellular signaling pathways. 
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Title: School of Engineering Professor of Biological and Mechanical Engineering 
 
Thesis Supervisor: Douglas A. Lauffenburger 
Title: Whitaker Professor of Biological Engineering, Biology, and Chemical Engineering 
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CHAPTER 1 
 
Introduction 
 
This thesis investigates the cellular signaling mechanisms governing the relationship 
between inflammatory cytokine signaling and therapeutics with inflammation-associated 
hepatotoxicities, such as adenoviral vectors and idiosyncratic hepatotoxic drugs through 
the use of quantitative experimental and computational cell biology approaches. This 
chapter contains background and motivating information pertaining to liver biology, 
hepatocyte culture methods, inflammatory cytokine signaling, drug hepatotoxicity, and 
systems biology methods and models fundamental to this thesis. 
 
1.1. Liver organization, function, and cell types 
The liver is a vascularized organ composed of multiple cell types in a highly ordered 
three-dimensional structure.  Important liver functions include xenobiotic, protein, 
steroid, and fat metabolism; blood detoxification; secretion of blood and bile components 
such as albumin, bile salts, and cholesterol; and storage of vitamins and sugars [1].  
Hepatocytes, or parenchymal cells, form single-layer cell plates of the liver lobule and 
are the key function cell of the liver.  Hepatic plates extend from the portal vein to the 
central vein and are separated by capillary-like sinusoidal spaces [2].  Tissue organization 
and extra-cellular matrix (ECM) molecules maintain hepatocyte polarity, as defined by 
three functionally different cellular domains.  The hepatic sinusoidal domain contacts 
ECM molecules and sinusoidal endothelial cells in the Space of Disse that lines the liver 
sinusoid.  The Space of Disse contains the primary hepatic ECM molecules types I-IV 
collagen, tenascin, laminin, fibronectin, and proteoglycans (heparan sulfate, heparin, 
chondroitin sulfate, dermatan sulfate).  The hepatic lateral domain consists of cell-cell 
adhesions that are mediated by homotypic E-cadherin associations and are important for 
cell-cell communication via desmosomes and gap junctions.  The hepatic canalicular 
domain contains bile canaliculi, which serve as functional conduits for bile secretion.  
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The maintenance of hepatocyte polarity is essential for biliary excretion and xenobiotic 
elimination. 
The non-parenchymal liver cells (NPC’s) are comprised of bile duct epithelial 
cells, sinusoidal endothelial cells (SEC’s), Kupffer cells, and stellate cells.  Sinusoidal 
endothelial cells line the sinusoidal space and contain fenestrations, which allow for the 
transfer of solutes between the hepatic blood and the Space of Disse [2].  Kupffer cells, 
the resident liver macrophages, are attached to the sinusoidal wall, have phagocytotic 
activity, and, upon activation, secrete proteases and cytokines.  Hepatic stellate cells 
reside in the Space of Disse and synthesize and secrete ECM components (and their 
proteases) and the growth factors epidermal growth factor (EGF), hepatocyte growth 
factor (HGF), and transforming growth factor beta-1 (TGF-β1).  Aberrant ECM 
regulation by stellate cells can lead to liver fibrosis or cirrhosis [2].   
 
1.2. Hepatocyte differentiation  
Differentiated hepatocytes are characterized by many specific functions including, but 
not limited to, urea and albumin synthesis; xenobiotic metabolizing activity via phase I 
and II enzymes, especially the family of inducible cytochrome P450 enzymes; bile acid 
transport and secretion via canalicular networks; and morphological hepatic polarity [1].  
This functional specialization is a consequence of precise transcriptional regulation of a 
cohort of liver-specific genes through the cooperation of multiple families of hepatocyte-
enriched DNA-binding proteins, promoters, and enhancers [3].  These hepatocyte-
enriched regulatory proteins include the hepatocyte nuclear factor (HNF) family 
consisting of HNF1α/β, HNF3α/β/γ, HNF4α, and HNF6; the CAAAT/enhancer binding 
protein (C/EBP) family.  Differentiated hepatocyte function and gene transcription is 
regulated by a combination of soluble (hormones, growth factors, cytokines) and 
insoluble (ECM adhesion, heterotypic and homotypic cell-cell contacts) factors (which 
are regulated, in part, by non-parenchymal cells), cellular morphology, and biophysical 
stimuli [1]. 
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1.3. Hepatocyte culture systems 
1.3.1. Two-dimensional culture systems 
Long-term primary hepatocyte cultures on two-dimensional (2D) surfaces have limited 
ability to retain liver-specific function and have albumin secretion and cytochrome P450 
expression levels below those of isolated hepatocytes [1].  The nature of hepatocyte-ECM 
interactions are thought to determine both cell shape, cytoarchitecture, and expression of 
liver-specific families of transcription factors [4, 5].  Many approaches have been studied 
for the culture of primary hepatocytes on 2D surfaces modified with ECM components.  
Typical approaches use either coated or gelled type I collagen and/or Matrigel, either in a 
monolayer or a “gel sandwich” configuration [5].  Matrigel (BD Biosciences) is 
reconstituted basement membrane from an acid-urea extract from Engelbreth-Holm-
Swarm tumor tissue consisting of ~60% laminin, ~30% type IV collagen, and ~3% 
heparin sulfate proteoglycan and trace other ECM components. 
On collagen-coated tissue culture polystyrene (TCPS) surfaces, primary 
hepatocytes exhibit a rapid loss of albumin section and cytochrome P450 expression and 
rapid increase on non-specific genes such as actin and tubulin, leading to a flattened, 
stretched cellular morphology that displays focal adhesion and actin stress fibers [6].  
Primary hepatocytes cultured on monolayer gels of type I collagen maintain a cuboidal 
shape and a cortical distribution of actin filaments and have better retention of liver-
specific gene expression [6].  Primary hepatocytes cultured on Matrigel monolayer gels 
form aggregated clusters, while retaining albumin secretion rates, cytochrome P450 
expression and inducibility levels, and C/EBP, HNF1, and HNF4 expression levels near 
to those in isolated hepatocytes [4, 5].  Primary hepatocytes cultured in between two 
layers of gelled type I collagen show enhanced cuboidal morphology and the formation 
of gap junctions and functional bile canalucilar networks and have improved bile acid 
transport and cytochrome P450 inducibility compared with monolayer collagen gel 
cultures.  Similarly, Matrigel overlay aids in the restoration and maintenance of long-term 
function of primary hepatocytes in regards to inducibility of cytochrome P450 enzymes, 
albumin secretion, and cellular morphology [7].  Matrigel and type I collagen gel overlay 
cultures exhibit no substantial differences in cytochrome P450 inducibility in long-term 
cultures [1].  Currently, type I collagen gel sandwich cultures serve as the standard long-
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term primary hepatocyte culture system for study of xenobiotic metabolism and toxicity, 
even considering their inability to retain in vivo expression levels of liver-specific 
transcriptional factor and cytochrome P450 enzymes [8]. 
 
1.3.2. Three-dimensional culture systems 
Scaffold- and capillary-based three-dimensional (3D) bioreactor culture systems have 
been developed to better retain the tissue structure and function of primary hepatocytes in 
long-term cultures [9].  The retention of in vivo-like hepatic function in long-term 
hepatocytes cultures is important for the development of high throughput tools for 
accurate prediction of xenobiotic metabolism and toxicity and other liver-specific 
functions [8].  Three-dimensional hepatocyte culture systems are proposed to enable 
primary hepatocytes to form hierarchical tissue structures and cell-cell interactions more 
closely resembling in vivo hepatic tissue than 2D culture systems.  In addition, these 
systems are capable of media perfusion similar to in vivo sinusoidal blood flow.  Long-
term culture (>7 days after cell isolation) of primary hepatocytes in this 3D perfused liver 
bioreactor has been shown to maintain constant albumin and urea secretion rates and to 
retain expression levels of HNF and C/EBP families of liver-specific transcription factors 
and cytochrome P450 enzymes at levels closer to those of freshly isolated hepatocytes 
than standard 2D collagen gel sandwiches [8-10].  It is hypothesized that the retention of 
more in vivo-like regulation of liver-specific gene expression in this 3D culture system 
compared to 2D collagen gel sandwich cultures is caused by differences  in  signaling 
pathways mediated by soluble paracrine signals, cell-ECM interactions, cell-cell 
interactions, and biophysical stresses. 
 
1.4. Inflammatory cytokine signaling in hepatocytes 
In the liver, inflammatory cytokines are primarily released by the resident liver 
macrophages, or Kupffer cells, following viral infection and/or injury.  These 
inflammatory cytokines include tumor necrosis factor-α (TNF), interleukin-1α/β (IL-
1α/β), interferon-γ (IFN-γ), and interleukin-6 (IL-6).  These cytokine binds to their 
cognate receptors on hepatocytes, activating a diversity of intracellular survival, stress, 
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and apoptosis pathways (see Figure 1-1).  The following section summarizes key features 
of their intracellular signaling pathways.  
 
1.4.1. Caspase cascade and NF-κB signaling 
TNF is a proinflammatory cytokine secreted macrophages that binds to two different 
transmembrane receptors, TNFR1 and TNFR2.  TNFR1 trimerization leads to the 
recruitment of TRADD (TNFR1 associated death domain protein) which further recruits 
FADD (Fas-associated death domain protein) and TRAF-2 (TNFR-associated factor-2) 
through binding with their death domains [11].  FADD binding leads to cleavage and 
activation of caspase 8, triggering both intrinsic and extrinsic apoptosis cascades.  
Caspase 8, through BID, induces a mitochondria membrane permeability changes leading 
to cytochrome c release and subsequent activation of caspase 9 and, finally, the effector 
caspase 3.  Caspase 8 can also directly activate caspase 3.  Activated caspase 3 cleaves 
many intracellular protein targets including cytokeratins and PARP.  TRAF-2 binding 
leads to the activation IKK proteins.  IKK-α phosphorylates IκB-α, targeting it for 
ubiquination and degradation by proteosomes, disassociating it from the transcription 
factor NF-κB thus allowing NF-κB to translocate to the nucleus [12].  Once translocated, 
NF-κB promotes the transcription of various anti-apoptotic (e.g. Bcl-2 and XIAP) genes.  
TRAF-2 also mediates c-Jun N-terminal kinase (JNK) activity leading to AP-1 promotion 
of the cell cycle. 
 
1.4.2. STAT3 and Akt signaling 
The pleotropic cytokine IL-6 (interleukin-6) binds to a complex of the transmembrane 
receptor gp130 (glycoprotein 130) and IL-6R (IL-6 receptor) to activate a variety of 
proinflammatory, pro- and anti-apoptotic, and acute-phase immune response pathways 
[13].  IL-6-bound gp-130 activates Janus kinase (JAK) via tyrosine phosphorylation.  
Phosphorylated JAK and gp-130 subsequently phosphorylates both STAT3 (signal 
transducer and activator of transcription-3) and SHP2 (SH2-domain-containing protein 
tyrosine phosphatase-2).   Phosphorylated STAT3 (at Y705) dimerizes and translocates to 
the nucleus, where it activates many “immediate-early” genes associated with liver 
regeneration, acute-phase response, and hepato-protection.  Activated SHP2 interacts 
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with Grb2 (growth factor receptor-bound protein-2) leading to downstream activation of 
the Ras–Raf–MEK–ERK pathway.  Also, activated gp130 is thought to lead to PI3K 
(phosphatidylinositol 3-kinase) activation via lipid phosphorylation [13].  This results in 
recruitment of PDK1 and Akt/protein kinase B (Akt), a serine/threonine kinase, via their 
Pleckstrin homology (PH) domains, to the plasma membrane, where PDK1 
(phosphoinositide-dependent kinase-1) phosphorylates Akt on T308 and Akt S473 is 
auto-phosphorylated [14].  Active Akt dimerizes and phosphorylates intracellular targets 
regulating pro-survival (Bad, caspase 9) and transcription (Forkhead transcription factor) 
regulators.  It has also been suggested that active PI3K can also lead to activation of JNK 
and p38 and their downstream stress/apoptotic pathways [15].  IL-6R/gp130 signaling is 
inhibited by SOCS3 (suppressor of cytokine signaling-3), which is expressed following 
STAT3 dimer translocation, forming a negative feedback loop [13].   JNK-mediated 
activation of AP-1 also contributes to the expression of “immediate-early” genes, 
including the c-Fos, c-Jos, and c-Myc [16]. 
 
1.4.3. p38 and JNK signaling 
The p38 mitogen-activated protein kinase (p38) and JNK pathways are activated by 
proinflammatory cytokines (TNF, IL-1) and cellular stresses (UV radiation, 
hyperosmolarity) [17].  Both pathways are controlled by multiple upstream MAP3K’s 
including MEKK1 and ASK1.  JNK phosphorylates the proto-oncogene c-Jun, a 
component of the transcription factor AP-1, which binds and activates transcription.  JNK 
mediates apoptosis through the phosphorylation of Bcl-2 family proteins.  p38 affects 
downstream effectors such as transcription factors MK2, ATF-2 and HSP27 and 
ultimately activates the caspase cascade [17]. 
 
1.4.4. Apoptosis: programmed cell death 
Apoptosis is a form of programmed cell death characterized by nuclear and cellular 
fragmentation and loss of plasma membrane polarity.  Apoptosis is an important 
physiological process in maintaining epithelial cell biology and is implicated in liver 
disease, response to injury, and fibrosis [18]; dysregulation of hepatocyte apoptosis 
occurs in hepatocellularcarcinoma.  Apoptosis occurs via two distinct pathways that 
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converge to activate the effector cysteine protease caspase 3: (1) the extrinsic pathway, 
extracellular ligands bind to death receptors (e.g. TNF/TNFR1) and activate a cascade of 
intracellular signals, leading to the activation of the initiator caspase 8; and (2) the 
intrinsic pathway, in which dysfunction of intracellular organelles (e.g. mitochondrial 
cytochrome c release) due to various cellular stresses leads to activation of the initiator 
caspase 9 [19]. 
 
1.5. Inflammation-related hepatotoxicity of therapeutics 
1.5.1. Adenoviral vectors 
Recombinant adenovirus vectors (Adv) are widely used as transfection tools for gene 
therapy and cell biology.  The liver is an important organ for Adv-based gene therapy due 
to the fact that a variety of human disorders originate from genetic defects in hepatocytes 
and that liver cells are exposed to systematically delivered viral vectors due to portal 
circulation.  In the liver, Kupffer cells readily uptake Adv via phagocytosis and, through 
an innate immune response, release the proinflammatory cytokines TNF, IL-1α/β and IL-
6 into the surrounding liver [20, 21].  Consequently, Adv administration as liver-directed 
gene therapy is confounded by hepatotoxicity through programmed cell death.   
Using a replication-deficient E1/E3-deleted adenovirus vector serotype 5, Miller 
et al demonstrated that Adv sensitizes multiple human epithelial cell lines (including the 
C3A hepatoblastoma cell line) to TNF-mediated apoptosis [22].  Adv and TNF both 
upregulate pro-survival (PI3K–Akt) and stress (p38–HSP27) signaling pathways [22, 23].  
Adv infection of epithelial cells is mediated by viral entry dependent of coxsackie- and 
adenovirus-receptor (CAR) and integrin docking and endocytosis [24].  Adv infection 
renders epithelial cells unable to generate sufficient survival signals (Akt activity 
becomes saturated) to overcome to TNF-mediated apoptosis [22]. Demonstrating another 
mechanism of virus-sensitization to TNF-mediated cell death, Wang et al have shown 
that hepatitis B virus X protein activates p38 kinase/JNK stress pathways leading to the 
upregulation of the death receptors TNFR1 and FasL and increased sensitivity to TNF-
mediated apoptosis [25].  These results have significant implications for our 
understanding of viral vector-induced hepatotoxicity and demonstrate that viral gene 
therapy vectors sensitize cells to cytokine-induced cell death. 
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1.5.2. Inflammation-associated idiosyncratic drug hepatotoxicity 
Idiosyncratic drug hepatotoxicity is defined as drug-induced liver injury that occurs in a 
very small fraction of human patients, is unrelated to the pharmacologic target of the 
drug, and exhibits no apparent relationship to dose or duration of drug exposure [26-28].  
Multiple hypotheses have been suggested to explain the mechanisms underlying 
idiosyncratic drug hepatotoxicity.  These include (i) variations in drug metabolism, 
particularly associated with alterations in the expression and/or activities of the 
cytochrome P450 family enzymes, due to variable environmental conditions and/or 
genetic polymorphisms in the human population [29]; and (ii) a relationship with 
concomitant liver inflammation associated with viral or bacterial infection or liver or 
inflammatory disease [26]. 
A number of preclinical models have been developed in attempts to predict 
idiosyncratic drug hepatotoxicity, including the assessment of reactive metabolites 
through glutathione (GSH) conjugation assays and the evaluation of animals models by 
toxicogenomic and metabolonomic approaches to identify common idiosyncratic 
hepatotoxicity-associated biomarkers, with little overall predictive success [27, 30, 31].  
Rodent models administered with bacterial lipopolysaccharide (LPS) have been recently 
developed to assess inflammation-associated idiosyncratic drug hepatotoxicity.  In these 
rodent models, LPS exposure induces a mild inflammatory response that has been 
demonstrated to synergistically induce hepatotoxicity in the presence of a number of 
idiosyncratic hepatotoxic drugs, including diclonfenac, sulindac, trovafloxacin, ranitidine, 
chlorpromazine, but not non- or less-toxic control drugs [32-35].  In rats, LPS 
administration upregulates plasma concentrations of the cytokines tumor necrosis factor-
α (TNF), interferon-γ (IFNγ), interleukin-1α and -1β (IL-1α/β), interleukin-6 (IL-6), and 
the chemokine interleukin-10 (IL-10) [36].  Of these, TNF, IFNγ, IL-1α/β, IL-6, and LPS 
itself all stimulate hepatocyte signaling responses.  In LPS-administered rat models, 
synergistic induction of hepatocellular death in the presence of the idiosyncratic 
hepatotoxins ranitidine and trovafloxacin has been reported to be dependent on TNF 
signaling [35, 37]. 
The observations in LPS-administered rodent models suggest that idiosyncratic 
drug hepatotoxicity can arise when mild drug-induced hepatocellular stress synergizes 
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with LPS-induced inflammatory cytokine signaling to elicit acute hepatocellular death 
[27, 38].  These stresses may be idiosyncratic in nature in human patients due variations 
in drug metabolism, exposure, and/or clearance.  The sensitizing role of hepatocellular 
stress is supported by the fact that drug-induced depletion of glutathione is known to 
sensitize hepatocytes to TNF-induced apoptosis [39].  Furthermore, both LPS and 
inflammatory cytokine signaling can alter hepatocyte expression of cytochrome P450 
enzymes and thus lead to dysregulated drug metabolism and clearance in conditions of 
LPS-induced liver inflammation [40, 41]. 
 
 
 
Figure 1-1. A schematic hepatocyte signaling network demonstrating the intersection of inflammatory 
cytokine signaling and hepatotoxic therapeutics, such as replication-deficient adenovirus and idiosyncratic 
hepatotoxic drugs. 
 
1.6. Systems biology models of cell behaviors 
Systems biology seeks a deep quantitative understanding of complex biological processes 
through the integration of multivariate molecular-level measurement and modeling 
approaches, and thus differs from proteomic and genomic efforts that aim to catalogue a 
broad listing of biological components and their functions [42, 43].  Advances in high-
throughput and multiplex techniques for quantifying the abundances and activities of the 
molecular components involved in gene expression [44], metabolism [45], and signal 
transduction [42] make it feasible to collect large data sets of diverse cellular processes.  
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Large-scale quantitative studies of complex biomolecular processes are difficult to 
interpret by inspection and intuition alone.  Computational modeling allows 
simplification of large-scale biological data sets and can suggest mechanistic insights and 
enable quantitative predictions of cellular processes [43, 46]. 
 
1.6.1. System-level measurement of cell signaling and behavioral phenotypes 
In systems biology, the collection of experimental data sets is organized and conducted 
with regard to intended modeling efforts and practical limitations.  Systems models 
largely require dynamic, highly multivariate, and quantitative data of protein activities 
and cell behavioral phenotypes collected in specific cell types subjected to defined, and 
often diverse, stimuli.  A wide variety of high-throughput and multiplex experimental 
techniques are utilized to collect data sets for systems models.  These include mass 
spectrometry [47], kinase activity assays [48, 49], immunoblotting [50], “in-cell 
westerns” [51], bead-based protein arrays [52], protein microarrays [53, 54], and 
multicolor flow [55, 56] and image [57, 58] cytometry. 
 In selecting appropriate measurement techniques, one often considers the identity 
and number of simultaneously measureable signals (whether assays can be 
“multiplexed”), the amount of sample required per assay, and whether single-cell or 
population-level behavior is measured [42].  Mass spectrometry can be used to quantify 
the relative abundance of hundreds of regulatory protein phosphorylation sites across 
multiple biological samples, but requires 105-107 cells per sample due to the fractionation 
required to detect low abundance peptides in a complex cellular lysate [59].  Kinase 
activity assays directly measure the enzymatic activity of kinases to phosphorylate 
substrates via radiochemical [48] or fluorescence [49] readouts and are multiplexible but 
require ~105 cells per kinase assayed.  In-cell westerns are a form of immuno-
fluorescence microscopy that measures protein levels or states in fixed cells still adherent 
to culture surfaces [51]; this method is not currently multiplexible but requires only 104-
105 cells per protein assayed.  Bead-based arrays utilize flow cytometric quantification of 
bead-conjugated, fluorescently-labeled antibody sandwich assays [52].  A number of 
commercial vendors provide well-validated, highly multiplexible reagents for 
phosphoprotein quantification in a cell lysate using the Luminex platform.  In practical 
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applications, ~10-20 phosphoproteins can be quantified in a lysate from 104-105 cells.  
Protein microarrays allow detection of binding avidities of cellular proteins to hundreds 
of printed protein and/or substrate features and can be conducted with a lysate from 104-
105 cells [54].  Multicolor flow and image cytometry can assess phosphoprotein levels 
and cellular phenotypes (such as proliferation, apoptosis, and migration) at a single-cell 
level.  Using well-validated antibodies and stains, multiplexing ~10 and ~4 parallel 
measurements are typical current practical upper limits for flow [55] and image [58] 
cytometry, respectively, but informative data sets can be collected in as few as 102-103 
cells per condition.  
 As no individual measurement technique can capture the full diversity of protein 
signals important to the operation of cell signaling networks, systems biology models of 
cell signaling and responses are increasingly relying on data compendia assembled from 
heterogeneous assay types [50].  Assembly of such data compendia requires careful 
consideration to data fusion, normalization, and scaling when applied to quantitative 
models (see [42, 50]). 
 
1.6.2. Data-driven modeling of cell signaling and behavioral phenotypes 
A wide spectrum of computational modeling approaches for studying cell signaling and 
its regulation of behavioral phenotypes is available [60].  Because the mechanisms 
connecting disparate cell signaling pathways to each other and to integrated cell 
behaviors are largely unknown, approaches such as differential equation-based 
physicochemical models [61] that require substantial mechanistic knowledge are 
currently limited in their practical applicability for analyzing relationships between 
regulatory network activities and downstream cell phenotypic behavior.  Accordingly, 
this discussion focuses on a set of more abstract modeling approaches more suitable for 
characterizing the operational relationships, influences, and logic of cell signaling 
networks as they relate to cell functions: partial least-squares regression, decision trees, 
and Bayesian network inference.  
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1.6.3. Partial least-squares regression 
Partial least-squares regression (PLSR) models are based on the hypothesis that, across 
multiple treatment conditions, cell behavioral phenotypes (“responses”) are inherently 
dependent on quantitative combinations of a subset of measureable activities or states of 
key signaling molecules (“signals”) [46, 62].  Measured signaling variables (including 
both protein activities at multiple time points and extracted time-dependent metrics) and 
measured cell behaviors are cast into two separate data matrices: an independent block of 
signaling variables (X) and a dependent block of response variables (Y), both arrayed 
across multiple cellular conditions.  Since the number of cellular conditions measured 
often is exceeded by the number of signaling variables, PLSR is necessary to calculate a 
unique regression solution to the hypothesized relationship Y = f (X).  PLSR identifies a 
linear solution to the signaling-response relationship within a reduced-dimensionality 
data space defined by a set of orthogonal principal components [63].  (It should be noted 
that nonlinear relationships can be readily modeled through inclusion of nonlinear 
combinations of variables and/or nonlinear variable transformations.)  The calculation of 
principal components-based regression weights is biased towards those signaling 
variables that most strongly correlate with the responses and to optimize prediction 
accuracy of the responses in cross-validation. 
 PLSR models can be used to elucidate an integrative model of network operation 
that can identify key combinations of signaling activities governing measured cell 
behaviors.  Moreover, they can be used to quantitatively and accurately predict responses 
of cells to additional treatments, such as pharmacologic perturbations, a priori using 
newly measured and/or estimated signaling data.  To generate a model capable of 
accurate a priori predictions, the conditions used to train a PLSR model need to strongly 
and differently activate the breadth of measured cell signaling activities and behaviors 
[50, 64].  PLSR models have been generated using cell signaling and response data from 
a number of the aforementioned measurement techniques, and have been successful at 
interpreting and predicting cell signaling-response relationships in varied contexts such as 
ECM-regulated embryonic stem cell self-renewal and differentiation [65], cytokine- and 
pathogen-induced epithelial cell apoptosis-survival [50, 62, 64], receptor agonist-induced 
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T-cell and B-cell cytokine release [66, 67], and growth factor-induced mammary 
epithelial cell proliferation and migration [68]. 
 
1.6.4. Decision trees 
Decision tree (DT) models can be useful as network-function models to interpret and 
predict cell signal-response relationships in terms of logical combinations of multiple 
signal activity levels.  Decision tree models are generated from a learning algorithm that 
approximates a cellular output by constructing a “tree” where the “branches” classify 
logical combinations of signals based on their measured or estimated levels, and the 
“leaves” at the end of the branches predict the cellular output.  The idea behind DT 
modeling is to recursively split signal-response data into successively smaller branches in 
order to end up with a tree in which signal combination branches are obtained that can 
classify response behavior as correctly as possible.  A decision tree model is usually 
obtained via a two-step process [69, 70].  The first step, tree growing, is done until all 
response observations are classified correctly.  The second step, tree pruning, is done in 
order to avoid over-fitting.  In generally, decision tree models have several properties that 
are appealing in biological research [69]: (a) they can be effectively applied to broad 
classes of data, in particular to discrete, continuous or mixed data; (b) they are capable of 
good prediction accuracy for highly nonlinear prediction problems; (c) their prediction 
rules are easy to visualize and interpret; and (d) they are very robust against outliers.  
Additionally, a DT model provides quantitative predictions to guide interventions, such 
as using pharmacologic inhibitors, even when such interventions only partially diminish 
the signal.  Moreover, the DT approach facilitates incorporation of nonlinear behavior 
more readily through its alternative inclusions of qualitatively diverse model branches 
characterizing different logical relationships among the signaling nodes.  Successful 
decision tree models have been developed for growth factor- and ECM-induced fibroblast 
migration [70, 71] and Fas-mediated T lymphoma apoptosis [72].  
 
1.6.5. Bayesian networks 
Bayesian networks offer a modeling technique for identifying causal relationships among 
multiple signals as well as from signals to responses.  Bayesian network models illustrate 
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the interactions of pathway components in the form of influence diagrams that can 
contain both direct molecular interactions (e.g. kinase-substrate phosphorylation) and 
indirect influences that proceed through unobserved intermediates [56].  Models are 
inferred through probabilistic calculations of covariations in activities of multiple 
signaling species, usually sparsely distributed across different signaling pathways, 
collected from single cells [56] or populations of cells [73] exposed to diverse 
combinations of extracellular stimuli and genetic and/or pharmacologic pathway 
interventions, with effective inference requiring many observations.  As such, flow 
cytometry data containing simultaneous measurement of multiple phosphoproteins of 
thousands of individual cells under a variety of treatment conditions are well-suited for 
Bayesian inference and have resulted in accurately inferred influence networks [56].  In 
comparison, Bayesian models based on population-based multivariate signaling data [56, 
73] require more diverse treatments and have reduced network inference accuracy, in part 
due to the obfuscation of informative heterogeneity at the single-cell level.  Inferred 
influence networks can suggest novel signal transduction hypotheses [56] but also could 
be useful in identifying context-specific signaling network structures.  This kind of model 
can also be used to make predictions about how interventions in the network influence 
downstream cell phenotypic behaviors, as demonstrated for the example of embryonic 
stem cell self-renewal and differentiation responses to combinations of cytokine and 
extracellular matrix cues [56].  Bayesian network modeling efforts to date have been 
restricted to static models, but the feedback loops inherent in cell signaling networks will 
likely often require dynamic Bayesian network models adapted to handle cyclic 
connectivities [74]. 
 
1.7. Thesis overview 
This work utilizes quantitative experimental and computational cell biology approaches 
to explore the relationship between inflammatory cytokine signaling and therapeutics 
with inflammation-associated hepatotoxicities, such as adenoviral vectors and 
idiosyncratic hepatotoxic drugs.  Initially, the role of autocrine signaling in governing the 
synergistic induction of rat hepatocyte cell death following adenoviral vector infection 
and TNF signaling is examined.  Subsequently, a multi-cytokine in vitro model of 
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inflammatory cytokine-associated idiosyncratic drug hepatotoxicity is developed and 
analyzed in primary rat and human hepatocytes and HepG2 cells.  Through the use of 
data-driven modeling, it is demonstrated that the synergistic induction of hepatocellular 
death by idiosyncratic hepatotoxins and inflammatory cytokines is governed through the 
network-level interaction of four key phosphoprotein signaling pathways. 
 
 
Figure 1-2. A schematic overview of the biological questions investigated in this thesis. In general, this 
work applies quantitative experimental and computational cell biology approaches to study hepatocyte 
responses to diverse inflammatory cytokine stimuli in the context of hepatotoxic therapeutics, such as 
replication-deficient adenovirus and idiosyncratic hepatotoxic drugs. 
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CHAPTER 2 
 
Autocrine signaling control of hepatocyte proliferation and apoptosis 
responses to tumor necrosis factor-α 
 
Note:  The content of this chapter is based on the published article: Cosgrove BD, Cheng 
C, Pritchard JR, Stolz DB, Lauffenburger DA, Griffith LG. Hepatology 2008, 48(1):276-
288.  This article is © 2008 American Association for the Study of Liver Diseases, and its 
content is reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & 
Sons, Inc. 
 
2.1. Introduction 
2.1.1. TNF-mediated hepatocyte signaling and responses 
Tumor necrosis factor-α (TNF) can stimulate multiple disparate hepatocyte responses –
proliferation, survival, or apoptosis – depending on the cellular context.  In the liver, TNF 
is secreted by Kupffer cells, the resident macrophages, following partial hepatectomy 
(PHx) and during inflammatory responses [75, 76].  Secreted TNF binds to and activates 
its receptor TNFR1, leading to downstream activation of the NF-κB, JNK, and p38 
MAPK signaling pathways and the cascade of caspase proteases [76] (see also Figure 1-
1).  The modulation of these and other intracellular signaling pathways by concomitant 
synergistic and antagonistic cytokine stimuli, viruses, and/or pharmacological treatments 
determine specific cell responses to TNF [11, 22, 77]. 
In the PHx model of liver regeneration, normally quiescent hepatocytes are 
stimulated to proliferate in a process regulated by multiple redundant signaling pathways 
and molecules [75].  Following PHx, Kupffer cells are activated and secrete TNF and IL-
6.  These cytokines stimulate the transcription of a set of “immediate early” genes and a 
G0–G1 cell cycle progression in hepatocytes [78, 79].  TNF signaling primes hepatocytes 
for DNA replication through subsequent stimulation by hepatocyte growth factor (HGF) 
and epidermal growth factor receptor (EGFR) ligands [75, 79-81].  In primary hepatocyte 
cultures, TNF not only potentiates growth factor-stimulated proliferation, but acts as a 
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mitogen itself [78, 82] through the induced release of autocrine transforming growth 
factor-α (TGF-α) and its activation of Akt and ERK signaling [83, 84].  The functionally 
similar interleukin-1 receptor (IL-1R) agonists IL-1α and IL-1β antagonize, through 
iNOS activation and nitric oxide production, hepatocyte proliferation when produced by 
non-parenchymal cells in vivo during liver regeneration and when added exogenously to 
mitogenic factors in vitro [85-87]. 
Hepatocytes are resistant to apoptosis stimulated by TNF alone as it activates both 
pro- and anti-apoptotic signaling pathways [11, 76].  Consequently, pharmacologic or 
genetic interference with anti-apoptotic signaling is commonly used to examine TNF-
induced hepatocyte apoptosis [11].  In diseased and/or virus-infected hepatocytes, TNF 
signaling contributes to apoptotic and necrotic cell death [11, 25].  Recently, we have 
shown that infection with a replication-deficient adenoviral vector (Adv) potently 
sensitizes human epithelial cell lines, including the C3A hepatocarcinoma cell line, to 
TNF-induced apoptosis [22].  In these human epithelial cell lines, Adv infection 
potentiates TNF-induced apoptosis through the activation of both pro-apoptotic p38 
MAPK signaling and anti-apoptotic NF-κB and Akt signaling [22].  Further, Adv 
infection saturates pro-survival signaling effectors downstream of Akt and thus limits 
insulin-mediated rescue of TNF-induced apoptosis [22].  Adenoviral gene therapy vectors 
targeting the liver and other organs are often compromised due to hepatocyte death 
induced by both the viral vector itself and cytokines of the innate immune response such 
as TNF and IL-1β [20].  Therefore, Adv infection might provide a physiologically 
relevant environment to potentiate TNF-induced apoptosis in primary hepatocytes and 
could lead to insights in liver adenoviral gene therapy. 
Hepatocyte death responses to TNF and other inflammatory cytokines can be 
antagonized by many of the same growth factors that stimulate hepatocyte proliferation 
[81, 88] or by naturally occurring inhibitors of cytokine signaling such as IL-1 receptor 
antagonist (IL-1ra) [89].  While many of the factors, such as TNF, that affect hepatocytes 
during injury or stress arise primarily from exogenous sources, hepatocytes themselves 
secrete numerous growth factors and cytokines that act in autocrine fashion to enhance or 
oppose exogenous stimuli [80, 81, 83, 84, 88, 90].  Recently, we have demonstrated that 
the response of IFN-γ-sensitized human epithelial cell lines to TNF involves release of 
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TGF-α, IL-1α, and IL-1ra, which provide conflicting and interlinked autocrine feedback 
signals governing apoptotic responses to TNF [62, 77].  Furthermore, this multi-ligand 
autocrine circuit can self-limit apoptosis when anti-apoptotic autocrine TGF-α and IL-1ra 
signaling outweigh pro-apoptotic signaling by exogenous TNF and autocrine IL-1α [77].  
Whether a similar multi-ligand autocrine circuit influences the disparate possible 
hepatocyte responses to TNF stimulation is unknown.  However, hepatocytes express 
TGF-α, IL-1α, IL-1β, and IL-1ra and their receptors but it is unknown whether these 
ligands operate via interlinked autocrine circuits to modulate hepatocyte proliferation and 
apoptosis responses to TNF [82, 83, 90-92]. 
 
2.1.2. Chapter overview 
Here we show that rat hepatocyte proliferation and apoptosis responses to TNF 
are both mediated by an inducible, coupled, and self-antagonizing TGF-α–IL-1α/β–IL-
1ra autocrine cascade.  The net effect of this coupled autocrine cascade is pro-
proliferative as induced by TNF alone but pro-apoptotic when induced by TNF in Adv-
infected hepatocytes.  Moreover, elucidation of this self-antagonizing autocrine cascade 
is a useful paradigm that helps rationalize the diverse landscape of hepatocyte phenotypic 
responses to TNF and TGF-α co-stimulation and their induction of autocrine IL-1α/β 
signaling. 
 
2.2. Experimental procedures 
2.2.1. Primary rat liver cell isolation 
Primary hepatocytes were isolated from 150-230 g male Fisher rats using a modified two-
step collagenase perfusion using Blendzyme 3 (Roche, Indianapolis, IN), essentially as 
described previously [8, 93, 94].  Following isolation, cells were suspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA) supplemented 
with 2 mg/ml bovine serum albumin (BSA) and 50 μg/ml gentamicin and centrifuged at 
50g for 2 minutes twice.  All non-sedimented cells from the 50g centrifugation were 
combined as the non-parenchymal cell (NPC)-enriched isolate, which was subsequently 
resuspended in red blood cell lysing buffer (NH4Cl 150 mM, KHCO3 1 mM, Na2EDTA 
0.1 mM, pH ~7.4) to remove red blood cells.  The remaining hepatocyte-enriched cell 
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pellet was resuspended to a concentration of 5×106 cells/ml in supplemented DMEM and 
then mixed with Percoll (45% final) and 10× Hank’s Balanced Salt Solution (HBSS; 5% 
final) and centrifuged at 50g for 10 minutes.  Final cell viability of the hepatocyte-
enriched isolates was assessed by trypan blue exclusion using a Vi-Cell instrument 
(Beckman-Coulter, Fullerton, CA) and was routinely 90-95%.  Flow cytometric analysis 
of immunostained cells (see below) showed that purified hepatocyte isolates comprised 
~97% hepatocytes (albumin+-cytokeratin-18+ cells), ~0.4% Kupffer cells (ED2+), ~0.4% 
stellate cells (GFAP+), and ~0.2% sinusoidal endothelial cells (SE-1+) (see Chapter 2.2.5, 
Figure 2-1, Table 2-1).  Unless noted, all products were obtained from Sigma (St. Louis, 
MO). 
 
2.2.2. Adenoviral vector 
A replication-deficient recombinant adenovirus type 5 vector with E1 and E3 regions 
deleted and expressing Escherichia coli β-galactosidase under a cytomegalovirus 
enhancer/promoter was obtained from Puresyn, Inc. (Malvern, PA).  This Adv vector has 
a ratio of 1 infectious viral particle (v.p.) per 6.6 total v.p. as determined by the 
manufacturer in a fluorescent focus assay.  The multiplicity of infection (MOI) is defined 
as the number of infectious Adv particles per seeded hepatocyte.  Storage buffer (10% 
glycerol in PBS) was used for mock infection controls. 
 
2.2.3. Rat hepatocyte cell culture and stimulation 
For all studies, rat hepatocyte isolates from after the Percoll purification step were 
cultured on single-layer collagen type I (BD Biosciences, Franklin Lakes, NJ) gels in 
HGM at 37°C and 5% CO2.  Collagen gels were made in 6-well tissue culture-treated 
polystyrene plates (BD Biosciences) by adding 600 μl/well of collagen type I (BD 
Biosciences) diluted to 1.6 mg/ml in PBS containing 2 mg/ml glucose and 3.7 mg/ml 
sodium bicarbonate (pH ~7.8) for 2 hours at 37°C [1, 8].  Collagen gels were blocked 
with 1% bovine serum album (BSA) in PBS for 2 hours at 37°C to inhibit cytokine 
binding.  Hepatocytes were maintained in a modified, serum-free hepatocyte growth 
medium (HGM; [95]) comprising DMEM supplemented with 2 mg/ml BSA, 100 nM 
dexamethasone, 2.25 mg/ml glucose, 2 mg/ml galactose, 110 μg/ml sodium pyruvate, 30 
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mg/ml L-proline, 100 μg/ml L-ornithine, 305 μg/ml niacinamide, 1 mM L-glutamine 
(Invitrogen), 5 μg/ml sodium selenite, 5 μg/ml transferrin (Roche), 54.4 ng/ml ZnCl2, 75 
ng/ml ZnSO4, 20 ng/ml CuSO4, 25 ng/ml MnSO4, 50 μg/ml gentamicin, and 5 μg/ml 
insulin.   
For proliferation studies, hepatocytes were seeded at 40,000 cells/cm2 and media 
were changed 4 hours post-seeding.  Twenty four hours after seeding, hepatocytes were 
stimulated with 0 or 100 ng/ml TNF (recombinant rat TNF; R&D Systems, Minneapolis, 
MN) and 0, 1, 10, or 100 ng/ml TGF-α (recombinant human TGF-α; R&D Systems) as a 
40× stock solutions in HGM.  After 24 hours of cytokine stimulation, 10 μM 5-bromo-2’-
deoxyuridine (BrdU; Invitrogen) was added as a 40× stock solution in HGM to label S-
phase cells.  After 24 hours of BrdU incubation, hepatocytes were harvested and fixed for 
flow cytometry.  Conditioned medium samples were collected at 0, 12, 24, 36, and 48 
hours following cytokine stimulation to assay cytokine release.  Lysates were collected at 
0, 0.25, 2, 12, and 24 hours following cytokine stimulation to assay phosphoprotein 
signaling. 
For apoptosis studies, hepatocytes were seeded at 50,000 cells/cm2 and media 
were changed 4 hours post-seeding.  Twenty four hours after seeding, hepatocytes were 
infected with 0, 12.5, 25, 50, or 100 MOI (0, 1.1, 2.2, 4.3, or 8.7×107 infectious v.p./ml) 
Adv in fresh media.  To remove non-infectious particles, Adv infection medium was 
removed after 6 hours and was replaced with fresh medium following a PBS wash.  
Twenty four hours after the start of Adv infection, hepatocytes were stimulated with 0, 1, 
5, 20, 100, or 200 ng/ml TNF and 0, 1, 5, 20, or 100 ng/ml TGF-α as a 40× stock 
solutions in HGM.  After 24 hours of cytokine stimulation, hepatocytes were harvested 
and fixed for flow cytometry.  Conditioned medium samples were collected at 0, 6, 12, 
18, and 24 hours following cytokine stimulation to assay cytokine and lactate 
dehydrogenase (LDH) release.  Lysates were collected at 0, 0.25, 2, 6, 12, and 24 hours 
following cytokine stimulation to assay phosphoprotein signaling. 
For both proliferation and apoptosis studies, 10 μg/ml anti-TGF-α neutralizing 
antibody (R&D Systems), 10 μM CI1033 (a pan-EGFR/ErbB receptor tyrosine kinase 
inhibitor; Pfizer, New York, NY), 10 μg/ml IL-1ra (recombinant rat IL-1ra; R&D 
Systems), 10 μg/ml anti-IL-1α neutralizing antibody (R&D Systems), or 10 μg/ml anti-
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IL-1β neutralizing antibody (R&D Systems) were added as 40× stock solutions one hour 
before cytokine stimulation to perturb autocrine ligand activity.  For analysis of cell types 
in hepatocyte cultures, hepatocyte-enriched isolates from both before and after the Percoll 
purification step were seeded and treated as described above for apoptosis studies with 
the treatments indicated in Table 2-1. 
 
2.2.4. Flow cytometry analysis of proliferation and apoptosis 
After 24 (apoptosis studies) or 48 hours (proliferation studies) of cytokine treatment, 
culture medium was collected and 0.12 mg/ml Blendzyme 3 in PBS was added to the 
culture wells to partially digest the collagen gel for ~6 minutes at 25°C.  Hepatocytes 
were then removed by adding PBS with 0.1% Tween-20 (PBS-T) and pipetting 
vigorously and then were combined with the culture media to ensure collection of both 
floating and adherent cells from each well.  Collected cells were centrifuged, fixed in 2% 
paraformaldehyde (PFA) for 20 minutes, washed in PBS-T, and then fixed in 100% 
methanol at -20°C for up to 1 week.  After centrifugation to remove excess methanol, 
cells were washed once in PBS-T.  For proliferation staining, cells were then incubated 
for 20 minutes in 2 M HCl to denature DNA and expose the BrdU epitope.  After 
centrifugation to remove excess HCl, cells were washed three times in PBS-T and then 
stained with anti-albumin (rat-specific polyclonal; MP Biomedicals, Solon, OH) and anti-
BrdU (clone PRB-1; Invitrogen) antibodies in PBS-T with 1% BSA (PBS-TB) for 1 hour.  
Cells were washed twice with PBS-TB and stained with AlexaFluor 488-conjugated goat 
anti-rabbit and AlexaFluor 647-conjugated goat anti-mouse secondary antibodies 
(Invitrogen) in PBS-TB for 1 hour.  Cells were then washed once with PBS-T, 
resuspended in PBS, and 30,000 cells from each biological replicate were analyzed by 
flow cytometry using a FACS-Calibur instrument (BD Biosciences) and FlowJo software 
(Tree Star, Ashland, OR).  Proliferating hepatocytes were reported as BrdU+ cells within 
the albumin+ population.  For apoptosis studies, cells were stained and analyzed as 
described for proliferation studies with the omission of the DNA denaturation step and 
were stained with an anti-cleaved caspase 3 primary antibody (clone C92-605; BD 
Biosciences) and an AlexaFluor 488-conjugated goat anti-rabbit secondary antibody 
(Invitrogen).  Apoptotic hepatocytes were reported as cleaved caspase 3+ cells. 
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2.2.5. Flow cytometry analysis of cell type markers 
Cell type markers were analyzed in freshly isolated NPC and hepatocyte fractions (from 
both immediately before and after the Percoll step) and in cultured hepatocytes (harvested 
as described above).  For both perfusion isolates and cultured hepatocytes, collected cells 
were centrifuged, fixed in 2% PFA for 20 minutes, washed in PBS-T, and then fixed in 
100% methanol at -20°C for up to 1 week.  After centrifugation to remove excess 
methanol, cells were washed once in PBS-T.  Cells were immunostained with anti-
albumin (rat-specific polyclonal; MP Biomedicals, Solon, OH), anti-cytokeratin-18 
(clone CY-90; Sigma), anti-CD163/ED2 (clone ED2; Serotec, Raleigh, NC), anti-GFAP 
(clone 4A11; BD Biosciences), and/or anti-SE-1 (clone SE-1; IBL America, Minneapolis, 
MN) primary antibodies in PBS-T with 1% BSA (PBS-TB) for 1 hour.  Cells were 
washed twice with PBS-TB and stained with AlexaFluor 488-conjugated goat anti-rabbit 
and AlexaFluor 647-conjugated goat anti-mouse secondary antibodies (Invitrogen) in 
PBS-TB for 1 hour.  Cells were then washed once with PBS-T, resuspended in PBS, and 
30,000 cells from each biological replicate were analyzed by flow cytometry using a 
FACS-Calibur instrument (BD Biosciences) and FlowJo software (Tree Star, Ashland, 
OR).  Cell populations were reported as follows: hepatocytes, albumin+-cytokeratin-18+ 
cells [95, 96]; Kupffer cells, ED2+ cells [97]; stellate cells, GFAP+ cells [98]; and 
sinusoidal endothelial cells, SE-1+ cells [94, 99]. 
 
2.2.6. Enzyme-linked immunoabsorbant assays 
Cytokines in culture supernatants were quantified using human TGF-α, rat IL-1α, rat IL-
1β, and mouse IL-1ra ELISA kits according to manufacturer’s recommendations (R&D 
Systems).  The human TGF-α ELISA kit was validated with a recombinant rat TGF-α 
standard (Phoenix Pharmaceuticals, Burlingame, CA), which showed a 26% cross-
reactivity relative to recombinant human TGF-α and linearity from 5-500 pg/ml (R2 = 
0.99; data not shown).  The mouse IL-1ra ELISA kit was validated with a recombinant 
rat IL-1ra standard (R&D Systems), which showed a 65% cross-reactivity relative to 
recombinant mouse IL-1ra and linearity from 100-1500 pg/ml (R2 = 0.97; data not 
shown). 
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Figure 2-1.  Representative flow cytometry scatter plots of cell population analysis of liver perfusion 
isolates and cultured hepatocytes. See Table 2-1 for a summary of cell type fractions in each perfusion 
isolate and in multiple cell culture conditions relevant to this study. 
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Table 2-1.  Flow cytometry analysis of liver cell populations in perfusion isolates and cell culture 
conditions related to TNF-induced hepatocyte proliferation and apoptosis studies. 
 
Cell isolate1   Cell culture treatment2 
 
Flow cytometry analysis of cell 
population3 
Isolate 
fraction Percoll   
Adv 
MOI 
TNF 
(ng/ml) 
TGF-α 
(ng/ml)   
%  
Alb+-    
Ck-18+ 
cells 
% 
ED2+ 
cells 
% 
GFAP+ 
cells 
%  
SE-1+ 
cells 
NPC n/a   perfusion isolate4   22.3 20.4 16.0 44.8 
Hepatocyte Pre   perfusion isolate   94.9 1.49 1.40 1.85 
Hepatocyte Post   perfusion isolate   96.5 0.41 0.39 0.24 
Hepatocyte Pre  0 0 0  86.0 0.27 2.25 0.05 
Hepatocyte Pre  0 0 20  86.4 0.68 2.62 0.04 
Hepatocyte Pre  0 5 0  80.7 0.40 1.24 0.05 
Hepatocyte Pre  0 5 20  79.4 0.28 1.18 0.02 
Hepatocyte Pre  50 0 0  79.0 0.21 0.89 0.03 
Hepatocyte Pre  50 0 20  76.4 0.17 0.96 0.01 
Hepatocyte Pre  50 5 0  78.3 0.16 0.67 0.02 
Hepatocyte Pre   50 5 20   73.7 0.14 0.63 0.02 
Hepatocyte Post  0 0 0  88.9 0.64 2.28 0.07 
Hepatocyte Post  0 0 20  81.1 0.47 1.80 0.07 
Hepatocyte Post  0 5 0  79.0 1.06 2.41 0.16 
Hepatocyte Post  0 5 20  82.9 0.44 2.23 0.11 
Hepatocyte Post  50 0 0  72.0 0.42 1.15 0.09 
Hepatocyte Post  50 0 20  87.4 0.32 1.09 0.06 
Hepatocyte Post  50 5 0  89.2 0.27 0.63 0.06 
Hepatocyte Post   50 5 20   88.9 0.24 0.80 0.09 
 
1Cell fractions from liver perfusions were isolated as described in Chapter 2.2.1.  Non-parenchymal cell 
(NPC)-enriched and hepatocyte-enriched isolates (before and after the Percoll isolation step) were analyzed 
for cell type population distribution by flow cytometry. 
2Hepatocyte-enriched perfusion isolates from both pre- and post-Percoll isolation steps were cultured as 
described in Chapter 2.2.3. Briefly, cells were seeded on collagen gel monolayers for 24 hours, infected 
with either 0 or 50 MOI Adv for 24 hours, and then stimulated with combinations of 0 or 5 ng/ml TNF and 
0 or 20 ng/ml TGF-α for 24 hours. 
3Cell type markers were analyzed by flow cytometry (see Chapter 2.2.5) using the gating presented in 
Figure 1-1. Hepatocytes are reported as albumin+-cytokeratin-18+ cells, Kupffer cells are reported as ED2+ 
cells, stellate cells are reported as GFAP+ cells, and sinusoidal endothelial cells are reported as SE-1+ cells. 
Mean values of duplicate biological samples are reported. Median SEM values were 4.4% for albumin+-
cytokeratin-18+, 0.18% for ED2+, 0.70% for GFAP+, and 0.03% for SE-1+. 
4Cell fractions from a Seglen 2-step collagenase isolation have previously been reported to be comprised of 
~98% hepatocytes and ~2% non-parenchymal cells including bile duct epithelial cells [93]. Bile duct 
epithelial cells, which immunostain positive for cytokeratin-19, were not quantified in this study. 
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2.2.7. Multiplexed phosphoprotein assays 
Phosphoprotein signaling was quantified using multiplexed bead-based Luminex assays.  
Cells were plated and treated as described above and lysates were collected at 0, 0.25, 2, 
6, 12, and 24 hours following cytokine stimulation.  Cells were placed on ice and culture 
medium was removed and centrifuged at 1000g for 4 minutes at 4°C to pellet non-
adherent cells.  Adherent cells and pelleted non-adherent cells were lysed with 
Phosphoprotein Lysis Buffer (Bio-Rad, Hercules, CA) for 20 minutes at 4°C.  Lysates 
were clarified by centrifugation at 16,000g for 15 minutes at  4°C.  Clarified lysates were 
analyzed using a bicinchonicic assay (Pierce, Rockford, IL) to determine the total protein 
concentration.  In each culture plate, a well without cells was maintained, lysed, and 
analyzed to calculate the protein contribution from the collagen gel alone and estimate 
the cellular protein concentration.  Bio-Plex assays (Bio-Rad) were used to quantify the 
following phosphoproteins: p-Akt (Ser473), p-c-Jun (Ser63), p-GSK-3α/β (Ser21/Ser9), p-
IκB-α (Ser32/Ser36), p-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), p-HSP27 (Ser78), p-JNK 
(Thr183/Tyr185), p-MEK1 (Ser217/Ser221), and p-p38 (Thr180/Tyr182).  Each phosphoprotein 
assay was individually validated using multiple positive control treatments over a range 
of cellular protein loading concentrations.  Optimal protein loading concentrations that 
maintained robust fold-change consistency across the positive control treatments were 
selected as follows: 5 μg/well for multiplexing p-Akt, p-c-Jun, and p-ERK1/2, and 10 
μg/well for multiplexing p-GSK-3α/β, p-IκB-α, p-HSP27, p-JNK, p-MEK1, and p-p38.  
Bio-Plex multiplexed phosphoprotein assays were conducted per manufacturer’s 
recommendations on a Luminex 200 instrument (Luminex, Austin, TX).  Multiple 
positive control treatments were loaded on each assay plate to scale raw fluorescence data 
to self-consistent relative values.  For each phosphoprotein assay, relative fluorescence 
data were then normalized to the minimum and maximum value observed across all 
conditions and time points.  See Appendix B for additional details. 
 
2.2.8. Lactate dehydrogenase assay 
Lactate dehydrogenase (LDH) activity in culture supernatants was quantified using the 
CytoTox-ONE Homogeneous Membrane Integrity Assay according to manufacturer’s 
recommendations (Promega, Madison, WI).  All LDH measurements were fold-change 
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normalized to the mock infection/mock treatment control at 24 hours post-cytokine 
stimulus. 
 
2.2.9. Statistical analysis 
For comparing two individual means, a Student’s t test was used.  For comparing two 
time courses or two dose-response curves, two-way analysis of variance (ANOVA) was 
used.  All tests were performed at a significance level of α = 0.05 with a false discovery 
rate correction for multiple comparisons of cytokine release and phosphoprotein signaling 
time courses.  False discovery rate-corrected P-values were calculated as:  
P = α·(N+1)/(2N), where N is the number of comparisons. 
 
2.3. Results 
2.3.1. TNF-induced hepatocyte proliferation is regulated by a set of coupled, self-
antagonizing autocrine circuits involving TGF-α, IL-1α/β, and IL-1ra 
Rat hepatocytes were cultured on a collagen gel monolayer for 24 hours then stimulated 
with TNF and other co-treatments for 48 hours, with BrdU added from 24 to 48 hours to 
capture maximal cytokine-induced hepatocyte DNA synthesis [78, 82, 84].  Cells were 
harvested and analyzed by flow cytometry for intracellular albumin and BrdU to quantify 
the fraction of proliferating hepatocytes (Figure 2-1A).  Proliferation of non-parenchymal 
cells (NPC’s) was negligible across all treatments as measured by BrdU+-albumin- cells 
(Figure 2-1A and data not shown) and by assaying changes in abundance of NPC’s by 
flow cytometry (Table 2-1). 
TNF modestly stimulated hepatocyte proliferation compared to basal media alone 
(Figure 2-1B).  Pretreatment with an antibody neutralizing TGF-α activity (Figure 2-1B-
C) or the EGFR kinase inhibitor CI1033 (Figure 2-1C) reduced hepatocyte proliferation 
stimulated by TNF to basal levels, demonstrating that autocrine TGF-α is necessary for 
TNF-induced hepatocyte proliferation in accordance with previous reports [83, 84].  
Pretreatment with IL-1ra, an inhibitor of IL-1α/β binding to IL-1R, slightly increased 
hepatocyte proliferation stimulated by TNF (Figure 2-1B), showing that autocrine IL-
1α/β inhibits TNF-induced hepatocyte proliferation.  Pretreatment with isoform-specific 
neutralizing antibodies for IL-1α and IL-1β showed that IL-1β contributes a larger anti-
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proliferative autocrine effect (Figure 2-1C).  Moreover, the increased proliferation 
observed under IL-1α/β inhibition was not evident when TGF-α was also inhibited 
(Figure 2-1B), indicating that the anti-proliferative effects of autocrine IL-1α/β are 
contingent on autocrine TGF-α activity.  TNF stimulated a slight increase in TGF-α 
release (Figure 2-1C) and more substantial increases in IL-1α (Figure 2-1E), IL-1β 
(Figure 2-1F), and IL-1ra (Figure 2-1G) release over 48 hours of treatment compared to 
untreated controls.  TNF-induced autocrine IL-1α and IL-1β release, at 24 hours post-
stimulus, were both completely inhibited by neutralizing autocrine TGF-α activity 
(Figure 2-1H-I), in accordance with previous reports in mammary and colonic epithelial 
cells [77].  TNF-induced IL-1ra release was not dependent on autocrine TGF-α or IL-
1α/β activity (data not shown).  Thus, TNF-induced hepatocyte proliferation is regulated 
by a set of coupled and self-antagonizing autocrine circuits involving pro-proliferative 
TGF-α, anti-proliferative IL-1α/β, and IL-1ra, with the release and anti-proliferative 
effects of autocrine IL-1α/β contingent on TNF-induced autocrine TGF-α signaling 
(Figure 2-4G). 
 
2.3.2. Autocrine TGF-α and IL-1α/β contribute to multiple signaling pathways 
related to TNF-induced hepatocyte proliferation 
To investigate how autocrine TGF-α and IL-1α/β signaling contributes to TNF-induced  
 
Figure 2-2.  (Following page) Coupled and self-antagonizing autocrine TGF-α, IL-1α/β, and IL-1ra circuits 
regulate TNF-induced hepatocyte proliferation. Primary rat hepatocytes were isolated, treated, and assayed 
as described in Chapter 2.2 for proliferation studies. (A) Representative scatter plots of BrdU+ flow 
cytometry assays for cells stimulated with carrier only (left) or 100 ng/ml TNF (right). The proliferative 
fraction of cultured hepatocytes is reported as percentage of BrdU+ cells within the albumin+ (hepatocyte) 
population. (B-C) Regulation of TNF-induced hepatocyte proliferation by autocrine TGF-α and IL-1α/β. 
Autocrine ligand inhibitors were added 1 hour before mock or 100 ng/ml TNF treatment. Autocrine TGF-α 
ligand activity was perturbed with 10 μg/ml anti-TGF-α or 10 μM CI1033 (a pan-EGFR/ErbB receptor 
tyrosine kinase inhibitor) pretreatment. Autocrine IL-1 activity was perturbed with 10 μg/ml IL-1ra, 10 
μg/ml anti-IL-1α, or 10 μg/ml IL-1β pretreatment. In panel (C), dashed red line indicates proliferation 
induced by 100 ng/ml TNF alone. (D-G) Conditioned media samples were collected from 0-48 hours 
following mock or 100 ng/ml TNF treatment and were assayed for autocrine TGF-α (D), IL-1α (E), IL-1β 
(F), and IL-1ra (G) release by quantitative ELISA. Differences between each pair of ligand release time 
courses were assessed using two-way ANOVA (TGF-α: P < 0.022; IL-1α: P < 0.032; IL-1β: P < 10-4; IL-
1ra: P < 0.005). (H-I) Perturbation of TNF-induced IL-1α and IL-1β release at 24 hours post-stimulus in the 
presence of 10 μg/ml anti-TGF-α. In panels (B), (C), (H), and (I), differences between mock and TNF 
treatments are labeled as significant (*) if P < 0.05. Differences between pairs of uninhibited and inhibitor 
treatments are labeled as significant (‡) if P < 0.05. In panel (C), the difference between TNF and TNF + 
IL-1ra is slightly less than significant (‡‡; P = 0.06). Data are presented as the mean ± SEM of three 
biological samples in panels (B), (C), (H), and (I) and six biological samples in (D) to (G). 
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hepatocyte proliferation, we quantified phosphoprotein signaling in multiple pathways 
associated with TNF signaling and hepatocyte proliferation.  TNF-induced hepatocyte 
proliferation in vitro is dependent on autocrine TGF-α and its activation of EGFR and 
downstream signaling through the pro-proliferative Akt and ERK pathways [83, 84].  
Here, TNF-induced activation of the Akt–GSK-3α/β and MEK–ERK signaling, on both 
transient and sustained time scales, was dependent on autocrine TGF-α (Figure 2-3A-D).  
IL-1 ligands activate multiple pathways downstream of IL-1R that are shared by TNF 
signaling, including JNK, IKK–NF-κB, and p38, but it is uncertain how these pathways 
contribute to IL-1’s antagonism of hepatocyte proliferation, which is largely attributed to 
nitric oxide (NO) signaling [87, 100].  TNF-induced activation of JNK–c-Jun and IKK– 
NF-κB (as measured by p-IκB-α) signaling at 2-12 hours post-stimulus were partially 
dependent on autocrine IL-1α/β signaling (Figure 2-3E-G).  These signaling pathways 
were similarly perturbed upon inhibition of autocrine TGF-α, again demonstrating that 
autocrine IL-1α/β signaling is contingent on autocrine TGF-α activity.  While both JNK 
and IKK–NF-κB signaling are activated by TNF immediately following partial 
hepatectomy and are associated with pro-proliferative functions, these pathways are not 
absolutely necessary for hepatocyte proliferation [11, 75, 76, 78, 101].  Sustained 
signaling via autocrine stimulation can govern cellular behaviors in counterintuitive 
manners, as has been observed in mammary epithelial cells in which TNF-induced 
autocrine IL-1α signaling contributes to sustained activation of IKK–NF-κB signaling, 
which is associated with a pro-apoptotic function rather than its canonical anti-apoptotic 
role [62, 77].  Similarly, the JNK and IKK–NF-κB pathways could function, through 
their sustained activation, to antagonize hepatocyte proliferation through mechanisms 
such as accumulation of reactive oxygen species (ROS), which is associated with JNK 
signaling [76] and inhibits hepatocyte proliferation [102]. 
Phosphoprotein signaling data can provide evidence of autocrine ligand activities 
with greater temporal resolution than can be inferred from their accumulation in culture 
media alone (Figure 2-2D-G).  The transient (15 minutes post-stimulus) activation of the 
MEK–ERK pathway (Figure 2-3C-D) depends on autocrine TGF-α, indicating that TGF-
α release and activity immediately follows TNF stimulation.  Similarly, the prolonged (2 
hours post-stimulus) activation of the JNK–c-Jun (Figure 2-3E-F) and IKK–NF-κB 
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Figure 2-3.  Autocrine TGF-α and IL-1α/β contribute to TNF-induced phosphoprotein signaling regulating 
hepatocyte proliferation. Primary rat hepatocytes were isolated, treated, and assayed as described in 
Chapter 2.2 for proliferation studies. Lysates were collected from 0, 0.25, 2, 12, and 24 hours following 
100 ng/ml TNF treatment with mock, 10 μg/ml anti-TGF-α, or 10 μg/ml IL-1ra pretreatments to perturb 
autocrine ligand activity. Lysates were analyzed using multiplexed phosphoprotein assays for p-Akt (A), p-
GSK-3α/β (B), p-MEK1 (C), p-ERK1/2 (D), p-JNK (E), p-c-Jun (F), p-IκB-α (G), p-p38 (H), and p-HSP27 
(I). In (A) to (D), IL-1ra inhibition treatments were unchanged from uninhibited treatments and thus not 
shown. Differences between uninhibited and inhibited phosphoprotein signaling time courses were assessed 
using two-way ANOVA and P values are shown in each panel for anti-TGF-α (red) and IL-1ra (blue) 
pretreatments. For phosphoproteins that did not demonstrate significant differences by ANOVA between 
uninhibited and inhibition treatment time courses for both autocrine ligands, individual time points that did 
demonstrate significant differences in both comparisons are labeled (*) if P < 0.05. Data are presented as 
the mean ± SEM of three biological samples. 
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(Figure 2-3G) pathways depends on autocrine IL-1α/β, indicating the early release and 
activity of IL-1α/β.  Lastly, the inability of exogenously added IL-1ra to perturb late-
phase JNK and IKK–NF-κB signaling (at ~24 hours) indicates the on-set of detectable 
autocrine IL-1ra activity.  Together, these data suggest that TGF-α, IL-1α/β, and IL-1ra 
operate in a coupled and time-varying autocrine “cascade”; TNF stimulates the 
immediate release of TGF-α and its activation of Akt and ERK signaling, the slightly 
delayed release of IL-1α/β and its activation of JNK and IKK–NF-κB signaling, and the 
late-phase release of IL-1ra, which antagonizes IL-1 signaling (Figure 2-9). 
 
2.3.3. TNF-TGF-α cooperation in inducing hepatocyte proliferation is self-limited by 
release of autocrine IL-1α/β 
Exogenous TGF-α stimulated a dose-dependent increase in hepatocyte proliferation in the 
absence of TNF and co-treatment with TNF did not elicit additional hepatocyte 
proliferation (Figure 2-4A) in discordance with previous reports demonstrating 
cooperation between TNF and EGFR ligands in stimulating hepatocyte proliferation in 
vitro under some media formulations [78, 82, 103].  We note that exogenous TNF and 
TGF-α exhibited slightly cooperative stimulation of hepatocyte proliferation when insulin 
was removed from the culture media (Figure 2-4B).  We were motivated to ask whether 
cooperation between exogenous TNF and TGF-α in the presence of insulin could be 
limited by anti-proliferative autocrine IL-1α/β. 
 
Figure 2-4.  (Following page) Exogenous TGF-α has limited effect in synergizing with TNF-induced 
hepatocyte proliferation due to an anti-proliferative IL-1α/β autocrine circuit. Primary rat hepatocytes were 
isolated, treated, and assayed as described in Chapter 2.2 for proliferation studies. (A) Hepatocyte 
proliferation induced by 0, 1, 10, or 100 ng/ml exogenous TGF-α with either mock or 100 ng/ml TNF co-
treatment. (B) TNF and TGF-α stimulate cooperative induction of hepatocyte proliferation in the absence, 
but not presence, of insulin. Rat hepatocytes were isolated, treated and assayed as referenced above, except 
5 μg/ml insulin was either excluded from or included in the culture and stimulation medium for all steps 
after the 4 hours post-seeding medium change. In medium containing either 0 or 5 μg/ml insulin, cells were 
stimulated with 0 or 100 ng/ml TNF and 0 or 10 ng/ml TGF-α. (C) “Cue-response landscape” plot of 
hepatocyte proliferation and autocrine IL-1α/β release induced by multiple combinations of TNF and TGF-
α stimuli. Mean values of three biological samples are plotted for BrdU+ hepatocytes (lines and vertices; z-
axis) and total autocrine IL-1α/β concentration at 24 hours post-stimulus (interpolated surface colormap) 
for multiple concentrations of exogenous TNF and either inhibited, autocrine (uninhibited), or exogenous 
TGF-α. See Table 2-2 for details of treatment conditions and measured values plotted. (D-E) IL-1α (D) and 
IL-1β (E) release at 24 hours post-stimulus induced by 0, 1, 10, or 100 ng/ml exogenous TGF-α with either 
mock or 100 ng/ml TNF co-treatment. Dashed red lines indicate ligand release level in the absence of 
exogenous TGF-α stimulus for clarity. (F) Hepatocyte proliferation induced by 100 ng/ml TNF, 1 ng/ml 
TGF-α, or TNF + TGF-α in the absence or presence of 10 μg/ml IL-1ra. (G) A molecular “logic” model of 
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the effects of autocrine TGF-α, IL-1α/β, and IL-1ra ligands in regulating TNF-induced hepatocyte 
proliferation. Exogenous TNF stimulates the release of anti-proliferative autocrine IL-1α and IL-1β ligands 
contingent of the activity of autocrine TGF-α, a pro-proliferative ligand itself, and the release of IL-1ra 
independent of activity of other autocrine ligands. Thus, this coupled autocrine circuit is self-antagonizing 
in its control of hepatocyte proliferation. In panels (A), (B), and (D) to (F), differences between pairs of 
treatments connected by brackets are labeled as significant (*) if P < 0.05. Data are presented as the mean ± 
SEM of three biological samples in panels (A), (B), and (D) to (F). 
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Table 2-2.  Measured values of proliferation and autocrine IL-1α/β release in TNF- and TGF-α-treated 
hepatocytes1. 
 
Exogenous 
TNF 
conc. 
(ng/ml) 
TGF-α 
conc.  
(ng/ml) 
TGF-α 
category 
% BrdU+ 
hepatocytes 
Autocrine    
IL-1α 
conc. 
(pg/ml) 
Autocrine 
IL-1β 
conc. 
(pg/ml) 
Total 
autocrine 
IL-1α/β 
conc. 
(pg/ml)2 
0 0 Inhibited3 17.8 55.4 67.2 122.6 
0 0.0068 Autocrine4 17.9 68.9 68.6 137.5 
0 1 Exogenous5 35.6 71.9 67.6 139.5 
0 10 Exogenous 41.0 76.4 70.4 146.7 
0 100 Exogenous 56.0 69.3 62.7 132.0 
5 0 Inhibited 24.7 61.0 71.2 132.2 
5 0.0071 Autocrine 32.5 86.4 96.3 182.7 
5 1 Exogenous 38.0 95.5 107.8 203.3 
5 10 Exogenous 42.1 88.4 94.1 182.5 
5 100 Exogenous 51.5 81.1 86.0 167.0 
100 0 Inhibited 25.6 61.0 71.2 132.2 
100 0.0072 Autocrine 37.7 82.5 98.4 180.9 
100 1 Exogenous 38.2 98.5 110.6 209.1 
100 10 Exogenous 41.1 84.9 94.0 178.8 
100 100 Exogenous 51.3 82.7 94.4 177.0 
 
1See Figure 2-4C for a surface plot of hepatocyte proliferation and autocrine IL-1α/β release induced by 
these combinations of TNF and TGF-α stimuli. 
2Total autocrine IL-1α/β concentration was calculated by adding the measured IL-1α and IL-1β 
concentrations and is an estimate of their net activity. 
3Endogenous TGF-α activity inhibited by 10 μg/ml anti-TGF-α and, accordingly, TGF-α is plotted as 
having an effective concentration of zero. 
4Autocrine TGF-α concentration measured by ELISA (in the absence of TGF-α neutralizing antibody). 
5Exogenous TGF-α concentration set by the addition of recombinant TGF-α. 
 
To examine whether autocrine IL-1α/β could affect TNF-TGF-α cooperativity in 
inducing hepatocyte proliferation, hepatocyte IL-1α/β release and proliferation were 
assayed under multiple combinations of exogenous TNF and autocrine/exogenous TGF-α 
stimuli and were plotted in a multivariate “cue-response landscape” (Figure 2-4C).  In 
this perspective, the two hepatocyte responses (IL-1α/β release and proliferation) show 
disparate dependences on the two stimulatory cues (TNF and TGF-α).  That is, the 
conditions that lead to maximal IL-1α/β release (100 ng/ml TNF + 1 ng/ml TGF-α; 
Figure 2-4C-E) are different than those associated with maximal proliferation (100 ng/ml 
TNF + 100 ng/ml TGF-α; Figure 2-4A,C).  This suggested that autocrine IL-1α/β could 
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serve as a negative regulator of hepatocyte proliferation under certain exogenous TNF-
TGF-α co-stimuli conditions – in particular, those with intermediate exogenous TGF-α 
concentrations.  Following this, IL-1ra pretreatment elicited a slight increase in 
proliferation stimulated by 100 ng/ml TNF and a more substantial increase upon 100 
ng/ml TNF + 1 ng/ml TGF-α co-stimulation, but not a significant increase in proliferation 
stimulated by 1 ng/ml TGF-α only (Figure 2-4F).  Moreover, TNF + TGF-α + IL-1ra 
treatment significantly increased hepatocyte proliferation compared to both TNF + IL-1ra 
and TGF-α + IL-1ra treatments (Figure 2-4F), demonstrating TNF and TGF-α can 
stimulate additive induction of hepatocyte proliferation, even in the presence of insulin, 
but this cooperation is inhibited by their induction of anti-proliferative autocrine IL-1α/β 
release.  Thus, induced autocrine IL-1α/β release not only antagonizes hepatocyte 
proliferation stimulated by exogenous TNF, contingent on its induced autocrine release of  
TGF-α, but also potently self-limits hepatocyte proliferation induced by exogenous TNF-
TGF-α co-stimulation (Figure 2-4G). 
 
2.3.4. Adenoviral vector infection synergistically sensitizes hepatocytes to TNF-
induced apoptosis 
Common models of TNF-induced hepatocyte apoptosis require non-physiological 
interference with anti-apoptotic signaling pathways [11, 76].  Here, we examined TNF-
induced hepatocyte apoptosis in the context of adenoviral infection because of the 
relevance of this condition to physiological and therapeutic applications and because we 
have found it to be an important modulator of TNF-induced apoptosis in other epithelial 
cell types [22, 64].  Rat hepatocytes were cultured on collagen gel for 24 hours, then 
infected with a replication-deficient adenovirus expressing a β-gal transgene at 0-100 
MOI.  Twenty four hours post-Adv infection, hepatocytes were stimulated with TNF and 
other co-treatments for 24 hours.  Cells were harvested and analyzed by flow cytometry 
for the cleaved form of the effector caspase 3 (Figure 2-5A) and LDH release (an 
indicator of loss of plasma membrane integrity in necrotic and apoptotic cell death) was 
measured in culture supernatants.  Over a range of infection levels, Adv potently 
sensitized TNF-induced apoptosis as measured by both LDH release (Figure 2-5B) and 
cleaved caspase 3+ cells (Figure 2-5C) with the sensitization effect plateauing at ~50 MOI  
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Figure 2-5.  Replication-deficient adenoviral vector infection synergistically sensitizes hepatocytes to 
TNF-induced apoptosis. Primary rat hepatocytes were isolated, treated, and assayed as described in Chapter 
2.2 for apoptosis studies. (A) Representative scatter plots of a cleaved caspase 3+ flow cytometry assay for 
cells infected with 50 MOI Adv and stimulated with carrier only (left) or 100 ng/ml TNF (right). (B-C) 
Effect of Adv infection level on TNF-induced (B) total cell death as assayed by relative LDH release and 
(C) apoptosis as assayed by the cleaved caspase 3+ cells. Cells were infected with storage buffer only or 
12.5, 25, 50, or 100 MOI Adv and then stimulated with mock or 100 ng/ml TNF for 24 hours. LDH release 
values were normalized to mock treatment condition at 24 hours post-stimulus and in (B) and (D). (D-E) 
Effect of TNF concentration on Adv infection-sensitized (D) total cell death and (E) apoptosis. Cells were 
infected with storage buffer only or 50 MOI Adv and then stimulated with 0, 1, 5, 20, 100, or 200 ng/ml 
TNF for 24 hours. Differences between all pairs of cell death and apoptosis dose-response curves in (B) to 
(E) were assessed using two-way ANOVA and were all statistically significant (P < 10-4). Data are 
presented as the mean ± SEM of three biological samples in panels (B) to (E). 
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Adv, which was used for all subsequent Adv infections.  At time points later than 24 
hours post-cytokine stimulation, hepatocyte death induced by Adv infection alone 
increased significantly, reducing the level of observed synergy between Adv and TNF in 
inducing hepatocyte death (data not shown).  In hepatocytes infected with 50 MOI Adv, 
TNF induced apoptosis as measured by both LDH release (Figure 2-5D) and cleaved 
caspase 3+ cells (Figure 2-5E), with half-maximal and maximal responses induced at ~5 
ng/ml and ~100 ng/ml TNF, respectively.  Thus, Adv infection potently sensitizes 
hepatocytes to TNF-induced apoptosis and provides a physiologically relevant model to 
examine the role of autocrine ligands in regulating TNF-induced apoptosis. 
 
2.3.5. TNF-induced apoptosis in Adv-infected hepatocytes is regulated by a coupled, 
pro-apoptotic TGF-α–IL-1α/β–IL-1ra autocrine cascade 
Because we found that a coupled TGF-α–IL-1α/β–IL-1ra autocrine cascade regulates 
hepatocyte proliferation induced by TNF, and a similar autocrine mechanism operates in 
determining apoptotic responses of colonic epithelial cells [62, 77], we investigated 
whether this autocrine cascade regulates TNF-induced apoptosis in Adv-infected 
hepatocytes.  In hepatocytes infected with 50 MOI Adv, TNF treatment significantly 
upregulated the release of autocrine TGF-α, IL-1α, IL-1β, and IL-1ra as measured over 
24 hours (Figure 2-6A-D).  Adv infection alone induced an increased release of TGF-α 
but not IL-1α, IL-1β, or IL-1ra compared to uninfected control cells (Figure 2-6E-G and 
data not shown).  Inhibition of autocrine TGF-α reduced the release of IL-1α induced by 
both Adv infection alone and Adv infection followed by 5 or 100 ng/ml TNF treatment 
(Figure2-6H) but only reduced the release of IL-1β upon Adv + 5 ng/ml TNF treatment 
(Figure 2-6I) and did not perturb the release of autocrine IL-1ra (data not shown).  
Pretreatment with anti-TGF-α, IL-1ra, or both inhibitors significantly reduced TNF-
induced apoptosis in Adv-infected hepatocytes treated with 5 ng/ml TNF, but did not 
perturb apoptosis in a statistically significant manner under 0 or 100 ng/ml TNF 
treatments (Figure 2-6J).  In Adv-infected hepatocytes, pretreatment with CI1033 and 
anti-IL-1β also reduced apoptosis induced by 5 ng/ml TNF (Figure 2-6K). 
Thus, in Adv-infected hepatocytes, TNF-induced apoptosis is regulated by the 
coupled activity of autocrine TGF-α and IL-1α/β.  At sub-saturating TNF concentrations  
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Figure 2-6.  (Previous page) Autocrine TGF-α, IL-1α/β, and IL-1ra regulate TNF-induced apoptosis in 
Adv-infected hepatocytes in a coupled autocrine circuit. Primary rat hepatocytes were isolated, treated, and 
assayed as described in Chapter 2.2 for apoptosis studies. (A-D) Conditioned media samples were collected 
from 0-24 hours following mock, 5 ng/ml (D) or 100 ng/ml (A-C) TNF treatment in hepatocytes infected 
with 50 MOI Adv and were assayed for autocrine TGF-α (A), IL-1α (B), IL-1β (C), and IL-1ra (D) release 
by quantitative ELISA. Differences between each pair of ligand release time courses were assessed using 
two-way ANOVA and were all statistically significant (P < 10-3). (E-G) Effect of both Adv infection and 
TNF treatment on hepatocyte autocrine TGF-α and IL-1α/β release. Rat hepatocytes were infected with 
storage buffer only (uninfected) or 50 MOI Adv and then stimulated with mock or 100 ng/ml TNF 
treatment. Conditioned media samples were collected at 24 hours following TNF stimulus and were 
assayed for autocrine TGF-α (E), IL-1α (F), and IL-1β (G) release by quantitative ELISA. (H-I) 
Perturbation of IL-1α (H) and IL-1β (I) release induced by 0, 5, or 100 ng/ml TNF treatment at 24 hours 
post-stimulus in 50 MOI Adv-infected hepatocytes in the presence of 10 μg/ml anti-TGF-α. (J-K) 
Regulation of TNF-induced apoptosis in Adv-infected hepatocytes by autocrine TGF-α and IL-1α/β. 
Autocrine ligand inhibitors were added 1 hour before 0, 5, or 100 ng/ml TNF treatment in 50 MOI Adv-
infected hepatocytes. Autocrine TGF-α ligand activity was perturbed with 10 μg/ml anti-TGF-α or 10 μM 
CI1033 pretreatment. Autocrine IL-1 activity was perturbed with 10 μg/ml IL-1ra, 10 μg/ml anti-IL-1α, or 
10 μg/ml IL-1β pretreatment. In panel (K), the dashed red line indicates apoptosis induced by Adv + 5 
ng/ml TNF alone. In panels (E) to (G), differences between uninfected and 50 MOI Adv infection 
treatments are labeled as significant (*) if P < 0.05. Differences between mock and 100 ng/ml TNF 
treatments are labeled as significant (‡) if P < 0.05. In panels (H) to (K), differences between mock and 
TNF treatments are labeled as significant (*) if P < 0.05 and differences between pairs of uninhibited and 
inhibitor treatments are labeled as significant (‡) if P < 0.05. Data are presented as the mean ± SEM of six 
biological samples in (A) to (D) and three biological samples (E) to (K). 
 
(5 ng/ml), the induced release of IL-1α and IL-1β is contingent on autocrine TGF-α, the 
induced release of IL-1ra is independent of autocrine TGF-α or IL-1α/β, and the net 
effect of the coupled TGF-α–IL-1α/β autocrine circuit in Adv-infected hepatocytes is pro-
apoptotic.  At saturating concentrations (100 ng/ml), TNF induces TGF-α and IL-1α/β 
release in Adv-infected hepatocytes, but these mediators only provide a negligible 
contribution to apoptosis and the requirement of autocrine TGF-α activity for IL-1β 
release is not apparent.  Taken together, the observations across all treatment conditions 
imply that autocrine TGF-α can act paradoxically as a pro-apoptotic signal in Adv-
infected hepatocytes by coupling TNF treatment to release of pro-apoptotic autocrine IL-
1α/β (Figure 2-8G). 
 
2.3.6. Autocrine TGF-α and IL-1α/β contribute to multiple signaling pathways 
related to TNF-induced apoptosis in Adv-infected hepatocytes 
To investigate how autocrine TGF-α and IL-1α/β signaling contributes to TNF-induced 
hepatocyte apoptosis, we quantified phosphoprotein signaling in hepatocytes infected 
with 50 MOI Adv and stimulated with TNF at 5 ng/ml, a sub-saturating concentration  
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Figure 2-7.  Autocrine TGF-α and IL-1α/β contribute to TNF-induced phosphoprotein signaling regulating 
hepatocyte apoptosis. Primary rat hepatocytes were isolated, treated, and assayed as described in Chapter 
2.2 for apoptosis studies. Lysates were collected 0, 0.25, 2, 6, 12, and 24 hours following 5 ng/ml TNF 
treatment of 50 MOI Adv-infected hepatocytes with mock, 10 μg/ml anti-TGF-α, or 10 μg/ml IL-1ra 
pretreatments to perturb autocrine ligand activity. Lysates were analyzed using multiplexed phosphoprotein 
assays for p-Akt (A), p-GSK-3α/β (B), p-MEK1 (C), p-ERK1/2 (D), p-JNK (E), p-c-Jun (F), p-IκB-α (G), 
p-p38 (H), and p-HSP27 (I). In panels (A) to (D), IL-1ra inhibition treatments were unchanged from 
uninhibited treatments and thus not shown. Differences between uninhibited and inhibited phosphoprotein 
signaling time courses were assessed using two-way ANOVA and P values are shown in each graph for 
anti-TGF-α (red) and IL-1ra (blue) pretreatments. For phosphoproteins that did not demonstrate significant 
differences by ANOVA between uninhibited and inhibition treatment time courses for both autocrine 
ligands, individual time points that did demonstrate significant differences in both comparisons are labeled 
(*) if P < 0.05. Data are presented as the mean ± SEM of three biological samples. 
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that showed dependence on autocrine signaling in its induction of apoptosis.  In Adv-
infected hepatocytes, TNF activated anti-apoptotic MEK–ERK signaling, dependent on 
autocrine TGF-α, but did not significantly activate Akt–GSK-3α/β signaling (Figure 2-
7A-D).  Adv infection itself strongly activates Akt signaling [22, 23], which can be 
observed by comparing basal Akt activation in uninfected (Figure 2-3A) and Adv-
infected (Figure 2-7A) cells.  TNF-induced activation of pro-apoptotic JNK–c-Jun and 
p38–HSP27 signaling (at ~6-12 hours post-stimulus) were both dependent on autocrine 
IL-1α/β signaling, as observed by direct inhibition with IL-1ra or through the inhibition 
of autocrine TGF-α (Figure 2-7E-F,H-I).  In contrast to uninfected hepatocytes (Figure 2-
3G), TNF-induced IKK–NF-κB signaling in Adv-infected hepatocytes was only 
marginally dependent on autocrine signaling (Figure 2-7G).  As observed in uninfected 
hepatocytes, TGF-α, IL-1α/β, and IL-1ra operate in an autocrine cascade that contributes 
to multiple signaling pathways related to TNF-induced apoptosis signaling in Adv-
infected hepatocytes (Figure 2-9). 
 
2.3.7. TGF-α biphasically regulates apoptosis/survival in Adv-infected, TNF-treated 
hepatocytes mediated by autocrine IL-1α/β 
To further investigate the paradoxical roles of TGF-α in regulating TNF-induced 
apoptosis in Adv-infected hepatocytes, we treated Adv-infected hepatocytes with 
multiple combinations of exogenous TNF and autocrine/exogenous TGF-α stimuli and 
assayed IL-1α/β release and apoptosis.  In examining the “cue-response landscape” of 
autocrine IL-1α/β release and apoptosis induced by these TNF-TGF-α co-stimuli in Adv-
infected hepatocytes, we observed that both IL-1α/β release and apoptosis responses were 
maximally stimulated at intermediate concentrations of exogenous TGF-α for both 5 and 
100 ng/ml TNF treatments (Figure 2-8A).  This indicated that exogenous TGF-α could 
induce increased apoptosis in Adv-infected, TNF-treated hepatocytes through the 
correlated release of additional autocrine IL-1α/β.  In Adv-infected hepatocytes treated 
with 100 ng/ml TNF, exogenous TGF-α co-treatment increased apoptosis at 1 and 5 
ng/ml TGF-α and a decreased apoptosis at 20 and 100 ng/ml TGF-α (Figure 2-8B).  In 
comparison, release of autocrine IL-1α (Figure 2-8C) and IL-1β (Figure 2-8D) was 
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Figure 2-8.  Exogenous TGF-α biphasically regulates apoptosis/survival in Adv-infected, TNF-treated 
hepatocytes through an autocrine IL-1α/β circuit. Primary rat hepatocytes were isolated, treated, and 
assayed as described in Chapter 2.2 for apoptosis studies. (A) “Cue-response landscape” plot of apoptosis 
and autocrine IL-1α/β release induced by multiple combinations of TNF and TGF-α stimuli in 50 MOI 
Adv-infected hepatocytes. Mean values of three biological samples are plotted for cleaved caspase 3+ cells 
(lines and vertices; z-axis) and total autocrine IL-1α/β concentration (interpolated surface colormap) at 24 
hours post-stimulus for multiple concentrations of exogenous TNF and either inhibited, autocrine 
(uninhibited), or exogenous TGF-α. See Table 2-3 for details of treatment conditions and measured values 
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plotted. (B) Apoptosis induced by 0, 1, 5, 20, or 100 ng/ml exogenous TGF-α with 100 ng/ml TNF co-
treatment in 50 MOI Adv-infected hepatocytes. Dashed red lines indicate apoptosis level in the absence of 
exogenous TGF-α stimulus for clarity. (C-D) IL-1α (C) and IL-1β (D) release at 24 hours post-stimulus 
induced by 0, 1, 5, 20, or 100 ng/ml exogenous TGF-α with 100 ng/ml TNF co-treatment in 50 MOI Adv-
infected hepatocytes. Dashed red lines indicate ligand release level in the absence of exogenous TGF-α 
stimulus for clarity. (E) Apoptosis induced by 100 ng/ml TNF only treatment or 100 ng/ml TNF + 5 ng/ml 
TGF-α co-treatment in the absence or presence of 10 μg/ml IL-1ra in 50 MOI Adv-infected hepatocytes. 
(F) Autocrine and sub-saturating exogenous levels of TGF-α both have a negligible anti-apoptotic effect in 
regulating TNF-induced apoptosis in Adv-infected hepatocytes. Apoptosis was measured by the fraction of 
cleaved caspase 3+ cells for Adv-infected hepatocytes treated with TNF alone; TNF + 10 μg/ml IL-1ra + 10 
μg/ml anti-TGF-α; TNF + IL-1ra; or TNF + IL-1ra + 5 ng/ml exogenous TGF-α. (G) A molecular “logic” 
model of the effects of autocrine TGF-α, IL-1α/β, and IL-1ra ligands in regulating TNF-induced apoptosis 
in Adv-infected hepatocytes. Exogenous TNF stimulates the release of pro-apoptotic autocrine IL-1α and 
IL-1β contingent of the activity of autocrine TGF-α, which is an anti-apoptotic ligand at saturating 
exogenous concentrations but not at autocrine concentrations, and the release of IL-1ra independent of 
activity of other autocrine ligands. In panels (B) to (E), differences between control treatments and 
treatments with exogenous TGF-α are labeled as significant (*) if P < 0.05. In panel (E), differences 
between pairs of control treatments and IL-1ra treatments are labeled as significant (‡) if P < 0.05. In panel 
(F), no differences were statistically significant. Data are presented as the mean ± SEM of three biological 
samples in panels (B) to (F). 
 
upregulated for TNF co-treated with TGF-α at 5 ng/ml but not other concentrations.  
Therefore, at high concentrations, exogenous TGF-α rescued TNF-induced apoptosis, in 
agreement with the recognized anti-apoptotic role of EGFR ligands [81, 88], but, at 
intermediate concentrations, exogenous TGF-α contributed to TNF-induced apoptosis, 
mirroring its role as a pro-apoptotic autocrine mediator in Adv-infected, TNF-treated 
hepatocytes.  A similar biphasic TGF-α synergism and antagonism in regulating 
apoptosis has been observed in interferon-γ-sensitized, TNF-treated human colonic 
epithelial cells [77].  Furthermore, the upregulation of apoptosis in Adv-infected, TNF-
treated hepatocytes by 5 ng/ml exogenous TGF-α, which coincided with increased IL-
1α/β release, was completely attenuated in the presence of IL-1α/β inhibition, confirming 
that autocrine IL-1α/β act as signaling mediators of the increased apoptosis stimulated by 
exogenous TGF-α (Figure 2-8E). 
Given that exogenous TGF-α at saturating concentrations acted as anti-apoptotic 
stimulus, we asked if autocrine or sub-saturating exogenous TGF-α could be serve as an 
anti-apoptotic stimulus when de-coupled from its induction pro-apoptotic IL-1α/β release.  
In Adv-infected hepatocytes pretreated with IL-1ra, then stimulated with 100 ng/ml TNF, 
TGF-α at autocrine or sub-saturating exogenous (5 ng/ml) concentrations induced a 
slight, but not statistically significant, reduction in apoptosis compared to treatment with 
anti-TGF-α (Figure 2-8F).  The negligible anti-apoptotic effect of autocrine and sub- 
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Table 2-3.  Measured values of apoptosis and autocrine IL-1α/β release in TNF- and TGF-α-treated, Adv-
infected hepatocytes1. 
 
Adv 
MOI 
Exogenous 
TNF 
conc. 
(ng/ml) 
TGF-α 
conc. 
(ng/ml) 
TGF-α 
category 
% 
cleaved 
caspase 
3+ cells 
Autocrine 
IL-1α 
conc. 
(pg/ml) 
Autocrine 
IL-1β 
conc. 
(pg/ml) 
Total 
autocrine 
IL-1α/β 
conc. 
(pg/ml)2 
50 0 0 Inhibited3 27.3 4.1 43.4 47.5 
50 0 0.030 Autocrine4 28.9 7.7 44.7 52.3 
50 0 1 Exogenous5 33.2 6.9 43.1 50.1 
50 0 5 Exogenous 26.8 7.1 43.1 50.2 
50 0 20 Exogenous 26.3 8.9 43.4 52.3 
50 0 100 Exogenous 23.9 7.0 40.7 47.7 
50 5 0 Inhibited 43.4 5.1 60.4 65.5 
50 5 0.032 Autocrine 57.7 8.7 97.5 106.2 
50 5 1 Exogenous 61.4 6.8 114.0 120.8 
50 5 5 Exogenous 60.7 6.0 66.1 72.0 
50 5 20 Exogenous 54.6 5.1 64.3 69.4 
50 5 100 Exogenous 46.8 7.8 72.3 80.1 
50 100 0 Inhibited 73.3 7.2 123.0 130.2 
50 100 0.041 Autocrine 70.5 10.0 121.5 131.4 
50 100 1 Exogenous 84.0 10.2 147.7 157.9 
50 100 5 Exogenous 78.8 13.2 160.4 173.5 
50 100 20 Exogenous 59.2 11.1 113.8 124.9 
50 100 100 Exogenous 53.8 12.6 105.8 118.5 
 
1See Figure 2-8A for a surface plot of apoptosis and autocrine IL-1α/β release induced by these 
combinations of TNF and TGF-α stimuli in Adv-infected hepatocytes. 
2Total autocrine IL-1α/β concentration was calculated by adding the measured IL-1α and IL-1β 
concentrations and is an estimate of their net activity. 
3Endogenous TGF-α activity inhibited by 10 μg/ml anti-TGF-α and, accordingly, TGF-α is plotted as 
having an effective concentration of zero. 
4Autocrine TGF-α concentration measured by ELISA and in the absence of TGF-α neutralizing antibody. 
5Exogenous TGF-α concentration set by the addition of recombinant TGF-α. 
 
saturating exogenous TGF-α are likely due to its limited ability to further supplement 
anti-apoptotic Akt signaling in the presence of Adv infection  and insulin (Figure 2-7A); 
and, instead, saturating concentrations of TGF-α are required to exert a substantial anti-
apoptotic effect.  Thus, an integrated balance of signaling by exogenous TNF, autocrine 
and exogenous TGF-α, and autocrine IL-1α/β determines hepatocyte apoptosis responses 
in the presence of Adv infection.  At autocrine and sub-saturating exogenous 
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concentrations, TGF-α exerts a negligible anti-apoptotic stimulus that is overwhelmed by 
pro-apoptotic signaling from exogenous TNF and induced autocrine IL-1α/β, which are 
antagonized by released IL-1ra.  But, at saturating exogenous concentrations, TGF-α 
effectively antagonizes pro-apoptotic signaling by these factors (Figure 2-8G). 
 
 
 
Figure 2-9.  A TGF-α–IL-1α/β–IL-1ra autocrine cascade contributes to TNF-induced hepatocyte 
proliferation and Adv-infection sensitized apoptosis through the regulation of multiple shared signaling 
pathways. TNF activates the Akt, ERK, JNK, IKK–NF-κB, and p38 signaling pathways both directly 
downstream of TNFR [11, 76] and indirectly through this autocrine cascade. Replication-deficient Adv 
infection can activate Akt, NF-κB, and p38 pathway signaling  [22, 23]. TNF induces TGF-α release, which 
activates Akt, ERK, and JNK signaling over a time scale of 0.25-24 hours. Induced IL-1α/β release is 
contingent on both TNF and autocrine TGF-α. Autocrine IL-1α/β activates JNK, IKK–NF-κB, and p38 
signaling over a time scale of 2-24 hours. Independent of autocrine TGF-α or IL-1α/β, TNF also induces 
the release of IL-1ra, which antagonizes IL-1α/β ligand activity and accumulates over a time scale of 12-24 
hours. These signaling pathways have diverse function in regulating hepatocyte proliferation and apoptosis 
[11, 75, 76, 84]. 
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2.4. Discussion 
We have demonstrated that hepatocyte responses to TNF are regulated by an inducible, 
coupled, and self-antagonizing TGF-α–IL-1α/β–IL-1ra autocrine cascade.  This autocrine 
cascade promotes both TNF-induced apoptosis in hepatocytes infected with Adv -- a 
therapeutically and physiologically relevant sensitization for hepatocyte apoptosis 
induced by TNF developed herein -- and TNF-induced proliferation in the absence of 
viral infection.   
 
2.4.1. Autocrine signaling control of adenovirus- and TNF-induced intracellular 
signaling pathways 
TNF-induced autocrine TGF-α and IL-1α/β contribute to multiple intracellular signaling 
pathways that govern both hepatocyte proliferation and apoptosis (Figure 2-9).  Autocrine 
TGF-α regulates pro-proliferative/anti-apoptotic signaling through the ERK and, in the 
absence of Adv infection, Akt pathways [83, 84].  Autocrine IL-1α/β regulates pro-
apoptotic signaling through JNK and p38 pathways.  From our results, it is unclear how 
autocrine IL-1α/β signaling antagonizes hepatocyte proliferation, but one possibility is 
through the sustained activation of JNK signaling and its association with anti-
proliferative ROS accumulation [102].  When added exogenously, IL-1 antagonizes 
hepatocyte proliferation through its induction of NO signaling [87], which was not 
assayed in our study.  NO has been shown to impair DNA synthesis through its activation 
of ribonucleotide reductase [87], but could also inhibit DNA synthesis, and effector 
caspase activation, through its S-nitrosylation and deactivation of initiator caspases [104], 
whose cleavage and activation is necessary for both DNA synthesis [38] and apoptosis.  
Thus, autocrine-dependent signaling modulates diverse signaling pathways and further 
investigation is necessary to identify how the pathways assayed herein and other 
signaling mechanisms interact to govern hepatocyte responses to TNF. 
 
2.4.2. Regulation of autocrine ligand expression and release 
Although not mechanistically investigated here, the expression and/or post-translational 
processing and shedding of TGF-α, IL-1α/β, and IL-1ra ligands are regulated by a 
number of signaling pathways activated by TNF and Adv infection, including JNK, IKK–
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NF-κB, and p38 [84, 90, 105-107].  TGF-α expression is regulated by ERK-, NF-κB-, 
and JNK–AP-1-related transcription factor activity [90, 108].  Post-translational 
processing, mediated by the protease ADAM17 (as known as TACE), is required for 
mature TGF-α release.  ADAM17 is activated by ERK and p38 signaling in mammary 
epithelial cells [107] and downstream of TNF stimulation in the AML-12 hepatocyte cell 
line [84].  Moreover, ADAM17 processes the EGFR ligands HB-EGF and amphiregulin 
and TNF itself, which were not examined in this study but are produced by hepatocytes 
under certain conditions [81, 109] and could provide additional autocrine feedback 
signals to exogenous TNF treatment.  Thus, NF-κB, JNK, and p38 signaling could 
mediate TNF-stimulated TGF-α transcription and processing in hepatocytes, with release 
of TGF-α leading to transactivation of ERK signaling and its further stimulation of TGF-
α release.  IL-1α and IL-1β maturation and release are also controlled by both 
transcriptional and post-translational mechanisms.  Although less is known about these 
mechanisms, both IL-1 transcription and processing, involving the proteases caspase-1 
and MMP-3, can be activated by signaling mediators downstream of toll-like receptors 
and TNFR1 [106]. 
The time courses of TGF-α, IL-1α, and IL-1β ligand accumulation reported here 
indicate that, in the absence of Adv infection, TNF-induced hepatocyte shedding of these 
ligands requires transcriptional activation, which could be further modified by post-
translational processing (Figure 2-2D-F).  In Adv-infected hepatocytes, TNF-induced 
release of TGF-α was upregulated earlier (by 4 hours post-TNF treatment; Figure 2-6A) 
and release of IL-1β was dramatically increased at later times (12-24 hours after TNF 
treatment; Figure 2-6C).  This suggests that Adv infection sensitizes TNF-treated 
hepatocytes to release TGF-α on time scales consistent with post-translational rather than 
transcriptional regulation.  The earlier and more pronounced IL-1β release suggests that 
Adv similarly potentiates TNF-induced IL-1β transcription and/or processing possibly 
due to shared activation of the NF-κB signaling by Adv and TNF (see Figures 2-3G and 
2-7G to compare TNF-induced NF-κB signaling in uninfected and Adv-infected 
hepatocytes).  Moreover, these results suggest that signaling activation via autocrine 
TGF-α is necessary for TNF-stimulated IL-1α/β release in hepatocytes in the presence 
(Figure 2-2H-I) or absence of Adv (Figure 2-6H-I). 
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During liver regeneration following PHx, both TNF and IL-1α/β levels in the liver 
peak within 24 hr post-PHx with IL-1α/β levels rising again at 48-96 hr post-PHx, 
coinciding with cessation of growth factor-stimulated hepatocyte proliferation [86, 110].  
Following this, the initial phase of IL-1α/β-mediated growth inhibition following PHx 
could be contributed by TNF-stimulated autocrine release and the later phase could be 
due to through Kupffer cell paracrine release.   
 
2.4.3. Interpretation of autocrine signaling mechanisms is context-dependent 
Our results also underscore the challenges in unraveling the complexities of context-
dependent cues such as TNF, and we note several factors that should be considered in 
interpretation of these results.  In this study, we inferred the activity of autocrine factors 
by assaying their accumulation in culture medium and their control of multiple 
phosphoprotein signaling pathways and resultant cellular responses.  The rate of ligand 
accumulation in culture medium does not, however, completely reflect activity of 
autocrine factors, especially when receptor-mediated ligand consumption is significant 
compared to production [111].  The outcome of autocrine effects can be influenced by 
cell density, which differed in the proliferation and apoptosis studies here, through the 
modulation of local ligand concentrations achieved by the net effects of ligand production 
and uptake [112].  Cell density could similarly influence hepatocyte autocrine signaling 
in physiological processes such as liver regeneration, in which hepatocyte cell density 
varies in different microenvironments and time points following PHx [75].  Further, 
ligand-dependent receptor degradation, prolonged culture duration, and viral infection 
can all modulate receptor expression levels in hepatocytes [25, 113], which in turn could 
lead to amplification and/or attenuation of the exogenous and autocrine ligand activities 
observed here.  Finally, autocrine factors not examined in this study might also be 
involved in hepatocyte responses to TNF.  These could include other ligands that are 
processed by ADAM17 in hepatocytes such as the EGFR ligands HB-EGF and 
amphiregulin and even TNF itself [81, 109].   
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2.4.4. Importance of autocrine signaling in hepatocyte biology 
Results herein, and those previously reported, collectively illustrate the integral role of 
autocrine factors in hepatocyte proliferation, apoptosis, survival [114], and 
transformation [88] responses to exogenous cytokine stimuli and implicate diverse 
autocrine signaling connections between cytotoxic, inflammatory, and mitogenic ligands 
in hepatocytes.  Integration of opposing positive and negative feedback mechanisms, 
such as those observed here, has previously been proposed to confer robustness in the 
control of cell phenotypic responses [115].  The disruption of self-limiting control 
mechanisms present in the TNF-induced TGF-α–IL-1α/β–IL-1ra autocrine cascade could 
provide means by which hepatocyte pathophysiological responses to inflammatory 
cytokine stimuli arise and lead to oncogenic transformation and hepatocellular carcinoma 
[100, 116].  Our results also suggest ways that manipulation of autocrine loops may 
influence therapeutic interventions in liver disease.  For example, targeted interference 
with IL-1 signaling has been shown to reduce hepatotoxicity and improve efficacy of 
Adv gene therapy in vivo [20], positive effects that may arise in part by disruption of 
autocrine IL-1 signaling.  Our findings that TGF-α is pro-apoptotic at, and slightly above, 
concentrations associated with autocrine secretion imply that adenoviral gene therapies 
might be especially hepatotoxic under conditions in which both TNF and TGF-α (or other 
EGFR ligands) are mildly upregulated, as is observed following PHx [75]. 
Clearly, the delicate balance between opposing signals requires careful 
examination using quantitative experimental models in order to achieve desired 
outcomes.  Moreover, further development of animal models will be critical to parse the 
complex autocrine and paracrine signaling mechanisms regulating TNF signaling in 
hepatocytes and other liver cell types in vivo and to validate any therapeutic interventions 
directed towards the autocrine control mechanisms identified in this study. 
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CHAPTER 3 
 
Development and analysis of an in vitro drug-cytokine hepatocellular 
death synergy model for the study of inflammation-associated 
idiosyncratic drug hepatotoxicity 
 
3.1. Introduction 
3.1.1. Idiosyncratic drug hepatotoxicity 
Idiosyncratic drug hepatotoxicity is defined as drug-induced liver injury that occurs in a 
very small fraction of human patients, is unrelated to the pharmacologic target of the 
drug, and exhibits no apparent relationship to dose or duration of drug exposure [26-28].  
Idiosyncratic drug hepatotoxicity is poorly predicted by standard preclinical cell culture 
and animal models as well as in clinical trials, and, consequently, most idiosyncratic drug 
hepatotoxicities are not evident until after approval for human use.  Due to the inability to 
predict idiosyncratic hepatotoxicities in the drug development process, idiosyncratic drug 
hepatotoxicity frequently leads to drug withdrawal or “black box” warnings and accounts 
for more than 10% of acute liver failure cases [27, 117].  Multiple hypotheses have been 
suggested to explain the mechanisms underlying idiosyncratic drug hepatotoxicity.  
These include (i) variations in drug metabolism, particularly associated with alterations in 
the expression and/or activities of the cytochrome P450 family enzymes, due to variable 
environmental conditions and/or genetic polymorphisms in the human population [29]; 
and (ii) a relationship with concomitant liver inflammation associated with viral or 
bacterial infection or liver or inflammatory disease [26].  Moreover, it is likely that 
multiple factors -- both genetic and environmental -- contribute, at relative degrees which 
are not predictable at the present time, to a drug’s hepatotoxicity idiosyncrasies [31]. 
 
3.1.2. In vitro and in vivo models of idiosyncratic drug hepatotoxicity 
A number of preclinical models have been developed in attempts to predict idiosyncratic 
drug hepatotoxicity, including the assessment of reactive metabolites through glutathione 
(GSH) conjugation assays and the evaluation of animals models by toxicogenomic and 
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metabolonomic approaches to identify common idiosyncratic hepatotoxicity-associated 
biomarkers, with little overall predictive success [27, 30, 31].  Rodent models 
administered with bacterial lipopolysaccharide (LPS) have been recently developed to 
assess inflammation-associated idiosyncratic drug hepatotoxicity.  In these rodent 
models, LPS exposure induces a mild inflammatory response that has been demonstrated 
to synergistically induce hepatotoxicity in the presence of a number of idiosyncratic 
hepatotoxic drugs, including diclonfenac, sulindac, trovafloxacin, ranitidine, 
chlorpromazine, but not non- or less-toxic control drugs [32-35].  In rats, LPS 
administration upregulates plasma concentrations of the cytokines tumor necrosis factor-
α (TNF), interferon-γ (IFNγ), interleukin-1α and -1β (IL-1α/β), interleukin-6 (IL-6), and 
the chemokine interleukin-10 (IL-10) [36].  Of these, TNF, IFNγ, IL-1α/β, IL-6, and LPS 
itself all stimulate hepatocyte signaling responses through the activation of a diversity of 
intracellular signal transduction pathways, including the IKK–NF-κB, p38, and JNK 
pathways (associated with TNF, IL-1α/β, and LPS signaling) and the STAT1 and STAT3 
pathways (associated with IFNγ and IL-6 signaling, respectively), which all are 
implicated in hepatocellular death in liver diseases and injuries (reviewed in [76, 118-
120]).  In LPS-administered rat models, synergistic induction of hepatocellular death in 
the presence of the idiosyncratic hepatotoxins ranitidine and trovafloxacin has been 
reported to be dependent on TNF signaling [35, 37]. 
The observations in LPS-administered rodent models suggest that idiosyncratic 
drug hepatotoxicity can arise when mild drug-induced hepatocellular stress synergizes 
with LPS-induced inflammatory cytokine signaling to elicit acute hepatocellular death 
[27, 38].  These stresses may be idiosyncratic in nature in human patients due variations 
in drug metabolism, exposure, and/or clearance.  The sensitizing role of hepatocellular 
stress is supported by the fact that drug-induced depletion of glutathione is known to 
sensitize hepatocytes to TNF-induced apoptosis [39].  Furthermore, both LPS and 
inflammatory cytokine signaling can alter hepatocyte expression of cytochrome P450 
enzymes and thus lead to dysregulated drug metabolism and clearance in conditions of 
LPS-induced liver inflammation [40, 41].  Although they offer promise for improved 
predictability of idiosyncratic hepatotoxicity in preclinical screening, LPS-administered 
rodent models lack sufficient throughput for preclinical screening of candidate 
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pharmaceuticals.  Moreover, it has been shown that animal models are in general not 
highly predictive of human drug hepatotoxicity, as combined preclinical testing in 
rodents, dogs, and monkeys can only identify ~50% of known human hepatotoxins [121]. 
Recent advances in the maintenance and characterization of in vitro hepatocyte 
culture systems offer substantial promise for their more wide-spread utilization in high-
throughput preclinical screening approaches for the prediction of both non-idiosyncratic 
and idiosyncratic drug hepatotoxicity in humans.  Amongst hepatocyte culture systems 
that are commonly employed for high-throughput preclinical studies, primary human 
hepatocytes are considered the “gold standard” for evaluating drug metabolism, transport, 
and toxicity [122, 123].  In comparison, primary rat hepatocytes, while more readily 
available and similarly capable of maintaining differentiated hepatic function in time-
scales of a few days in vitro, do not reproduce some aspects of human drug metabolism 
[8, 124].  Immortalized and transformed human cell lines (e.g. HepG2 cells) are also 
frequently employed but have poor maintenance of liver-specific functions and are 
relatively insensitive to human hepatotoxins in simple cytotoxicity assays [124, 125].  A 
small number of hepatocyte cell culture models have been recently developed to assess 
idiosyncratic drug hepatotoxicity.  Of note, Xu et al utilized human hepatocyte cell 
culture models to assay four sub-lethal hepatotoxicity injuries with high-throughput live-
cell microscopy for over 300 drugs, including many that cause idiosyncratic liver toxicity 
in humans [126].  Using a well-calibrated random forest prediction model of the imaging 
data, they were able to predict drug hepatotoxicity with a ~50% true-positive rate and 
~5% false-positive rate.  A rat hepatocyte-Kupffer cell co-culture model has been 
developed and shown to successfully predict chlorpromazine idiosyncratic hepatotoxicity 
through its synergistic induction of hepatocellular death following LPS treatment [127].  
The further development and validation of hepatocyte cell culture models would provide 
much-needed tools for the preclinical evaluation of idiosyncratic drug hepatotoxicity and 
could offer greater predictive ability and higher throughput than LPS-administered 
animal models. 
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3.1.3. Chapter overview 
Here, we describe a model of inflammatory cytokine-associated idiosyncratic 
drug hepatotoxicity in three standard hepatocyte cell culture systems amenable to high-
throughput preclinical screening -- primary rat and human hepatocytes and the HepG2 
human hepatoblastoma cell line.  We initially validate this model to demonstrate that a 
number of idiosyncratic hepatotoxic drugs (ranitidine, trovafloxacin, nefazodone, 
nimesulide, clarithromycin) synergistically induce hepatocellular death in vitro when co-
administered with a cytokine mix containing the LPS-upregulated cytokines TNF, IFNγ, 
and IL-1α, and LPS itself.  We then collect a hepatotoxicity data compendium comprised 
of combinations of drug and cytokine mix co-treatments covering ~1500 experimental 
conditions and analyze it to identify informative cytokine mix treatments and hepatocyte 
cell systems for predicting inflammation-associated idiosyncratic drug hepatotoxicity.  
Using this data compendium, we show that in vitro drug-cytokine synergies are 
predominantly potentiated by TNF, IL-1α, and LPS within the context of multi-cytokine 
mixes and that patterns of drug-cytokine mix synergies across a landscape of multi-
cytokine environments can be shown to correlate to drug-induced sub-lethal hepatocyte 
injuries.  Lastly, we demonstrate the predictive utility of this drug-cytokine mix co-
treatment model by screening a set of 90 drugs in human hepatocytes and show that a 
significantly larger fraction of idiosyncratic hepatotoxins synergize with a single cytokine 
mix at physiologically relevant dosing concentrations than do non-toxic drugs.  Our 
results indicate promise for employing our approach for efficient in vitro investigation of 
inflammation-associated idiosyncratic drug hepatotoxicity. 
 
3.2. Experimental procedures 
3.2.1. Drugs and cytokines 
Most drugs were obtained from Sigma (St. Louis, MO) or Sequoia Research Products 
(Pangbourne, UK).  Trovafloxacin was obtained from Pfizer’s chemical sample bank 
(Groton, CT).  Unless otherwise noted, the following drug concentrations were used: 450 
μM ranitidine, 450 μM trovafloxacin, 70 μM nefazodone, 450 μM nimesulide, 175 μM 
clarithromycin, and 175 μM telithromycin.  TPCA-1, an IKK-2 inhibitor, was obtained 
from Tocris Bioscience (Ellisville, MS).  All drugs were suspended in 0.25% final 
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DMSO.  Recombinant rat or human cytokines were obtained from R&D Systems 
(Minneapolis, MN) and were used at the following concentrations: 100 ng/ml tumor 
necrosis factor-α (TNF), 100 ng/ml interferon-γ (IFNγ), 20 ng/ml interleukin-1α (IL-1α), 
and 20 ng/ml interleukin-6 (IL-6).  Lipopolysaccharides (LPS) serotype 1 from E. coli 
0111:B4 was used at 10 μg/ml.  Unless noted, all reagents were obtained from Sigma. 
 
Table 3-1.  Drug-induced liver injury (DILI) categories. 
 
DILI categories (sorted by hepatotoxicity level) 
Group Category Description 
P1 associated with drug-induced liver injury, type 1:  hepatotoxic in animals and/or humans in a dose-dependent manner 
O1 hepatotoxic in animals, untested in humans hepatotoxic 
P2 
associated with drug-induced liver injury, type 2:  
hepatotoxic in animals and/or humans in a dose-independent manner, 
generally regarded as idiosyncratic hepatotoxicity 
O2 elevated liver enzymes in humans, but generally regarded as safe 
N3 sporadic cases of liver injury in humans, but generally safe 
N2 not known to cause liver injury, but known to cause other organ injury 
minimally 
or not 
hepatotoxic 
N1 not known to cause liver injury 
 
3.2.2. Drug hepatotoxicity classifications and pharmacokinetic properties 
Drug hepatotoxicity classifications were made according to a drug-induced liver injury 
(DILI) scale (see Table 3-1) based on clinical data collected from PubMed searches, as in 
[126].  For select drugs, idiosyncratic hepatotoxicity classifications were assigned 
according to literature references (see Table 3-2).  Therapeutically appropriate drug 
exposure levels were defined by average plasma maximum concentration (Cmax) values 
observed in humans upon single- or multi-dose administration at commonly 
recommended therapeutic doses.  Cmax values were obtained from a combination of 
literature searches and available databases, as in [126], and are reported in Table 3-3.  
Unless noted otherwise, a concentration of 100-fold Cmax, encompassing a scaling factor 
to account for human population pharmacokinetic and toxicodynamic variabilities, was 
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considered as a therapeutically relevant dosing limit for each drug, as previously 
discussed [126]. 
 
3.2.3. Hepatocyte cell isolation, culture, and stimulation 
Primary rat hepatocytes were isolated from male Fisher rats using a modified collagenase 
perfusion and Percoll isolation, routinely yielding >90% viability and >97% purity, as in 
Chapter 2.2.1.  Rat hepatocytes were seeded on collagen type I-coated 96-well plates (BD 
Biosciences, Franklin Lakes, NJ) at 1×105 cells/cm2 in insulin-containing, serum-free 
hepatocyte growth medium (HGM; as in Chapter 2.2.3, but supplemented with 1 μM 
trichostatin A).  One day post-seeding, rat hepatocytes were overlayed with 0.25 mg/ml 
Matrigel (growth factor-reduced; BD Biosciences) in fresh HGM.  One day following 
Matrigel overlay, primary rat hepatocytes were stimulated with drugs and/or cytokines in 
fresh HGM.  For rat and human hepatocyte studies, multiple donors were used 
throughout this work, with a single donor used for each self-consistent data set.
 Primary human hepatocytes were obtained in suspension from CellzDirect 
(Durham, NC).  Human hepatocytes were seeded on collagen type I-coated 96-well plates 
at 1.5×105 cells/cm2 in “plating medium” consisting of Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 5% fetal bovine serum (FBS; Hyclone, Logan, 
UT), 100 U/ml penicillin, 100 μg/ml streptomycin, 0.58 mg/ml L-glutamine, 1 μM 
trichostatin A, 0.5 μM dexamethasone, and 5 μg/ml insulin.  One day post-seeding, 
human hepatocytes were overlayed with 0.25 mg/ml Matrigel in “culturing medium” 
consisting of William’s E medium (WEM) supplemented with 15 mM HEPES, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 0.29 mg/ml L-glutamine, 1 μM trichostatin A, 0.1 μM 
dexamethasone, 5 μg/ml insulin, 5 μg/ml transferrin, and 5 ng/ml sodium selenite.  One 
day following Matrigel overlay, human hepatocytes were stimulated with drugs and/or 
cytokines in “dosing medium” (consisting of “culturing medium” but without transferrin 
and sodium selenite).   
 HepG2 cells were obtained from ATCC (Manassas, VA) and were maintained per 
ATCC recommendations.  HepG2 cells were seeded on collagen type I-coated 96-well 
plates at 1×105 cells/cm2 in Eagle’s minimum essential medium (EMEM; ATCC) 
supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.  One day 
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after seeding, medium was changed to fresh EMEM without FBS.  One day after medium 
change, HepG2 cells were stimulated with drugs and/or cytokines in fresh EMEM 
without FBS.  All cells were maintained at 37°C and 5% CO2. 
 
3.2.4. Quantitative cell death assays 
At 12, 24, or 48 hours post-drug and/or cytokine treatment, conditioned medium samples 
were collected to assay lactate dehydrogenase (LDH) release (indicator of necrotic and 
apoptotic cell death) and cells were assayed for caspase 3/7 activity (indicator of 
apoptotic cell death).  LDH activity in culture supernatants was quantified using a 
CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega, Madison, WI) 
according to manufacturer’s recommendations.  Cellular caspase 3/7 activity was 
quantified using a Caspase-Glo 3/7 Assay (Promega) according to manufacturer’s 
recommendations.  For each cell system and time-point, LDH and caspase 3/7 activity 
assay results were fold-change normalized to the average DMSO control/no cytokine 
treatment value from four or more biological samples from the same 96-well culture 
plate. 
 
3.2.5. Quantitative sub-lethal hepatotoxicity imaging assays 
Drug-induced sub-lethal hepatotoxicity phenotypes were quantitatively imaged in human 
hepatocytes in the absence of cytokine co-treatment, essentially as described previously 
[126].  Briefly, human hepatocytes at 24 or 48 hours post-treatment were stained with 
four fluorescent probes: DRAQ5 (Biostatus, Shapshed, UK) to stain nuclei and lipids, 
CM-H2DCFDA (Invitrogen, Carlsbad, CA) to stain reactive oxygen species (ROS), 
TMRM (Invitrogen) to stain mitochondrial membrane potential (MtMP), and mBCl 
(Invitrogen) to stain glutathione (GSH).  Automated live-cell, multi-color image 
acquisition was performed on a Kinetic Scan Reader (Cellomics, Pittsburgh, PA) using a 
20× objective and a XP93 filter set (Omega Optical, Brattleboro, VT).  Quantitative 
image analysis was performed using ImagePro Plus software (Media Cybermetrics, 
Bethesada, MD).  In each image, five features were quantified: nuclei count and 
intracellular lipid (non-nuclear DRAQ5 stain), ROS, MtMP, and GSH contents.  For each 
feature, the summed intensity value from each well was normalized by the total nuclei 
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count (~500 imaged per well), and then the intensity-per-cell values were fold-change 
normalized to the average DMSO control value from eight or more biological samples 
from the same 96-well culture plate. 
 
3.2.6. Factorial analysis 
The drug-cytokine mix hepatotoxicity compendium was collected such that a full 
factorial design of the five cytokine or LPS treatments (25 = 32 mixes) was included for 
each drug co-treatment in each cell system.  For each drug/cell system, the fold-change 
normalized toxicity assay values were subjected to factorial analysis.  One-, two-, three-, 
four-, and five-factor effects and their associated errors were calculated according to 
standard factorial analysis formulae [128]. 
 
3.2.7. Hierarchical clustering 
The drug-cytokine mix combinatorial hepatotoxicity compendium was fused across all 
cell systems and assay types to generate a hepatotoxicity matrix spanning 192 
“experimental conditions” (i.e., combinations of cell type, assay readout, and cytokine 
treatment) and 8 drug treatments.  For each combination of cell system and assay type, 
the fold-change normalization values were linearly mapped to a scale from the minimum 
observed value (set to 0) and the maximum observed value (set to 1).  The fused data 
compendium was subjected to two-way clustering using the unweighted pair group 
method with arithmetic mean and a Pearson distance metric. 
 
3.2.8. Statistical analysis 
To identify drug-cytokine mix co-treatment conditions that elicited supra-additive 
hepatotoxicity synergies, additive projections of drug-cytokine mix co-treatments were 
estimated by adding mean values of drug-only and cytokine mix-only toxicities and 
propagating their associated variances.  Supra-additive synergies were identified for 
conditions in which the observed drug-cytokine mix co-treatment results exceeded the 
additive projections as assessed by two-sample, one-tailed (Student’s) t test with a false 
discovery rate correction for multiple comparison testing for multiple drug doses or 
multiple cytokine mixes.  The statistical significance of each factorial effect and its 
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associated error was assessed using one-sample, two-tailed t test with a false discovery 
rate correction for multiple cytokine mixes.  Statistical significance of drug-induced sub-
lethal hepatotoxicities was assessed by a Student’s t test.  In the 90-drug study, a 
threshold two-fold above the additive projection was used instead of a Student’s t test to 
identify supra-additive drug-cytokine mix synergy due to the limited number of replicate 
samples.  The statistical significance of the observed number of synergistic drugs in the 
each hepatotoxic group was assessed using a hypergeometric test (see Table 3-4 for 
details).  All tests were performed at a significance level of α = 0.05.  False discovery 
rate-corrected P-values were calculated as: P = α·(N+1)/(2N), where N is the number of 
comparisons. 
 
3.3. Results 
3.3.1. Several idiosyncratic hepatotoxic drugs, but not their control-paired 
compounds, exhibit drug-cytokine mix hepatotoxicity synergies in vitro 
We developed an in vitro model of inflammation-associated idiosyncratic drug 
hepatotoxicity by co-administering drug compounds with known idiosyncratic 
hepatotoxicities in humans with a variety of inflammatory cytokines mixtures (comprised 
of the cytokines TNF, IFNγ, IL-1α, and IL-6, along with LPS) in multiple hepatocellular 
cell culture systems (primary human and rat hepatocytes and HepG2 human 
hepatoblastoma cells).  For each drug compound associated with idiosyncratic 
hepatotoxicity, a less- or non-hepatotoxic “comparison” control compound was used.  In 
this study, the term "comparison” compound was applied to drugs with similar molecular 
target and clinical indication and, were possible, similar chemical structure.  Initially, this 
in vitro drug-cytokine mix co-treatment model was applied to primary rat hepatocytes 
and HepG2 cells treated with five pairs of drug compounds in the presence or absence of 
a single cytokine mix containing TNF, IFNγ, IL-1α, and LPS and assayed for LDH 
release as a marker of both apoptotic and necrotic cell death (Figure 3-1).  In developing 
this model, we investigated drug-cytokine mix hepatotoxicity synergies for the following 
idiosyncratic hepatotoxic drugs (in conjunction with corresponding control compounds): 
ranitidine and its control compounds cimetidine and famotidine (histamine H2-receptor 
antagonists); trovafloxacin and its non-toxic control levofloxacin (fluoroquinolone  
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Figure 3-1.  Identification of drug dose-dependent hepatotoxicity synergies between a cytokine mix and 
multiple idiosyncratic hepatotoxic drugs in primary rat hepatocytes (A-E) and HepG2 cells (F-J). Primary 
rat hepatocytes and HepG2 cells were cultured, treated, and assayed for LDH (at 24 or 48 hours post-
treatment) as described in Chapter 3.2. Drugs were dosed at varying concentrations in the presence or 
absence of a cytokine mix containing 100 ng/ml TNF, 100 ng/ml IFNγ, 20 ng/ml IL-1α, and 10 μg/ml LPS. 
LDH release values were fold-change normalized to DMSO/no cytokine control samples from the same 
cell system. (Note that LDH release axes are separately scaled for each plot.) Drugs from similar chemical 
class and/or molecular target are plotted together, with the less or non-hepatotoxic drug in blue and the 
more idiosyncratic hepatotoxic drug in red. Data are presented as mean ± SEM of four biological samples. 
For results from additional time points, with drug doses plotted with respect to both molecular 
concentrations and drug Cmax values, see [129]. 
 
antibiotics); nefazodone and its non-toxic control buspirone (serotonin receptor 
inhibitors); nimesulide and its non-toxic control aspirin (non-steroidal anti-inflammatory 
drugs); and telithromycin and the less idiosyncratic control compound clarithromycin 
(ketolide and macrolide antibiotics, respectively, binding to bacterial ribosomal subunit 
50S).  For additional information on these drugs, see Table 3-2 and [27, 31, 130, 131].  
Synergistic induction of hepatocellular death was assessed by a supra-additive synergy 
criterion that compares the experimentally observed cell death induced by drug and 
cytokine co-treatment to the additive projection of cell death observed for drug-only and 
cytokine mix-only treatments (Figure 3-2). 
 In this co-treatment model, we observed drug-cytokine mix synergies for 
ranitidine but not cimetidine or famotidine (data not shown) in rat hepatocytes (but not 
HepG2 cells), matching similar observations in a LPS-administered rat model [34].  We 
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observed drug-cytokine mix synergies for trovafloxacin but not levofloxacin in both rat 
hepatocytes and HepG2 cells, again matching similar observation in a LPS-administered 
mouse model [35].  For drugs not previously examined in LPS-administered animal 
models, we observed drug-cytokine mix synergies for nefazodone (but not buspirone) and 
clarithromycin in both rat hepatocytes and HepG2 cells, and nimesulide (but not aspirin) 
and telithromycin in only HepG2 cells.  In this initial study, drug-cytokine mix synergies 
were only observed for the more idiosyncratic hepatotoxic drugs, except for 
clarithromycin and telithromycin, which both have associated idiosyncratic 
hepatotoxicity with telithromycin having a greater incidence (see Table 3-2 and [31, 
132]).  Drug-cytokine mix hepatotoxicity synergies were observed within 24 hr following 
co-treatment except for ranitidine in rat hepatocytes, which required 48 hr of co-treatment 
to elicit hepatotoxicity synergy, demonstrating that, at the drug and cytokine treatment 
concentrations used, this in vitro model captures acute, rather than chronic, hepatotoxicity 
responses.  The delay in ranitidine-cytokine mix synergy compared to other compounds, 
in concert with the observation that it only occurs in rat hepatocytes and not HepG2 cells, 
indicates that a more prolonged mechanism (e.g. requiring significant accumulation of 
ranitidine metabolites) may be required to potentiate ranitidine-cytokine hepatotoxicity 
synergy. 
Specific concentrations and time-points for each drug were selected for further 
investigation (see summary in Table 3-2) based on the criteria that the concentration 
induce robust supra-additive hepatotoxicity synergy with this representative cytokine mix 
(see Figure 3-2) and elicit minimal drug-only hepatotoxicity.  This selection criteria 
allowed for identification of drug concentrations within a physiologically relevant dosing 
limit of 100-fold its Cmax value (see Chapter 3.2.2 for additional explanation) for all 
cytokine-synergizing drugs except ranitidine, for which a dose of 450 μM or 317*Cmax 
was used. 
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Figure 3-2.  Identification of drug dosing concentration ranges that elicit supra-additive drug-cytokine 
hepatotoxicity synergies. Primary rat hepatocytes and HepG2 cells were cultured, treated, and assayed for 
LDH release (24 or 48 hours post-treatment) as described in Chapter 3.2. LDH release values were fold-
change normalized to DMSO/no cytokine control samples. Drug concentrations are plotted with respect to 
molar concentration (μM) on the bottom axis and each drug’s Cmax value on the top axis. Optimal drug 
dosing concentrations for combinatorial studies were selected by identifying drug concentrations that 
elicited supra-additive drug-cytokine hepatotoxicity synergies for a single cytokine mix (TNF, IFNγ, IL-1α, 
and LPS).  Projections of drug-cytokine mix co-treatments were estimated by adding mean values of drug-
only and cytokine mix-only toxicities and propagating their associated variances. Observed drug and 
cytokine mix co-treatment toxicity results that exceeded the additive projections in a statistically significant 
manner (P < 0.029, as assessed by a false discovery rate-corrected Student’s t test) are overlayed with a 
gray coloring. Drug concentrations that demonstrated robust supra-additive drug-cytokine mix 
hepatotoxicity synergy and minimal drug-only hepatotoxicity were selected by inspection for additional 
combinatorial cytokine mix studies and are indicated on each graph and in Table 3-2. Data are presented as 
the mean ± SEM of four biological samples. 
 78
 
 
Table 3-2.  Drugs examined in initial drug-cytokine mix co-treatment model studies. 
 
 
1Idiosyncratic hepatotoxin classification based on published reports and reviews [27, 31, 130-132]. 
2Drug hepatotoxicity synergy with LPS administration in rodent models ranitidine but not famotidine has 
been reported in [34] and trovafloxacin but not levofloxacin has been reported in [35]. 
3Observed drug-cytokine supra-additive hepatotoxicity synergy using a cytokine mix containing TNF, 
IFNγ, IL-1α, and LPS in primary rat hepatocytes and/or HepG2 cells (see Figures 3-1 and 3-2).   
4The listed conditions were selected, as shown in Figure 3-2, for further investigation in combinatorial 
cytokine co-treatment experiments. Abbreviations: DILI, drug-induced liver injury; Cmax, average plasma 
maximum drug concentration in human use; n.r., not reported in the literature; n.s., not selected; NSAID, 
non-steroidal anti-inflammatory drug. 
 
Synergy with 
cytokine mix cell 
culture model3 
 
Conditions 
selected for 
combinatorial 
cytokine 
experiments4 Drug DILI category 
Drug 
class 
Idiosyn-
cratic 
hepato-
toxin1 
Synergy 
with 
LPS in 
animal 
models2 
 
Primary 
rat 
hepat-
ocytes 
Hep
G2 
cells 
 
Conc. 
(μM, 
Cmax) 
End 
point 
Famotidine N3 - -  - -  n.s. n.s. 
Cimetidine  N3 - n.r.  - -  n.s. n.s. 
Ranitidine N3 
histamine 
H2-
receptor 
antagonist 
++ +  + -  450 μM 317*Cmax 
48 hr 
Levofloxacin N3 - -  - -  n.s. n.s. 
Trovafloxacin P2 
fluoro-
quinolone 
antibiotic ++ +  + +  450 μM 59*Cmax 
24 hr 
Buspirone N1 - n.r.  - -  n.s. n.s. 
Nefazodone P2 
serotonin 
receptor 
inhibitor ++ n.r.  + +  70 μM 73*Cmax 
24 hr 
Aspirin O2 - n.r.  - -  n.s. n.s. 
Nimesulide P2 
NSAID 
++ n.r.  - +  450 μM 21*Cmax 
24 hr 
Clarithromycin N1 + n.r.  + +  175 μM 52*Cmax 
24 hr 
Telithromycin P2 
macrolide 
and 
ketolide 
antibiotic ++ n.r.  - +  
175 μM 
63*Cmax 
24 hr 
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3.3.2. Collection of a combinatorial drug- and cytokine mix-induced hepatotoxicity 
compendium from multiple hepatocyte cell systems 
To characterize drug-cytokine mix synergies in a more diverse set of cytokine 
environments and to make comparisons across hepatocyte cell culture systems, we 
collected a multi-cue data compendium from all combinations of six idiosyncratic 
hepatotoxic drugs from the initial study, each at one concentration and time-point, and a 
DMSO control, and the 32 combinatorial mixtures of TNF, IFNγ, IL-1α, IL-6, and LPS.  
(Note that IL-6, not included in the initial study due to its presumed pro-survival effects 
[133], was included in this combinatorial study.)  Experiments were performed in rat 
hepatocytes, human hepatocytes, and HepG2 cells and then assayed for both LDH release 
and caspase 3/7 activity, a marker specific to apoptotic cell death (Figure 3-3).  For rat 
and human hepatocyte studies, multiple donors were used throughout this work, with a 
single donor used for each self-consistent data set (i.e. each cell system’s data 
compendium in Figure 3-3 represents a single donor).  For rat hepatocytes, donor-to-
donor variability was assessed by comparing two drug- and cytokine mix-induced 
hepatotoxicity data compendia (each consisting of the same 256 treatment conditions) 
collected from two separate primary rat hepatocyte isolations.  The two separate data 
compendia showed a high degree of reproducibility (R = 0.98; see Figure 3-4). 
The hepatotoxicity data compendium, comprised of ~1500 combinations of cell system, 
assay type, and drug-cytokine treatment, was observed to contain a diverse array of drug-
cytokine synergy patterns not clearly interpretable by inspection alone, so we subjected it 
to three analytical approaches.  (i) We discretized the hepatotoxicity data compendium 
into conditions that did or did not elicit supra-additive drug-cytokine mix synergy (Figure 
3-5).  (ii) We subjected the hepatotoxicity data compendium to factorial analysis to 
identify which underlying cytokine treatment factors potentiate cell death across the 
entire combinatorial landscape of cytokine environments (Figure 3-6).  (iii) We employed 
hierarchical clustering of the hepatotoxicity data compendium with respect to both drug 
treatments and “experimental” conditions (i.e., combinations of cell type, assay readout, 
and cytokine treatment; Figure 3-8). 
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Figure 3-3.  A drug- and cytokine mix-induced hepatotoxicity data compendium.  Primary rat hepatocytes 
(left), primary human hepatocytes (center), and HepG2 cells (right) were cultured, treated, and assayed for 
caspase 3/7 activity (top) or LDH release (bottom) at 24 or 48 hours post-treatment as described in Chapter 
3.2. Caspase 3/7 activity and LDH release values were both fold-change normalized to DMSO/no cytokine 
samples from the same cell system. Mean toxicity assay values of three to six biological samples are 
plotted in the heatmaps using linear color-scales indexed separately to the minimum and maximum 
observed value for each combination of cell system and assay type. The cytokine mix (TNF, IFNγ, IL-1α, 
and LPS) used in Figure 3-1 is noted as “Mix”. Abbreviations: Cla, clarithromycin; Tel, telithromycin; Nef, 
nefazodone; Tro, trovafloxacin; Nim, nimesulide; Ran, ranitidine. 
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Figure 3-4.  Evaluation of reproducibility in collection of drug-cytokine mix hepatotoxicity data 
compendium in primary rat hepatocytes. From two separate rat liver cell isolations conducted on different 
days, primary rat hepatocytes were cultured, treated with multiple drug and cytokine co-treatments, and 
assayed for LDH release (24 or 48 hours post-treatment) as described in Chapter 3.2. LDH release values 
were fold-change normalized to DMSO/no cytokine samples at the same time-point from the same 
isolation. (A) Mean LDH release assay values, of three to six biological samples per condition, from each 
individual drug-cytokine data compendium experiment are plotted in heatmaps. (B) LDH release assay 
values from the two compendium collections are plotted as mean ± SEM. Across all conditions, these two 
experiments had a Pearson correlation coefficient (R) of 0.98. Abbreviations: Cla, clarithromycin; Tel, 
telithromycin; Nef, nefazodone; Tro, trovafloxacin; Nim, nimesulide; Ran, ranitidine. 
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Figure 3-5.  Drug-cytokine mix supra-additive synergy classifications in combinatorial treatment 
compendium. The drug-cytokine mix hepatotoxicity compendium (see Figure 3-3 for experimental details) 
was analyzed to identify cytokine mix co-treatment conditions that demonstrated supra-additive 
hepatotoxicity synergy for each drug in each combination of cell system (primary rat hepatocytes, primary 
human hepatocytes, and HepG2 cells) and toxicity assay (caspase 3/7 activity and LDH release). Drug-
cytokine mix supra-additive synergy was assessed by comparing the observed drug-cytokine mix co-
treatment result and an additive projection of the drug-only and cytokine mix-only results. (A) Discretized 
synergy classifications. All conditions which demonstrated supra-additive synergy with a statistical 
significance of P < 0.026 in a false discovery rate-corrected Student’s t test are presented in white. The 
cytokine mix (TNF, IFNγ, IL-1α, and LPS) used in Figure 3-1 is noted as “Mix”. Conditions used for the 
large-scale primary human hepatocyte toxicity study (assayed by LDH release; see Figure 3-9) are noted: 
(1) no cytokines and (2) TNF, IL-1α, IL-6, and LPS. (B-C) Cytokine treatment synergy efficacy. (B) The 
fraction of observed synergies from possible synergies across all 32 combinations of cell system, toxicity 
assay, and drug co-treatment for each cytokine mix are presented. (C) The fraction of possible synergies are 
presented (mean ± SEM) grouped by number of cytokines in the treatment. Abbreviations: Cla, 
clarithromycin; Tel, telithromycin; Nef, nefazodone; Tro, trovafloxacin; Nim, nimesulide; Ran, ranitidine; 
n.a., not applicable. 
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3.3.3. Discretization of the drug-cytokine mix data compendium into synergistic 
toxicity conditions 
From the first analysis approach, examining discretized drug-cytokine synergy 
classification (Figure 3-5), it is evident that higher-order (four- or five-factor) cytokine 
environments were more efficient at identifying possible drug synergies (~50% of 
possible synergies across combination of all cell systems and drugs) than were lower-
order (one-, two-, or three-factor) environments (~15-35% of possible synergies).  Of 
note, there are higher-order cytokine mixes other than the mix of TNF, IFNγ, IL-1α, and 
LPS (which was used in the initial study) that are more efficient at synergizing with these 
idiosyncratic drugs in human hepatocytes.  This is in part due to the fact that the initial 
cytokine mix is mildly toxic by itself for human primary hepatocytes, limiting its ability 
to synergize with drug co-treatments in a supra-additive manner.  Instead, slightly less-
toxic five-factor mixes (in particular, the five-factor mixes that instead do not contain 
either TNF or IFNγ [the latter noted as “2” in Figure 3-5A]) are far more efficient at 
eliciting supra-additive hepatotoxicity synergies with these six idiosyncratic drugs in 
human hepatocytes, and therefore would likely serve as a more predictive cytokine 
environment for assessing drug-cytokine synergies in human hepatocytes. 
 
3.3.4. Factorial analysis of drug-cytokine mix hepatotoxicity identifies TNF and IL-
1α as key cytokine factors potentiating inflammation-associated idiosyncratic drug 
hepatotoxicity 
We applied factorial analysis to the hepatotoxicity data compendium (which 
contained a full factorial design of 25 = 32 cytokine combinations) to identify underlying 
cytokine effects potentiating drug-cytokine hepatotoxicity synergies across the entire 
landscape of cytokine environments.  As applied here, factorial analysis calculates the 
effect of the addition or removal of component treatment “variables”, each containing 
one-to-four cytokines and/or LPS, from all treatment conditions in which they are present 
or absent, and, as such, summarizes the average effect of each cytokine treatment 
“variable” within each data set in which it is applied [128].  Factorial analysis was 
applied separately to each combination of hepatocyte cell system, hepatotoxicity assay,  
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Figure 3-6.  Factorial analysis of the drug-cytokine mix hepatotoxicity compendium. Each combination of 
cell system, toxicity assay type, and drug treatment from the drug-cytokine mix hepatotoxicity 
compendium (see Figure 3-3) was subjected to factorial analysis (see Chapter 3.2.6 for details). Factorial 
effects are plotted as heatmaps organized by assay type (top, caspase 3/7 activity; bottom, LDH release) 
and drug co-treatment to compare effects across cell systems (left) and as bar plots (with ± factorial error) 
for only DMSO control and ranitidine treatments in primary rat hepatocytes at 48 hours post-treatment 
(right). The factorial effect color-scales used in these heatmaps are indexed separately for each toxicity 
assay type to capture the full range of factorial effects in each assay type (±3.4 fold-change for the caspase 
v3/7 activity assay effects and ±8.7 fold-change for the LDH release assay effects). Statistical significance 
of each effect was assessed by a false discovery rate-corrected one-sample, two-tailed t test. In the bar 
plots, factorial effects are labeled as significant (*) if P < 0.026. Abbreviations: Cla, clarithromycin; Tel, 
telithromycin; Nef, nefazodone; Tro, trovafloxacin; Nim, nimesulide; Ran, ranitidine; RH, primary rat 
hepatocytes; HH, primary human hepatocytes; G2, HepG2 cells. 
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and idiosyncratic drug co-treatment, and factorial effects were interpreted by comparing 
the calculated effects between drug and DMSO control treatments for each combination 
of cell system and assay type (Figure 3-6). 
Across all three hepatocytic cell types, higher-order factorial effects (those 
containing more than two cytokine variables) are generally modest, indicating that there 
is minimal cytokine-cytokine synergy in these multi-cytokine treatment environments.  
Instead, one- and two-cytokine factorial effects dominate the observed drug- and cytokine 
mix-induced hepatotoxicities, with the most significant effects arising from the single-
cytokine treatment variables of TNF and, to a lesser extent, IL-1α and LPS.  LPS yielded 
significant factorial effects predominantly in human hepatocytes.  Some drugs appear to 
potentiate hepatotoxicity synergy with cytokines by amplifying the effects of the 
cytokines alone, and thus magnifying but not altering the pattern of the factorial effects 
(compare DMSO control to clarithromycin in human hepatocytes).  By contrast, other 
drugs dramatically altered the pattern of cytokine synergies and their calculated factorial 
effects (compare DMSO control to telithromycin in human hepatocytes).  Whereas some 
drugs (e.g. clarithromycin) had very similar patterns of factorial effects across all three 
cell types, drugs such as trovafloxacin had dramatically altered patterns of factorial 
effects among them, indicating a significant degree of cell type-specificity in certain 
drug-cytokine hepatotoxicity responses.  This high degree of cell type-specificity to 
particular cytokine effects is in agreement our recent findings that primary human 
hepatocytes and HepG2 cells, in response to numerous inflammatory cytokine treatments, 
utilize dramatically different intracellular signaling mechanisms and secrete different 
patterns of cytokines and chemokines [134]. 
In LPS-administered rodent models, the induction of hepatotoxicity upon both 
ranitidine and trovafloxacin treatment has been shown to be partially dependent on TNF 
[35, 37].  In concordance with those reports, we observed that TNF contributed a 
significant factorial effect in potentiating the toxicity of both ranitidine and trovafloxacin 
in rat hepatocytes (Figure 3-6).  It should be noted that the treatment of TNF alone did 
result in the induction of supra-additive hepatotoxicity synergy in trovafloxacin- but not 
ranitidine-treated rat hepatocytes (Figure 3-5), indicating that higher-order combinations 
of TNF with other cytokine co-treatments were necessary to potentiate TNF’s 
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Figure 3-7.  Quantitative imaging assays of drug-induced sub-lethal hepatotoxicities. Primary human 
hepatocytes were cultured and treated with drugs (but no cytokines) as described in Chapter 3.2. The 
following drug doses were used: 175 μM Cla, 175 μM Tel, 70 μM Nef, 175 μM Tro, 450 μM Nim, and 450 
μM Ran. At 24 or 48 hours post-treatment, cells were stained with multiple fluorescence probes and imaged 
on a four-color, live-cell Cellomics instrument (see Chapter 3.2.5 for additional details). Representative 
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images from DMSO control wells (A-D) and nimesulide treatment (E-H) are shown for: DRAQ5 stain 
(nuclei and lipid content; A,E), CM-H2DCFDA probe (ROS content; B,F), TMRM stain (mitochondrial 
membrane potential; C,G), and mBCl stain (GSH content; D,H). Image insets are 2.5× magnified from the 
remainder of the image. Quantitative image analysis was performed as described in Chapter 3.2.5. Intensity 
of each stain was normalized to the number of nuclei counted in each sample then fold-change normalized 
to the DMSO/no cytokine control samples at 24 hr post-treatment. Increases in intracellular lipid (I) and 
ROS (J) content and decreases in mitochondrial membrane potential (K) and intracellular GSH (L) are 
indicative of sub-lethal hepatotoxicity. In panels (I) to (L), data are presented as mean ± SEM of five 
biological samples. Treatments significantly different from the DMSO control at the same time point are 
labeled as significant (*) if P < 0.05 by a Student’s t test. Abbreviations: Cla, clarithromycin; Tel, 
telithromycin; Nef, nefazodone; Tro, trovafloxacin; Nim, nimesulide; Ran, ranitidine; ROS, reactive 
oxygen species; GSH, glutathione. 
 
synergizing effect, as elucidated by factorial analysis, with ranitidine in rat hepatocytes. 
 
3.3.5. Clustering of the drug-cytokine mix hepatotoxicity compendium identifies 
correlations between drug-cytokine mix hepatocellular death synergies and drug-
induced sub-lethal hepatocyte injuries 
Factorial analysis of the hepatotoxicity data compendium suggested a significant degree 
of variability in cytokine factors potentiating idiosyncratic drug hepatotoxicity synergies 
in different drug backgrounds and cell systems.  To further assess these differences, we 
fused the hepatotoxicity data compendium into a single data matrix of 192 
“experimental” conditions (comprised of all combinations of three cell systems, two 
assay types, and five cytokine/LPS treatment variables) by eight “drug” conditions (six 
idiosyncratic drugs and two DMSO controls).  This hepatotoxicity data matrix was 
subjected to two-way hierarchical clustering using a Pearson correlation metric to group 
similar patterns of drug-cytokine synergies across both the 192 experimental conditions 
and the 8 drug or DMSO backgrounds (Figure 3-8). 
Pearson clustering yielded the most distinct separation with respect to assay 
readouts due to the fact that they are poorly correlated (R = 0.18) across the entire data 
set.  A second notable grouping was that of the different cell types, with large sections of 
each assay type cluster consisting solely of the conditions from each cell system, showing 
that there was little overlap between the three hepatocyte cell systems.  Within the LDH 
data cluster, human hepatocytes clustered closer to rat hepatocytes, but within the caspase 
data cluster, human hepatocytes clustered closer to HepG2 cells, suggesting that neither 
rat hepatocytes nor HepG2 cells were distinctly better correlated with human hepatocytes  
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Figure 3-8.  Hierarchical clustering of the drug-cytokine mix hepatotoxicity compendium allows 
comparison of drug- and cytokine-induced hepatotoxicities between different cell systems and with sub-
lethal hepatotoxicities in human hepatocytes. The drug-cytokine mix combinatorial hepatotoxicity 
compendium was fused across all cell systems and assay types into a single data matrix, which was then 
subjected to two-way Pearson clustering (top left; see Chapter 3.2.7 for additional details). First, this 
clustering was used to re-sort a matrix of 192 “experimental” conditions, comprised of combinations of 
three cell systems, two assay types, and five cytokine treatment variables (top right). Second, this clustering 
was used re-sort to a sub-lethal hepatotoxicity data matrix of eight drug conditions and four drug (only)-
induced sub-lethal hepatotoxicities (bottom). The sub-lethal hepatotoxicities (measured by quantitative 
imaging in primary human hepatocytes; see Figure 3-7) are plotted in the bottom heatmap using linear 
color-scales indexed separately to the minimum and maximum observed toxicity value for each assay type. 
(Note that the MtMP and GSH assay scales are inverted compared to Figures 3-7K-L.) Conditions used for 
the large-scale primary human hepatocyte toxicity study (assayed by LDH release; see Figure 3-9) are 
noted: (1) no cytokines and (2) TNF, IL-1α, IL-6, and LPS. Abbreviations: RH, primary rat hepatocytes; 
HH, primary human hepatocytes; G2, HepG2 cells; Cla, clarithromycin; Tel, telithromycin; Nef, 
nefazodone; Tro, trovafloxacin; Nim, nimesulide; Ran, ranitidine; ROS, reactive oxygen species; MtMP, 
mitochondrial membrane potential; GSH, glutathione.  
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in this drug-cytokine data compendium.  This indicated it would be difficult to make 
accurate predictions of drug- and cytokine-induced hepatotoxicities in primary human 
hepatocytes (generally considered as the most predictive cell culture system for 
evaluating acute human hepatotoxicity [123, 135]) from primary rat hepatocyte and/or 
HepG2 data, especially when the comparison is dependent on only a few cytokine 
treatment conditions. 
It has been hypothesized that a conserved mechanism of inflammation-associated 
idiosyncratic toxicity is that sub-lethal hepatocellular injuries (e.g. oxidative stress, GSH 
depletion) induced by idiosyncratic drugs and/or their metabolites sensitize hepatocytes 
to undergo cytokine-stimulated cell death [27].  To investigate this hypothesis for the six 
idiosyncratic drugs in this study, we examined the correlations between the patterns of 
drug-cytokine mix lethal hepatotoxicities across all cell systems and assay types and a set 
of four drug-induced sub-lethal hepatocyte injury measurements.  Drug-induced sub-
lethal hepatocyte injuries were measured in human hepatocytes, in the absence of any 
cytokines, using a high-throughput live-cell microscopy approach [126], which quantifies 
lipid content, reactive oxygen species (ROS), mitochondrial membrane potential (MtMP), 
and glutathione (GSH) depletion (see Figure 3-7).  Nimesulide induced a substantial ROS 
and lipid accumulation and depletion of both MtMP and GSH, in concordance with 
previous reports that it can induce oxidative stress and mitochondrial injury in 
hepatocytes [136].  Clarithromycin induced mild ROS and lipid accumulation and mild 
MtMP depletion.  Nefazodone induced mild lipid accumulation and substantial MtMP 
and GSH depletion, in concordance with previous reports that it depletes GSH and causes 
mitochondrial injury in hepatocytes [137, 138].  Telithromycin and trovafloxacin induced 
mild depletions of MtMP. 
Pearson clustering with regards to the idiosyncratic drugs yielded three groups of 
drug/DMSO backgrounds.  One group contained the DMSO controls and ranitidine, 
which induced only mild MtMP depletion in the sub-lethal assays.  A second group 
contained nefazodone and trovafloxacin, and a third group contained nimesulide, 
telithromycin, and clarithromycin.  The sub-lethal injuries induced by the second group 
of drugs are largely MtMP and GSH depletion and notably absent of ROS accumulation, 
whereas the third group of drugs similarly induced MtMP depletion but notably induced 
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ROS accumulation.  While these correlations are not statistically verifiable due to the 
limited number of drugs and sub-lethal injuries assayed, these comparisons nonetheless 
strongly suggest that drugs that induce similar sub-lethal injuries also make hepatocytes 
susceptible to the induction of apoptosis by similar combinations of cytokine treatments. 
 
3.3.6. Large-scale screen in primary human hepatocytes demonstrates predictive 
utility of cytokine co-treatment synergy model as a tool for identifying idiosyncratic 
hepatotoxic drugs 
To test the drug-cytokine mix hepatotoxicity synergy model as a tool for predicting 
inflammation-associated idiosyncratic drug hepatotoxicity, we assayed drug-cytokine mix 
synergy for 90 drugs in human hepatocytes.  This set of 90 drugs included 53 hepatotoxic 
drugs from DILI classes P1, O1, and P2 and 36 non-hepatotoxic drugs from DILI classes 
O2, N3, N2, and N1 (see Tables 3-1 and 3-3 for additional details).  DILI class P2 is 
substantially comprised of drugs with idiosyncratic hepatotoxicities in humans and 
therefore assumed for analysis purposes here and previously [126] to represent 
idiosyncratic drugs.  The non-hepatotoxic group (DILI O2, N3-N1) is used to provide 
corresponding non-toxic control compounds, although we note that the idiosyncratic 
drugs clarithromycin and ranitidine used in the initial study here are in DILI classes N1 
and N3, respectively.  In this ninety drug screen, comparisons were made by examining 
the differences between the idiosyncratic group (DILI P2) and the non-hepatotoxic group 
(DILI O2, N3-N1) as not all idiosyncratic drugs could be individually paired with 
“comparison” control drugs.  This has the effect of neglecting the idiosyncratic 
hepatotoxicity signature of drugs such as ranitidine in order to provide a simplified 
comparison. 
Due to practical limitations in conducting medium-to-high-throughput screens in 
primary human hepatocytes, we assessed drug-cytokine mix synergy only for a single 
cytokine mix (TNF, IL-1α, IL-6, and LPS), which was equally effective at inducing 
hepatotoxicity synergies across the six idiosyncratic drugs as the full set of cytokine 
mixes in the initial drug-cytokine mix data compendium (see Figure 3-5A, mix noted as 
“2”).  Human hepatocytes were treated with one of 90 drugs, each dosed between 0 and 
150 μM, in the presence or absence of TNF, IL-1α, IL-6, and LPS and assayed for LDH  
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Table 3-3.  Drugs used in the large-scale human hepatocyte study. 
 
Drug name DILI category 
Cmax 
(μM)  Drug name 
DILI 
category 
Cmax 
(μM) 
Acetaminophen P1 75.1  Nimodipine P2 0.13 
Benzbromarone P1 5.79  Fluvoxamine P2 0.12 
Didanosine P1 4.43  Bumetanide P2 0.11 
Demeclocycline HCl P1 3.89  Nortriptyline HCl P2 0.10 
Azathioprine P1 3.19  Mebendazole P2 0.09 
Amiodarone P1 1.86  Busulphan P2 0.07 
Retinoic acid P1 1.13  Estrone P2 0.02 
Albendazole P1 0.91  Norgestrel P2 0.01 
Danazol P1 0.03  Aspirin O2 8.72 
Menadione O1 102  Tacrine O2 0.04 
Cyclophosphamide P2 247  Levofloxacin N3 12.9 
Nimesulide P2 20.5  Erythromycin N3 8.84 
Fluconazole P2 17.7  Cimetidine N3 6.03 
Bromfenac P2 16.4  Ranitidine N3 4.00 
Lomefloxacin P2 12.1  Pioglitazone N3 3.48 
Trovafloxacin P2 11.9  Rosiglitazone N3 1.43 
Trazodone HCl P2 11.0  Glyburide N3 0.94 
Phenacetin P2 9.83  Bupropion HCl N3 0.79 
Diclofenac P2 9.77  Benazepril N3 0.54 
Erythromycin estolate P2 9.49  Amoxapine N3 0.20 
Quinine P2 9.26  Famotidine N3 0.18 
Telithromycin P2 7.30  Maprotiline N3 0.18 
Troglitazone P2 5.27  Amitriptyline HCl N3 0.11 
Chlorzoxazone P2 2.77  Paroxetine N3 0.07 
Captopril P2 2.62  Fluoxetine N3 0.04 
Labetalol P2 2.49  Colchicine N3 0.01 
Bepridil HCl P2 2.34  Moxifloxacin N2 6.39 
Pyrimethamine P2 2.29  Citalopram N2 0.16 
Diethylcarbamazine P2 2.12  Bupivacaine N2 0.14 
Methotrexate P2 1.50  Memantine N2 0.06 
Quinapril P2 1.39  Phenelzine N2 0.05 
Nefazodone P2 1.34  Clarithromycin N1 3.34 
Chlorpromazine P2 1.11  Dexamethasone N1 0.37 
Riluzole P2 1.07  Nadolol N1 0.28 
Tamoxifen P2 1.06  Pindolol N1 0.25 
Hydrochlorothiazide P2 0.95  Pyridostigmine bromide N1 0.25 
Mexiletine HCl P2 0.88  Propranolol N1 0.23 
Methimazole P2 0.86  Clotrimazole N1 0.10 
Nifedipine P2 0.76  Promethazine HCl N1 0.06 
Flutamide P2 0.40  Brompheniramine maleate N1 0.05 
Progesterone P2 0.23  Nalmefene N1 0.04 
Spironolactone P2 0.19  Oxybutynin HCl N1 0.03 
Nomifensine P2 0.19  Loperamide HCl N1 0.01 
Nicardipine HCl P2 0.16  Buspirone N1 0.01 
Clomipramine P2 0.13  TPCA-1 (IKK inhibitor) n.a. unknown 
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Figure 3-9.  (Previous page) Large-scale drug-cytokine mix hepatotoxicity study in primary human 
hepatocytes demonstrates utility of cytokine co-treatment approach for identifying idiosyncratic 
hepatotoxic drugs. Primary human hepatocytes were cultured, treated, and assayed for LDH release (at 24 
hours post-treatment) as described in Chapter 3.2. Ninety drugs (see Table 3-3) were each dosed at seven 
non-zero concentrations (2.5× serial dilutions from a high concentration of 150 μM) in the presence (left) 
or absence (middle) of a cytokine mix containing TNF, IL-1α, IL-6, and LPS. The differential between + 
and - cytokine mix co-treatment for each drug dose was calculated and plotted (right). Note that DILI 
classes P1, O1, and P2 are hepatotoxic, with DILI class P2 is substantially comprised of drugs with 
idiosyncratic hepatotoxicities in humans, and DILI classes O2, N3, N2, and N1 are not or minimally 
hepatotoxic (see Table 3-1). Within each DILI class, drugs are sorted in order of 100*Cmax value (a 
physiologically relevant dosing limit). Drug 100*Cmax values are plotted in an overlayed line plot, with 
values exceeding 150 μM not shown. Individual drug doses that exhibited supra-additive drug-cytokine mix 
synergy (see Chapter 3.2.8 and Table 3-4) at concentrations less than their drug’s 100*Cmax limit are 
highlighted with gray boxes. Drugs with one or more dose exhibiting drug-cytokine mix supra-additive 
toxicity synergy at less than their 100*Cmax concentration are listed in red font. A representative DILI P2 
drug (chlorpromazine) displaying drug-cytokine mix synergy at dosing concentrations less than 100*Cmax is 
shown in the expanded plot at the bottom right (data presented mean ± SEM of two biological samples). 
TPCA-1, a small molecule IKK inhibitor (IKKi), was used (at ten-fold lower concentrations than are noted 
by the axis labels for the other drugs) as a positive control for drug-cytokine mix synergy, as inhibition of 
pro-survival IKK–NF-κB signaling sensitizes hepatocytes to apoptosis induced by TNF [139], but is not 
labeled in red as its Cmax is unknown. 
 
release at 24 hr post-treatment (Figure 3-9).  Supra-additive drug-cytokine synergy was 
assessed with regards to two different methods of defining a physiologically relevant 
dosing limit: (i) using each drug’s own 100*Cmax concentration, or (ii) using multiples 
(33× or 100×) of the median Cmax concentration for all drugs in this study (0.91 μM) as an  
general estimate of physiological exposure limit, which may be a necessary 
approximation if clinical human pharmacokinetic data is unavailable.  For doses less than 
each drug’s own 100*Cmax concentration, drug-cytokine mix synergy was observed for 
the P1 compounds benzbromarone, demeclocycline, azathioprine, amiodarone, retinoic 
acid; the O1 compound menadione; the P2 compounds trovafloxacin, diclofenac, quinine, 
chlorpromazine, riluzole, mexiletine, clomipramine, nortriptyline; and the N1 compound 
clarithromycin (which has reported idiosyncratic hepatotoxicity in humans [31, 132] and 
was used as a test idiosyncratic hepatotoxin in the initial study here).  Among these 
cytokine mix synergy compounds, three of the six overtly hepatotoxic drugs (P1 
compounds benzbromarone and azathioprine and the O1 compound menadione) and two 
of the eight idiosyncratic hepatotoxic drugs (P2 compounds quinine and chlorpromazine) 
also induced significant drug-only hepatotoxicity at doses less than each drug’s own 
100*Cmax concentration (Figure 3-9).  In this data set, drug-only hepatotoxicity was 
defined as greater than two-fold increase in LDH release.  Using this approach to  
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Table 3-4.  Drug-cytokine hepatotoxicity synergies in the large-scale human hepatocyte toxicity study 
evaluated by DILI class and physiological dosing limit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1DILI categories are described in Table 3-1.   
2Hepatotoxicity in this large-scale primary human hepatocyte study was assayed by LDH release (see 
Figure 3-9). Drug-cytokine synergies that were at least two-fold (with respect to the LDH release, reported 
as fold-change compared to the DMSO/no cytokine control condition) greater than the calculated supra-
additive synergy threshold were characterized as synergistic. This “rule-of-thumb” threshold was used 
instead of a supra-additive Student’s t test (see Chapter 3.2.8 and Figure 3-2) as two or three biological 
samples per condition were used due to the screening nature of this large-scale study, thus limiting the 
ability to satisfy statistical significance tests. Drug-cytokine synergy was assessed with regards to two 
different methods of defining a physiologically relevant dosing limit: (i) using each drug’s own 33*Cmax or 
100*Cmax concentration, or (ii) using the median 33*Cmax (30 μM) or 100*Cmax (91 μM) concentration for 
all drugs in this study (as an general estimate of physiological exposure limit). If a drug demonstrated 
cytokine synergy at one or more dosing concentration within the physiological dosing limit applied, it was 
included in the aggregate for its hepatotoxicity class. See Figure 3-9 for a list (those drugs in red font) of 
the drugs that satisfied synergy condition using each drug’s 100*Cmax concentration limit. 
3The statistical significance of the observed number of synergistic drugs in the idiosyncratic hepatotoxic 
class was assessed using a hypergeometric test with a null hypothesis that synergistic drugs would not 
preferentially populate either of the hepatotoxicity groupings. 
 
physiological concentration limit, a significantly larger fraction of the idiosyncratic 
hepatotoxic drugs (8 of 43 = 19%) demonstrated hepatotoxicity synergy with the cytokine 
mix than did the non-hepatotoxic drugs (1 of 36 = 3%; see Table 3-4).  In contrast, using 
100-fold the median Cmax concentration (91 μM) as an general estimate of physiologically 
relevant dosing limit, the idiosyncratic hepatotoxic drugs (9 of 43 = 21%) did not elicit 
more frequent hepatotoxicity synergy then the non-hepatotoxic drugs (7 of 36 = 19%).  
But in using 33-fold the median Cmax concentration (30 μM), the idiosyncratic 
hepatotoxic drugs (7 of 43 = 16%) did elicit more frequent hepatotoxicity synergy then 
the non-hepatotoxic drugs (0 of 36 = 0%). 
  Drugs with one or more dose with cytokine synergy within the applied physiological dosing limit2 
Using each drug’s  
Cmax value 
Using the median  
Cmax value 
Drug hepatotoxicity 
classification by  
DILI categories1 
 
N 
100*Cmax 33*Cmax 100*Cmax 33*Cmax 
Idiosyncratic hepatotoxic 
(DILI P2) 43 8 (19%) 7 (16%) 9 (21%) 7 (16%) 
Not or minimally hepatotoxic 
(DILI O2, N3-N1) 36 1 (3%) 0 (0%) 7 (19%) 0 (0%) 
Hypergeometric test P-value3 0.028 0.011 0.55 0.011 
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This demonstrates that synergistic induction of hepatotoxicity with a cytokine 
mix, even when limited to a single hepatocyte cell system and cytokine mix, can be 
utilized as a predictive tool for evaluating inflammation-associated idiosyncratic drug 
hepatotoxicity.  As implemented here, optimized prediction requires knowledge of the 
drug’s Cmax value, which necessitates human clinical pharmacokinetic data, but a reduced 
set of idiosyncrasies can be predicted with a more conservative estimate of liver exposure 
(33*Cmax rather than 100*Cmax) based on a generalized Cmax estimate calculated from 
many drugs.  Moreover, idiosyncratic hepatotoxic drugs (P2 compounds) largely induce 
drug-cytokine mix synergies in the absence of drug-only hepatotoxicities, which are more 
often evident for synergizing drugs that associated with overt hepatotoxicity (P1 and O1 
compounds).  This dependency on Cmax to optimally calibrate the drug-cytokine mix 
synergy model to distinguish between drugs with idiosyncratic hepatotoxicity and those 
with either no or overt hepatotoxicity is in concert with Paracelsus’ concept that 
“exposure makes a poison”. 
 
3.4. Discussion 
3.4.1. In vitro drug-cytokine mix synergy as a model for inflammation-associated 
idiosyncratic drug hepatotoxicity 
Hepatotoxicity is a major cause of failures in both the clinical and post-approval stages of 
drug development and thus represents a major challenge for the pharmaceutical industry 
[140, 141].  Furthermore, drug hepatotoxicity represents a serious public health problem, 
as it is the leading cause of acute liver failure in the United States [142].  Idiosyncratic 
drug hepatotoxicity -- a hepatotoxicity subset that occurs in a very small fraction of 
human patients (~1 in 10,000) and accounts for ~10% of acute liver failure cases -- is 
poorly predicted by standard preclinical models and in clinical trials and frequently leads 
to post-approval drug failure [27].  Thus, the development and validation of novel 
preclinical tools that demonstrate successful prediction of idiosyncratic drug 
hepatotoxicity is a paramount need for the pharmaceutical industry and the public health.  
Recent findings in LPS-administered rodent models suggest that idiosyncratic drug 
hepatotoxicity can arise when mild drug-induced hepatocellular stresses synergize with 
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inflammatory cytokine signaling to elicit hepatocellular death, but these models lack 
sufficient throughput for preclinical hepatotoxicity screening [26, 27].   
In this work, we develop and evaluate in vitro hepatocyte cell culture models of 
idiosyncratic drug hepatotoxicity, which are more suitable to the high-throughput 
demands of preclinical pharmaceutical screening.  We demonstrate that numerous 
idiosyncratic hepatotoxic drugs, but not comparison non-toxic control compounds, 
synergistically induce death in multiple hepatocyte cell systems when co-administered 
with multi-cytokine mixes associated with LPS-induced liver inflammation (Figure 3-1).  
These drug-cytokine synergies, depending upon the cell system, appear to be both drug 
dose-independent (above some dose threshold; Figures 3-1A,B,G,H,I), matching the 
characteristic that idiosyncratic drug hepatotoxicity is poorly correlated with dose [27], 
and drug-dose dependent (Figures 3-1C,J), agreeing with a recently published report that 
certain idiosyncratic hepatotoxins can exhibit dose-dependent toxicity [143].  In primary 
rat and human hepatocyte cultures in particular, drug-cytokine mix synergies were most 
frequently observed for higher-order (containing four or five cytokines or LPS) cytokine 
mixes (Figure 3-5), whose hepatotoxicity was potentiated in a drug- and cell system-
specific manner by the additive combination of the single-factor effects of TNF, IL-1α, 
and/or LPS (Figure 3-6).  Potentiation of drug-cytokine synergy by TNF, IL-1α, and LPS, 
more so than by IFNγ or IL-6, suggests that intracellular signal transduction pathways 
that are similarly activated by these factors, namely IKK–NF-κB, p38, and JNK, are 
likely critical components of hepatocellular toxicity responses to idiosyncratic drug-
inflammatory cytokine co-exposure. 
 
3.4.2. Drug-induced sub-lethal injury as a sensitizing stress for drug-cytokine 
hepatocellular death synergy 
Idiosyncratic hepatotoxins are hypothesized to induce a diversity of sub-lethal injuries 
that sensitize hepatocytes to inflammatory cytokine-induced cell death [27].  This 
hypothesis is supported by the demonstration that acetaminophen (APAP), at high doses, 
can elicit an idiosyncratic-like hepatotoxicity that is dependent on cytokine signaling as 
part of the innate immune response [27].  At high doses, accumulation of a cytochrome 
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P450-dependent APAP metabolite leads to depletion of GSH in hepatocytes, which is 
known to sensitize hepatocytes to TNF-induced apoptosis [39].  
Here, we implemented hierarchical clustering of a drug-cytokine hepatotoxicity 
data compendium to identify if particular drug-induced sub-lethal injuries sensitize 
hepatocytes to specific combinations of cytokine-induced death (Figure 3-8).  It was 
difficult to discern clear correlations between sub-lethal injuries (measured in human 
hepatocytes) and cytokine synergy patterns (across all three hepatocyte systems) for 
nimesulide, clarithromycin, and nefazodone due to the numerous sub-lethal 
hepatotoxicities induced by these drugs, and thus synergy correlations possibly reflect the 
convolution of multiple sub-lethal injury-cytokine synergy mechanisms.  In contrast, the 
only sub-lethal injury induced by both telithromycin and trovafloxacin that was 
statistically significant was MtMP depletion (Figure 3-7).  In human hepatocytes, 
telithromycin and trovafloxacin elicited markedly similar patterns of cytokine synergy as 
assayed by caspase 3/7 activity and represented through factorial analysis (Figure 3-6).  
For both drugs, cytokine synergy effects were evident, in decreasing magnitude, for LPS 
and IL-1α but not other treatment variables.  This pattern of cytokine synergy effects was 
not shared by any other drugs at 24 hours post-treatment in human hepatocytes.  This 
unique and specific sub-lethal injury-cytokine synergy relationship suggests that drug-
induced mitochondrial injury may sensitize hepatocytes to apoptosis induced by LPS and 
IL-1α, as has been similarly hypothesized for alcoholic hepatitis-induced mitochondrial 
injury in hepatocytes [144]. 
 
3.4.3. Cytokine mix-specific hepatotoxicity synergizes suggest personalized 
administration of idiosyncratic hepatotoxic drugs 
The cytokine mix-specific responses evident in the hepatotoxicity data compendium 
collected here (Figures 3-3 and 3-5) suggest that inflammation-associated idiosyncratic 
drug hepatotoxicities might be avoided by limiting drug treatments to patients that do not 
have plasma cytokine signatures (due to pre-existing inflammatory episodes, for 
example) corresponding to known synergizing inflammatory environments.  Further 
investigation of drug-cytokine mix synergies over across greater number of drug 
compounds and cytokine environments, beyond those  associated with LPS-induced 
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inflammation, would have to be conducted to more thoroughly capture the diversity of 
patient-specific drug-cytokine interactions in humans.  This suggestion of “personalized” 
or “stratified” drug treatment [145] to avoid toxicity would likely be necessitated only for 
drugs for which comparably efficacious compounds are not available and could be 
combined with pharmaco-metabolonomic phenotyping approaches [146] to avoid both 
inflammation- and metabolism-associated idiosyncratic hepatotoxicities in a patient-
specific manner. 
 
3.4.4. Applying drug-cytokine hepatotoxicity synergy model to high-throughput 
pharmaceutical screening 
In a ninety-drug screen in human hepatocytes, ~20% of idiosyncratic hepatotoxins (those 
compounds associated with DILI category P2; see Table 3-1) elicited hepatocellular 
death synergy with a cytokine mix compared to only 3% of non-hepatotoxic drugs when 
using each drug’s 100*Cmax concentration as a physiological dosing limit (Figure 3-9, 
Table 3-4).  Using a generalized physiological dosing limit of 30 μM (based on 33-times 
the median Cmax concentration across all drugs in the study), ~15% of idiosyncratic 
hepatotoxins and none of non-hepatotoxic drugs elicited synergy.  This demonstrates that, 
given drug pharmacokinetic parameters to define a physiologically relevant dosing 
window (ideally individually defined for each drug), in vitro drug-cytokine hepatocellular 
death synergy can be utilized as a much-needed preclinical tool for assessing 
inflammation-associated idiosyncratic drug hepatotoxicity in a high-throughput manner.  
As conducted here, successful prediction of inflammation-associated idiosyncratic drug 
hepatotoxicity based on in vitro hepatocellular models depends on human 
pharmacokinetic data and would be most reasonably used within an iterative preclinical-
clinical toxicity assessment paradigm.  Furthermore, this work demonstrates the utility of 
a physiologically relevant drug dosing limit of 100*Cmax as many non-hepatotoxic drugs 
synergistically induced human hepatocyte death at concentrations exceeding 100*Cmax 
(see Figure 3-9).  Hence the application of a 100*Cmax limit was critical to obtain a low 
false-positive rate. 
At least for a subset of six drugs, this study demonstrates that, in addition to 
human hepatocytes, both rat hepatocytes and HepG2 cells can be useful hepatocellular 
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systems for identifying idiosyncratic drug hepatotoxicities in humans.  This unexpected 
success in using hepatocellular systems more amenable to high-throughput screening 
suggests that cytokine mix synergy screens may be implementable to the demands of 
preclinical drug evaluation.  The utility of rat hepatocytes and HepG2 cells for screening 
inflammation-associated idiosyncratic drug hepatotoxicity will need to be evaluated for a 
greater diversity drug compounds to generate more confidence in their predictive ability.  
We also employed an information theoretic technique to identify a subset of ~15 cytokine 
co-treatment conditions that maintains the “information” contained in the full set of 32 
cytokine conditions across the three hepatocytic cell types (B.D.C., B. M. King, B. Tidor, 
unpublished observations).  Further, we showed that these “informative” condition sets 
can act as better training sets for predicting drug- and cytokine-induced hepatotoxicities 
in primary human hepatocytes from observations in primary rat hepatocytes and HepG2 
cells (B.D.C., B.M.K., B.T., unpublished observations). 
The in vitro cytokine synergy model developed herein and other complementary 
cell culture [126] and animal models [32, 34, 35] offer much-needed preclinical tools for 
the assessment and prediction of idiosyncratic drug hepatotoxicity.  This cytokine 
synergy model would be most useful simply for its ability to identify likely idiosyncratic 
hepatotoxicity phenomenologies, although particular trends in cytokine mix synergy and 
identification of important cytokine factor effects can suggest the underlying mechanistic 
relationships between the drug-induced hepatocellular injuries and possible points of 
signal transduction convergence with inflammatory cytokine signaling.  As such, 
screening drug-cytokine mix hepatotoxicity synergies in cell culture may allow for 
suggestion of more detailed follow-up experiments to parse the mechanisms of particular 
candidate idiosyncratic hepatotoxins to help guide drug compound development. 
This work suggests numerous improvements in the further development of high-
throughput cell culture models used to predict inflammation-associated idiosyncratic drug 
hepatotoxicity.  In the large-scale screen conducted here (Figure 3-9), the limited number 
of cytokine synergies with idiosyncratic hepatotoxins (8 of 43 = 19%) was likely due to 
the use of only one cytokine environment and one hepatocyte cell system and the fact that 
not all DILI P2 drugs have idiosyncratic hepatotoxicities associated with inflammation.  
More accurate prediction of idiosyncratic drug hepatotoxicity could be obtained using a 
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multi-variate predictive model [126] calibrated from expanded measurements of drug-
cytokine synergies at multiple doses (up to the 100*Cmax limit) across multiple hepatocyte 
cell systems, additional cytokine environments, and/or toxicity assays.  Additionally, 
hepatocyte cell culture models, such as three-dimensional microreactor cultures using 
primary rat hepatocytes, that better maintain hepatic drug metabolism and biliary 
transport characteristics over a chronic time-scale (more than 7 days) and are scalable to 
medium-throughput screening demands [8, 10] could be utilized to develop more 
physiologically relevant models of inflammation-associated idiosyncratic drug 
hepatotoxicity.  These systems could better capture the mix of chronic and acute 
hepatocyte responses to drugs and inflammatory cytokines [26].  This is particularly 
motivated by the observation that ranitidine-cytokine mix synergy was delayed compared 
to other compounds and was only observed with high frequency in rat hepatocytes and 
not human hepatocytes or HepG2 cells (Figures 3-1 and 3-3).  These observations suggest 
that a more prolonged mechanism, perhaps requiring significant accumulation of 
ranitidine metabolites that only occurs in the rat hepatocyte cultures, is necessary to 
potentiate ranitidine-cytokine hepatotoxicity synergy and therefore future screening 
would benefit from a hepatocyte cell culture system that maintains in vivo-like 
metabolism over a chronic time-scale. 
Nonetheless, the work presented here validates the use of synergistic induction of 
hepatocellular death by idiosyncratic hepatotoxins and an inflammatory cytokine 
environment as a much-needed in vitro tool for predicting inflammation-associated 
idiosyncratic drug hepatotoxicity and provides a framework for further development of 
such in vitro models to capture a greater complexity of and to elucidate the mechanistic 
basis of inflammation-associated idiosyncratic drug hepatotoxicity.   
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CHAPTER 4 
 
Signaling network modeling of drug- and cytokine-induced 
hepatotoxicity 
 
4.1. Introduction 
4.1.1. Signaling control of inflammatory cytokine-induced idiosyncratic drug 
hepatotoxicity. 
Recent findings in animal [26, 27, 35, 37] and cell culture models (see Chapter 3 and 
[127]) suggest that a subset of idiosyncratic drug hepatotoxicities are caused by 
synergistic interactions with inflammatory cytokine signaling.  These findings have led to 
the proposal of model that suggests idiosyncratic hepatotoxins induce mild hepatocellular 
stresses that synergize with cytokine signaling to elicit hepatocellular death in a context-
specific manner [27], but there is little experimental evidence demonstrating the 
hepatocellular signaling mechanisms underlying this drug-cytokine synergy model. 
Supporting this model is the example of acetaminophen (APAP), which, at high 
doses, can elicit an idiosyncratic-like hepatotoxicity that is dependent on cytokine 
signaling as part of the innate immune response [27].  At high doses, accumulation of a 
cytochrome P450-dependent APAP metabolite leads to depletion of glutathione (GSH) in 
hepatocytes, which is known to sensitize hepatocytes to TNF-induced apoptosis [39].  
Recent findings suggest that APAP toxicity is controlled by JNK pathway signaling 
[147], but it is unclear how the hepatocyte signaling network integrates multiple survival, 
stress, and apoptosis signaling pathways to elicit a death response even for the well-
studied case of APAP toxicity.  Further complicating this model, most idiosyncratic 
hepatotoxins induce a diversity of hepatocellular stresses, ranging from GSH depletion to 
reactive oxygen species (ROS) accumulation to mitochondrial injury, with individual 
compounds inducing unique spectrums of these and other cellular stresses [126].   
The inflammatory cytokines identified as potentiating inflammation-associated 
idiosyncratic drug hepatotoxicity (TNF, IL-1α, IFN-γ, IL-6, and LPS; see Chapter 3.1) 
stimulate a diversity of intracellular signaling pathways related to cell survival, 
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Figure 4-1.  A schematic of the drug- and cytokine-induced hepatocellular death signaling network. 
Cytokines bind to their cognate receptors and activate shared downstream phosphoprotein signaling 
pathways regulating cell death. Drugs lead to various cellular stresses (e.g. ROS accumulation) that are 
integrated into stress-related phosphoprotein signaling (such as the JNK pathway) and mitochondrial 
control of apoptosis. Experimentally measured phosphoproteins and cell death phenotypes are indicated. 
 
survival, stress, and apoptosis (reviewed in [35, 37, 76, 118-120]; see also Chapter 1-4 
and Figure 4-1).  Many of the complex signaling mechanisms activated by these 
individual cytokines are well-studied.  For example, TNF activates numerous signaling 
pathways in hepatocytes including the MEK–ERK, IKK–NF-κB, JNK, and p38–HSP27 
pathways and the caspase cascade (reviewed in [76, 148]), whose integrated activities 
specificity hepatocyte responses to TNF in a context-sensitive manner.  Moreover, 
physiologically relevant growth factor co-stimuli such as insulin can provide activation of 
survival signaling pathways that antagonize cytokine-induced apoptosis [62, 77].  
Similarly, drug-induced hepatocellular stresses can induce activation of many of the 
signaling pathways stimulated by inflammatory cytokine and/or growth factors.  GSH 
depletion can perturb cellular nutrient levels, possibly leading to attenuation of mTOR 
signaling [149, 150], and can alter mitochondrial redox potentials, increasing 
susceptibility to mitochondria-mediated apoptosis [151].  ROS accumulation can activate 
the JNK and p38–HSP27 stress-response signaling pathways [76].  Clearly, investigation 
of the signaling mechanisms governing hepatocyte cell death responses to idiosyncratic 
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hepatotoxins and inflammatory cytokines requires a broad, network-level examination of 
multiple intracellular signaling pathways in a physiologically complex context. 
 
4.1.2. Chapter overview 
 To gain greater mechanistic understanding of the signaling mechanisms 
regulating inflammatory cytokine-associated idiosyncratic drug hepatotoxicity, we 
collected a “cue-signal-response” (CSR) drug- and cytokine-induced hepatotoxicity data 
compendium in primary human hepatocytes.   In this data compendium, human 
hepatocytes were treated with 66 different combinations of 11 “drug” conditions (six 
idiosyncratic hepatotoxins, four corresponding control-paired [or “comparison”] 
compounds, and a DMSO control condition) and six “cytokine” conditions (no cytokine, 
IL-1α, LPS, TNF, IL-6, and a mix containing all three cytokines plus LPS) in the 
presence of insulin to capture a diverse physiological complexity.  This multi-cytokine 
mix was selected based on previous observations that it serves as a highly efficient 
inflammatory environment for the potentiation of idiosyncratic drug hepatotoxicities in 
human hepatocytes (see Figure 3-5A).  We quantitatively assayed the dynamic activation 
of 17 phosphoproteins mechanistically connected to eight key signaling pathways 
(including the MEK–ERK, mTOR–p70 S6K, Akt, IKK–NF-κB, JNK, p38–HSP27, 
STAT3, and STAT6 pathways), cell cycle regulatory pathways, and DNA damage 
pathways that are plausibly induced by these combinations of drug-cytokine co-stimuli 
(see Figure 4-1).  Inspection of this multivariate data set identified multiple signaling 
network features that were reasonably correlated with, but poorly predictive of, the 
measured hepatotoxicities.  So, we subjected the CSR data compendium to orthogonal 
partial-least squares regression (OPLSR), a data-driven modeling approach useful for 
suggesting relationships between intracellular signals and cell phenotypes without 
requiring a priori mechanistic knowledge [46, 62, 64, 66, 68].  An OPLSR model 
suggested that hepatocytes integrate signals from four key pathways -- Akt and mTOR–
p70 S6K signaling, associated with pro-survival function by the model, and MEK–ERK 
and p38–HSP27 signaling, associated with pro-death function by the model -- to specify 
their cell death responses to toxic drug/cytokine conditions.  The model-suggested pro-
death signaling contributions from MEK–ERK and p38–HSP27 signaling were 
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confirmed using small molecule kinase inhibitors.  Furthermore, an OPLSR model 
focused on the four informative signaling pathways (together, comprising a useful and 
simplified signaling network “gauge”) demonstrated quantitatively accurate predictions 
of drug- and cytokine-induced hepatotoxicities in a second human hepatocyte donors and 
qualitatively accurate predictions of the effects of MEK and p38 inhibitor treatments in a 
third human hepatocyte donor.  This signaling network approach suggests that 
inflammatory cytokine-associated idiosyncratic drug hepatotoxicity is governed at the 
hepatocellular level through the integration of four key signaling pathways -- MEK–
ERK, Akt, mTOR–p70 S6K, and p38–HSP27 -- and allows for accurate prediction of 
hepatocellular death responses across human hepatocyte donors and drug/cytokine 
treatment conditions. 
 
4.2. Experimental procedures 
4.2.1. Human hepatocyte cell culture and stimulation 
Primary human hepatocytes were obtained in suspension from CellzDirect (Durham, 
NC).  Human hepatocytes from multiple donors were used in this study, and donor 
identification is noted for each data set.  Detailed donor information is provided in 
Appendix C.  Human hepatocytes were seeded on collagen type I-coated 12- or 96-well 
plates (BD Biosciences) at 1.5×105 cells/cm2 in medium containing 5% FBS (Hyclone) 
and 5 μg/ml insulin (Sigma), as described in Chapter 3.2.3.  One day post-seeding, 
human hepatocytes were overlayed with 0.25 mg/ml Matrigel (BD Biosciences) in 
medium containing insulin but not FBS, as described in Chapter 3.2.3.  One day 
following Matrigel overlay, fresh culture medium containing insulin but not FBS was 
added.  For kinase and autocrine ligand inhibition studies, this medium contained 
inhibitors at 2× final concentration.  One hour later, an equal volume of medium 
containing drugs and/or cytokines at 2× final concentration was added.   
 
4.2.2. Drug, cytokines, and inhibitors 
Hepatotoxic and corresponding “comparison” drugs were obtained from Sigma 
(cimetidine, ranitidine, levofloxacin, buspirone, nefazodone, aspirin, nimesulide, 
chlorpromazine, nortriptyline, clomipramine, mexiletine, and riluzole), Sequoia Research 
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Products (clarithromycin and telithromycin), or Pfizer’s chemical sample bank 
(trovafloxacin).  All drugs were dosed at 100*Cmax concentrations, corresponding to the 
following molecular concentrations: 1.5 mM cimetidine, 142 μM ranitidine, 1.6 mM 
levofloxacin, 770 μM trovafloxacin, 0.46 μM buspirone, 86 μM nefazodone, 552 μM 
aspirin, 2.1 mM nimesulide, 334 μM clarithromycin, 277 μM telithromycin, 111 μM 
chlorpromazine, 10 μM nortriptyline, 13 μM clomipramine, 88 μM mexiletine, and 107 
μM riluzole.  Additional information on the relevance of 100*Cmax dosing concentrations 
and the drug-induced liver injury classifications of these drugs can be found in Chapter 
3.2.2 and Table 3-3, respectively.  All drugs were suspended in 0.25% final DMSO.   
Recombinant human cytokines were obtained from R&D Systems and were used 
at the following concentrations: 100 ng/ml tumor necrosis factor-α (TNF), 20 ng/ml 
interleukin-1α (IL-1α), and 20 ng/ml interleukin-6 (IL-6).  Lipopolysaccharides (LPS) 
serotype 1 from E. coli 0111:B4 (Sigma) was used at 10 μg/ml. 
The MEK kinase inhibitors PD98059, U0126, and MEK inhibitor I were obtained 
from EMD Biosciences (San Diego, CA).  The p38 kinase inhibitors SB202474 (inactive 
control), SB202190 and SB203580 were obtained from EMD Biosciences.  The MEK 
kinase inhibitor PD325901 and p38 kinase inhibitors PHA-460448 (inactive control), SC-
80036A, PF-04334950-00, PHA-666859, and PHA-818637 were obtained from Pfizer’s 
chemical sample bank.  All inhibitors were suspended in 0.1% final DMSO.  To perturb 
autocrine EGFR ligand activity, 5 μg/ml anti-TGF-α neutralizing antibody (R&D 
Systems) or 10 μg/ml c225 monoclonal antibody (a generous gift of H. S. Wiley) were 
used.  To perturb autocrine IL-1 activity, 10 μg/ml recombinant human IL-1ra (R&D 
Systems) was used. 
 
4.2.3. Multiplexed phosphoprotein assays 
Phosphoprotein signaling was quantified using multiplexed bead-based Luminex assays.  
Cells were plated and treated as described above.  Cell lysates were collected at 0 and 20 
minutes and 4, 24, and 48 hours following drug and/or cytokine stimulation.  At the 
desired time point, cells were placed on ice and culture medium was removed.  Matrigel 
overlays were partially dissolved by adding ice cold PBS for 15 minutes at 4°C.  PBS 
was removed and cells were lysed with Phosphoprotein Lysis Buffer (Bio-Rad) for 20 
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minutes at 4°C.  Lysates were collected by scrapping and vigorous pipetting.  Lysates 
were clarified by centrifugation at 16,000g for 15 minutes at 4°C.  Clarified lysates were 
analyzed using a bicinchonicic assay (Pierce) to determine the total protein concentration.  
In each culture plate, a well without cells was maintained, lysed, and analyzed to 
calculate the protein contribution from the Matrigel overlay alone and estimate the 
cellular protein concentration in the other wells.  Bio-Plex bead-based assays (Bio-Rad) 
were used to quantify the following 17 phosphoproteins: p-Akt (Ser473), p-CREB (Ser133), 
p-c-Jun (Ser63), p-GSK-3α/β (Ser21/Ser9), p-IκB-α (Ser32/Ser36), p-IRS-1 (Ser636/Ser639), 
p-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), p-Histone H3 (Ser10), p-HSP27 (Ser78), p-JNK 
(Thr183/Tyr185), p-MEK1 (Ser217/Ser221), p-STAT3 (Ser727), p-STAT6 (Tyr641), p-p38 
(Thr180/Tyr182), p-p53 (Ser15), p-p70 S6 kinase (Thr421/Ser424), and p-p90 RSK 
(Thr359/Ser363).  Bio-Plex assays were conducted per manufacturer’s recommendations on 
a Luminex 200 instrument (Luminex) with protein lysates loaded at 10 μg/well in 
technical duplicate.  Multiple positive control treatments were loaded on each assay plate 
to scale raw fluorescence data to self-consistent relative values.  See Appendix B for 
more details. 
 
4.2.4. Lactate dehydrogenase cell death assay 
At 20 minutes and 4, 24, and 48 hours post-drug and/or cytokine treatment, conditioned 
medium samples were collected to assay lactate dehydrogenase (LDH) release (indicator 
of necrotic and apoptotic cell death) using a CytoTox-ONE Homogeneous Membrane 
Integrity Assay (Promega) according to manufacturer’s recommendations. 
 
4.2.5. Collection and normalization of signal-response data compendia 
We collected a cue-signal-response (CSR) data compendia in human hepatocytes from 
two separate donors.  In the initial data compendium (donor #1), human hepatocytes were 
treated with 66 different combinations of 11 “drug” conditions (six idiosyncratic 
hepatotoxins, four “comparison” compounds, and a DMSO control condition) and six 
“cytokine” conditions (no cytokine, IL-1α, LPS, TNF, IL-6, and a mix containing all 
three cytokines plus LPS).  To broadly measure a diverse set of key phosphoprotein 
activities mechanistically connected to numerous drug- and/or cytokine-induced signaling 
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pathways, we quantitatively assayed the aforementioned 17 phosphoproteins at both early 
(0 and 20 minutes) and delayed time-points (4, 24, and 48 hours) following drug and/or 
cytokine stimulation.  In this initial data compendium, single biological replicates were 
used for both phosphoprotein and LDH assays.  The total number of individual 
phosphoprotein signaling measurements in the initial compendium was 4488 (= 66 
conditions × 17 phosphoproteins × 4 time-points × 1 biological replicate). 
 In the second data compendium (donor #2), human hepatocytes were treated with 
18 different combinations of nine “drug” conditions (three idiosyncratic hepatotoxins 
used in initial compendium, five idiosyncratic hepatotoxins not used in the initial 
compendium, and a DMSO control condition) and two “cytokine” conditions (no 
cytokine and the 3-cytokine/LPS mix).  In this second compendium, quantitative 
phosphoprotein assays were focused on a reduced set of six highly informative signals (p-
MEK1, p-ERK1/2, p-Akt, p-70 S6K, p-p38, p-HSP27).  These phosphoproteins were 
assayed at the same time-points as in the CSR from donor #1, but with some 
drug/cytokine co-treatment conditions (all those containing the DMSO control, 
trovafloxacin, nefazodone, or clarithromycin) also assayed at 1 and 12 hours post-
stimulation.  Biological triplicates were used for both phosphoprotein and LDH assays.  
The total number of individual phosphoprotein signaling measurements in the second 
compendium was 1296 (= 18 conditions × 6 phosphoproteins × 4 time-points × 3 
biological replicates). 
 Phosphoprotein data was fold-change normalized to untreated samples (at 0 
minutes) for each phosphoprotein assay and separately for each hepatocyte donor.  LDH 
release data was fold-change normalized to untreated samples at 48 hours post-drug 
and/or cytokine stimulation separately for each hepatocyte donor. 
 
4.2.6. Metric extraction and scaling 
For each phosphoprotein signaling time-course, two time-dependent signaling “metrics” 
were extracted: (i) the integral, or area-under-the-curve, for the entire time-course, and 
(ii) the average of the late time-points (4-48 hr), reflecting the steady-state signaling level 
[62].  These were added to the four time-points (20 minutes and 4, 24, and 48 hours) to 
yield six signaling metrics for each assayed phosphoprotein.  For each compendia, the 
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signaling metrics from all measured phosphoproteins were then fused into a signaling 
network data matrix (X).  Separately, the toxicity response data were cast into a vector 
(Y), with both X and Y arrayed across all treatment conditions.   In the compendium from 
donor #1, X was a matrix of 66 rows of treatments and 102 columns (= 17 phospho-
proteins × 6 metrics) of signaling metrics, and Y was a vector of 66 rows of treatments 
and single column (LDH release measured at 48 hours).  Before modeling, all columns in 
the signaling data matrix and response vector were separately mean-centered and scaled 
to unit variance to non-dimensionalize different assay measurement dynamic ranges [50].  
In modeling test data sets not present in model training, scaling parameters from the 
training data set were used to scale the test data. 
 
4.2.7. Signal-response modeling through orthogonal partial-least squares regression  
To relate the measured signaling and cell death response data, we assumed a linear 
relationship between the two data sets, such that: 
( ) BXXfY ⋅== , 
where X is the signaling network data matrix, Y is the cell death response vector, and B 
is a vector of regression coefficients that reflect how each phosphoprotein signaling 
metric contributes to cell death.  Framed as such, the signaling matrix X is a block of 
independent variables and the response vector Y is a block of dependent variables.  Since 
the number of signaling metrics (columns of X) exceeds the number of treatment 
conditions (rows of X), an unique solution to this linear regression problem cannot be 
identified.  Thus, we implemented partial least-squares regression (PLSR) to solve this 
regression problem.  Instead of performing the linear regression in the original multi-
dimensional data space, PLSR casts the problem in a principal-component space and 
regresses principal components-based coefficients associated with independent and 
dependent variables [63].  The calculation of principal components-based regression 
coefficients (or, “loadings”) is biased towards those signaling variables that are most 
covariant with the response data and to optimize prediction accuracy of the response data 
in cross-validation. 
We implemented PLSR using the NIPALS algorithm in SIMCA-P software 
(Umetrics, Inc., Kinnelon, NJ) following standard methods [62-64, 152, 153].  All PLSR 
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models were generated using four principal components under standard optimization 
criteria [63].  All calibrated PLSR models were subjected to a principal-component space 
linear transformation by rotating the projection of the single cell death response variable 
completely into the first principal-component, thus yielding an “orthogonal” PLSR 
(OPLSR) model (see Appendix D and [154]), to allow for simplified interpretation of 
model loadings and scores.  Signaling metric model loadings were calculated using the 
mean-centered regression coefficients wa*ca from the a-th OPLSR principal-component 
[62].  Model calibration was conducted using leave-one-out cross-validation, and model 
uncertainties were calculated by jack-knifing [155].  The accuracy of model predictions 
for both training and test data were assessed using the model fitness parameter R2 [50]: 
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where Predictedi is the predicted cell death value of the i-th treatment condition, 
Observedi is the experimentally observed cell death value of the i-th treatment condition, 
and n is the total number of treatment conditions.  This assessment of model fitness 
postulates a one-to-one equivalence between observed and predicted response values, and 
is more stringent than a simple correlation assessment that does not penalize for 
quantitatively inaccurate predictions that are nonetheless qualitatively correlative [153].  
An R2 value of 1 corresponds to a perfect fit between observed and predicted responses.  
An R2 value of 0 corresponds a model break-point [153].  Negative R2 values imply 
highly inaccurate model predictions. 
 To interpret the contributions of various signaling pathways to drug- and/or 
cytokine-induced hepatotoxicity, an initial OPLSR model was trained on the 17-phospho-
protein, 66-condition CSR data compendium from human hepatocyte donor #1, and 
demonstrated good model fitness (R2 = 0.92) of cross-validated predictions.  All models 
were regressed against the LDH release data measured at t = 48 hours, as models of the 
LDH release response at earlier time-points were poorly fit (data not shown). 
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4.2.8. Model reduction 
To identify the relative importance of individual phosphoprotein signaling metrics, the 
information content of each signaling metric was assessed by its variable importance of 
projection (VIP) score [156]: 
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where K is the total number of signaling metrics, wa,k is the weight of the k-th metric for 
principal component a, A is the total number of principal components, and SSa is the sum 
of squares explained by principal component a.  Signaling metrics with a VIP > 1 have 
significant importance in the model and metrics with a VIP << 1 significantly lack unique 
information in the model [50, 156].   
To reduce the initial 17-phosphoprotein model, phosphoproteins and all six of 
their associated signaling metrics were removed from the model step-wise in order of the 
lowest average VIP score across all six metrics.  This model reduction approach yielded a 
set of 4-to-6-phosphoprotein models (R2 = 0.87-0.91) that retained the model fitness of 
the full 17-phosphoprotein model (R2 = 0.92; see Figure 4-5).  The robustness of this 
model reduction approach was examined by testing the ability of a reduced 6-phospho-
protein model, trained on CSR data from human hepatocyte donor #1, to accurately 
predict signal-response relationships in a 18-condition, 6-phosphoprotein CSR data 
compendium collected from human hepatocyte donor #2. 
 
4.2.9. Kinase inhibitor evaluation and selection 
Kinase inhibitors were evaluated for efficacy and toxicity in human hepatocytes (from 
donor #3) over a range of concentrations at seven 8× serial dilution concentrations from 
20 μM (20 μM, 2.5 μM, 0.31 μM, 39 nM, 4.9 nM, 0.61 nM, 76 pM).  To evaluate MEK 
kinase inhibitor efficacy, human hepatocytes were pretreated with inhibitor for one hour 
before treatment with 100 ng/ml TGF-α for 15 minutes and then were assayed for p-
ERK1/2 activation.  To evaluate p38 kinase inhibitor efficacy, human hepatocytes were 
pretreated with inhibitor for one hour before treatment with 100 ng/ml TNF for 15 
 111
minutes and then were assayed for p-HSP27 activation.  To evaluate MEK and p38 
kinase inhibitor toxicity, inhibitors were added at 1× final concentrations in fresh medium 
for 48 hours, then medium samples were assayed for LDH release.  LDH results were 
normalized to wells from the same culture plate lysed in 1% Triton X for 10 minutes, and 
values were reported as % cell death (with the lysed samples assumed to represent 100% 
cell death).  The following kinase inhibitors/concentrations were selected for their potent 
signaling inhibition and minimal toxicity and were used to perturb kinase activities in 
drug- and cytokine co-treatment experiments: 10 μM U0126, 1 μM PD325901, 1 μM 
PHA-666859, and 1 nM PHA-818637. 
 
4.2.10. Model predictions of kinase inhibitor effects on drug- and cytokine-induced 
hepatotoxicity 
To make a priori predictions of kinase inhibitor perturbation of drug- and/or cytokine-
induced hepatocellular death responses, a set of “computationally inhibited” signaling 
time-courses was generated by reducing the activation levels of the specific 
phosphoprotein signaling molecules targeted by the kinase inhibitor of interest.  These 
time courses were generated for the treatment conditions of DMSO ± cytokine mix and 
nortriptyline ± cytokine mix, in the presence or absence of 10 μM U0126, 1 μM 
PD325901, 1 μM PHA-666859, and 1 nM PHA-818637.  To generate the uninhibited 
time-courses, mean values across donor #1 and #2 (DMSO ± cytokine mix) or from 
donor #2 only (nortriptyline ± cytokine mix) were used.  For a phosphoprotein signals 
targeted by an inhibitor, the mean observed level at each time-point was reduced by a 
fraction equivalent to the percent signal reduction observed for that inhibitor in the 
signaling inhibition studies in donor #3 (as in [64, 66]; see Chapter 4.2.9).  For MEK 
inhibitors, the phosphoprotein levels of both MEK and ERK at all time-points were 
reduced by 70% (U0126) and 99% (PD325901), but all other signaling proteins were not 
changed.  For p38 inhibitors, the phosphoprotein levels of both p38 and HSP27 at all 
time-points were reduced by 93% (PHA-666859) and 99.5% (PHA-818637), but all other 
signaling proteins were not changed.  After computationally inhibiting the time-point 
data, the integral and late average metrics were re-calculated.  Predictions of kinase 
inhibitor effects based on these “computationally inhibited” signaling metric sets were 
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generated from two different 6-phosphoprotein OPLSR models (featuring either non- or 
log-scaled LDH release response data) trained on a fused CSR data compendium from 
both donors #1 and #2.  Logarithmic transformation of response data can provide a more 
accurate OPLSR model prediction of low response level observations, especially for non-
uniformly distributed response data sets (B.D.C., unpublished observations).  Prediction 
accuracy was assessed by comparing to experimental observations collected in human 
hepatocytes from donor #4 using the model fitness metric. 
 
4.2.11. Statistical analysis 
Supra-additive drug-cytokine synergy was assessed as described in Chapter 3.2.8.  For 
comparing two individual means, a Student’s t test was used.  All tests were performed at 
a significance level of α = 0.05. 
 
4.3. Results 
4.3.1. Drug and cytokine co-treatments elicit shared regulation of multiple 
phosphoprotein signaling pathways 
We collected a cue-signal-response (CSR) drug- and cytokine-induced hepatotoxicity 
data compendium in primary human hepatocytes to examine the signaling mechanisms 
regulating inflammatory cytokine-associated idiosyncratic drug hepatotoxicity (Figure 4-
2).  Human hepatocytes (donor #1) were treated with 66 different combinations of 11 
“drug” conditions (six idiosyncratic hepatotoxins, four corresponding “comparison” 
compounds, and a DMSO control condition) and six “cytokine” conditions.  Rigorously 
quantitative bead-based phosphoprotein (see Appendix B) and cell death assays were 
utilized to allow for investigation of the quantitative relationships between signaling 
pathway activation and cell death measurements.  Seventeen phosphoproteins, 
mechanistically associated with the MEK–ERK, mTOR–p70 S6K, Akt, IKK–NF-κB, 
JNK, p38–HSP27, STAT3, STAT6, cell cycle regulatory, and DNA damage signaling 
pathways, were measured at both early (0 and 20 minutes) and delayed time-points (4, 
24, and 48 hours) following drug and/or cytokine stimulation to capture a diversity of 
intracellular signaling pathways and dynamics.   
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Figure 4-2.  A cue-signal-response (CSR) drug- and cytokine-induced hepatotoxicity data compendium for 
model training.  Primary human hepatocytes (from donor #1) were cultured, treated, lysed, and assayed for 
phosphoproteins and LDH release as described in Chapter 4.2. Human hepatocytes were treated with 66 
different combinations of 11 “drug” conditions (six idiosyncratic hepatotoxins, four corresponding 
“comparison” compounds, and a DMSO control condition) and six “cytokine” conditions (no cytokine, 20 
ng/ml IL-1α, 10 μg/ml LPS, 100 ng/ml TNF, 20 ng/ml IL-6, and a mix containing all three cytokines plus 
LPS). All drugs were dosed at 100*Cmax concentrations, corresponding to the following molecular 
concentrations: 1.5 mM cimetidine (CIM), 142 μM ranitidine (RAN), 1.6 mM levofloxacin (LEV), 770 μM 
trovafloxacin (TRO), 0.46 μM buspirone (BUS), 86 μM nefazodone (NEF), 552 μM aspirin (ASP), 2.1 mM 
nimesulide (NIM), 334 μM clarithromycin (CLA), and 277 μM telithromycin (TEL). Idiosyncratic 
hepatotoxins (listed in red font) and corresponding “comparison” compounds are placed in vertical 
juxtaposition in the ordering of treatment conditions. (Note: clarithromycin serves as a less, but still 
idiosyncratic hepatotoxic, “comparison” compound to telithromycin.) To broadly measure a diverse set of 
key phosphoproteins mechanistically connected to numerous drug- and/or cytokine-induced signaling 
pathways, we quantitatively assayed the 17 phosphoprotein levels (and LDH release levels) at both early (0 
and 20 minutes) and delayed time-points (4, 24, and 48 hours) following drug and/or cytokine stimulation. 
Single biological replicates were used for both phosphoprotein and LDH assays. The total number of 
individual phosphoprotein signaling measurements in this CSR compendium is 4488 (= 66 conditions × 17 
phosphoproteins × 4 time-points × 1 biological replicate). Phosphoprotein levels were fold-change 
normalized to untreated samples at 0 minutes and are plotted on a log2-scaled colormap to capture both up- 
and down-regulated signaling levels. LDH release data were fold-change normalized to untreated samples 
at 48 hours post-stimulation and are plotted on a linearly-scaled colormap. 
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Figure 4-3.  The most correlative signaling metrics are poorly predictive of the observed hepatotoxicity 
response. In the CSR compendium from donor #1, the single signaling metrics most positively (p-HSP27 at 
t = 4 hr; A) and negatively (p-Akt at t = 24 hr; B) correlated with the observed cell death response (LDH 
release at t = 48 hr) are plotted. One-to-one correlation lines shown for clarity. Pearson correlation 
coefficients (R) are shown in the insets. 
 
Across this CSR compendium (Figure 4-2), it was evident that cytokine-only 
treatments induced early activation of multiple signals, including p-MEK1, p-STAT3, p-
IκB-α, and p-p38, and many toxic drug-only treatments induced a late-phase down-
regulation of certain pro-survival signals (e.g. p-Akt) and sustained activation of some 
stress signals (e.g. p-HSP27).  Moreover, multiple drug-cytokine co-treatments elicited 
synergistic induction of sustained p38–HSP27 signaling.  For the treatment conditions of 
trovafloxacin ± the 3-cytokine/LPS mix, this synergistic induction of sustained p38–
HSP27 pathway signaling was correlated with synergistic induction of cell death, as 
measured by LDH release (Figures 4-2 [donor #1], 4-6B-C [donor #2]).  This paired 
synergy suggested that perhaps a single phosphoprotein signal could be well-correlated 
with the observed cell death responses and yield a highly predictive readout of cell death 
across the entire data compendium.  We then calculated Pearson correlation coefficients 
for the relationship between the observed cell death at 48 hours post-drug/cytokine 
treatment and all 17 phosphoprotein signal levels at each of the four time-points.  Even 
the most positively (p-HSP27 at t = 4 hr, R = 0.78) and negatively (p-Akt at t = 24 hr, R = 
-0.74) correlated single phosphoprotein signaling features were poorly predictive of the 
measured cell death (Figure 4-3).   These poorly predictive individual signaling 
relationships to the measured cell death responses suggested the need for a multivariate 
modeling approach to interpret the signal-response relationships present in this drug- and 
cytokine-induced hepatotoxicity data compendium. 
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4.3.2. Multipathway OPLSR modeling of a cue-signal-response data compendium 
identifies key molecular signals regulating drug- and cytokine-induced 
hepatotoxicity 
To generate a multipathway model relating the observed signaling activities and cell 
death responses, we subjected the initial CSR data compendium to orthogonal partial-
least squares regression (OPLSR), a data-driven modeling approach useful for suggesting 
relationships between intracellular signals and cell phenotypes without requiring a priori 
mechanistic knowledge (see Chapter 4.2.7 and [46, 62, 64, 66, 68]).  The 102-signaling 
metric (17 phosphoproteins × 6 time-dependent metrics) OPLSR model demonstrated 
good model fitness (R2 = 0.92) for cross-validated predictions of the observed cell death 
responses for all 66 drug/cytokine coo-treatment conditions (Figure 4-4A).  An 
examination of the OPLSR model scores projections (Figure 4-4B) demonstrated the 
model’s ability to distinguish between toxic and non-toxic treatment conditions by their 
scores in the first principal component (PC), which represents pro-death model 
contributions.  The second PC of this OPLSR model captures remaining, orthogonal 
variation in the CSR data compendium, but is not used for prediction of the LDH release 
response. 
An examination of OPLSR model loadings (w1*c1; Figures 4-4C, 4-5A) and 
variable importance of projection (VIP) scores (Figures 4-4C, 4-5B) identified four 
signaling pathways (MEK–ERK, Akt, mTOR–p70 S6K, and p38–HSP27) with 
phosphoproteins having informative model contributions at multiple time-points.  
Positive model loadings imply signaling metrics with pro-death contributions, and 
negative model loadings imply pro-survival contributions.  p-ERK1/2, p-p38, and p-
HSP27 were all identified as having significant pro-death contributions from multiple 
metrics, and p-Akt and p-p70 S6K were identified as having significant pro-survival 
contributions from multiple metrics.  For all 17 phosphoprotein signals, the early time-
point (20 min) metrics were uniformly uninformative (as assessed by VIP scores), likely 
due to these signaling activities being similarly activated by cytokines in the both the 
presence and absence of drug co-stimuli causing them to be minimally covariant with the 
measured cell death responses. 
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The distinct importance of these four signaling pathways suggested that many of 
the phosphoproteins in the full CSR data compendium were unnecessary for the model 
predictions and consequently the model could be reduced to a more interpretable set of 
protein signals.  To reduce the complexity of the original 17-phosphoprotein model, 
 
 
 
Figure 4-4.  An OPLSR model trained on the CSR data compendium from human hepatocyte donor #1 
identifies key molecular signals regulating drug- and/or cytokine-induced hepatotoxicity. An OPLSR 
model was trained on the 66-condition CSR data compendium from human hepatocyte donor #1 to relate 
the activities of 102 time-dependent phosphoprotein signaling metrics (17 phosphoproteins × 6 metrics) to 
the observed cell death response (LDH release at t = 48 hr), as described in Chapter 4.2. (A) A correlation 
plot relating the observed and model-predicted LDH release responses for all 66 drug/cytokine co-treatment 
conditions shows good model fitness (R2 = 0.92) [50, 153]. A one-to-one correlation line demonstrating 
perfect model fitness (R2 = 1) is shown for clarity. (B) A scores plot of the OPLSR model demonstrates the 
model’s ability to distinguish between toxic and non-toxic treatment conditions by their scores in the first 
principal component (PC). The second PC of this OPLSR model captures remaining, orthogonal variation 
in the CSR data compendium, but is not used for prediction of the LDH release response. Conditions 
containing idiosyncratic hepatotoxins are highlighted. (C) Examination of OPLSR model loadings and 
variable importance of projection (VIP) scores identifies MEK–ERK, Akt, p70 S6K, and p38–HSP27 as 
key signaling pathways regulating drug/cytokine-induced hepatotoxicity. Positive model loadings (w1*c1) 
contribute to the predicted cell death, whereas negative loadings antagonize the cell death prediction. VIP 
scores identify the relative importance of individual phosphoprotein signaling metrics. Signaling metrics 
with a VIP > 1 have significant importance in the model and metrics with a VIP << 1 significantly lack 
unique information in the model [50, 156]. Note that VIP scores from the early time-point metric (20 min) 
are uniformly uninformative. 
 117
phosphoproteins (and all six of their associated signaling metrics) were removed from the 
model step-wise in order of the lowest average VIP score across all six metrics (Figure 4-
5B-C).  Model fitness was maintained until the top ~4-5 phosphoproteins remained (R2 = 
~0.87-0.91).  Further removal of phosphoproteins resulted in the significant losses in 
model fitness (Figure 4-5C).  This emphasized that an equivalently predictive 
multipathway network model could be generated by focusing on representative 
phosphoproteins from four pathways -- MEK–ERK, Akt, mTOR–p70 S6K, and p38–
HSP27 -- and that these representative phosphoproteins (e.g. p-ERK1/2, p-Akt, p-p70 
S6K, and p-HSP27) could serve as a useful signaling network “gauge” [68], whose 
integrated activities accurately specify hepatocellular death responses to drug and/or 
cytokine stimulation (Figure 4-5E). 
 
4.3.3. A multipathway OPLSR model accurately predicts hepatotoxicity signal-
response relationships across human hepatocyte donors 
To test the utility of this reduced multipathway OPLSR model, we collected a second 
drug- and cytokine-induced CSR hepatotoxicity data compendium containing just six 
phosphoprotein signals (p-MEK1, p-ERK1/2, p-Akt, p-p70 S6K, p-p38, and p-HSP27) 
from the four “network gauge” pathways (Figure 4-6A).  p-MEK1 and p-p38 are likely 
redundant measurements to p-ERK1/2 and p-HSP27, respectively, but were necessary to 
test subsequent model predictions pertaining to the effects of MEK and p38 inhibitors.  In 
this second CSR data compendium, human hepatocytes (donor #2) were treated with 18 
different combinations of nine “drug” conditions (three idiosyncratic hepatotoxins used in 
initial compendium, five idiosyncratic hepatotoxins not used in the initial compendium, 
and a DMSO control condition) and two “cytokine” conditions (no cytokine and the 3-
cytokine/LPS mix). 
An OPLSR model trained on the CSR data compendium from donor #1 but 
limited to signaling metrics from these six “network gauge” phosphoproteins was used to 
predict LDH release responses from signaling data collected in a human hepatocytes from 
donor #2 (Figure 4-7A).  Model predictions of cell death responses from donor #2 were 
inaccurate for both the eight drug/cytokine co-treatment conditions present in the training  
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Figure 4-5.  Reduction of the 17-phosphoprotein OPLSR model identifies equivalently predictive 4-to-6-
phosphoprotein models. (A-B) Model loadings (A) and VIP scores (B) are plotted for all 102 
phosphoprotein signaling metrics, with metrics from p-ERK1/2, p-Akt, p-p70 S6K, and p-HSP27 noted. 
Model loadings and VIP scores are presented as the mean values ± cross-validation standard error, 
calculated by jack-knifing [155]. (C) VIP scores for each phosphoprotein signal are shown, with the 
phosphoproteins ordered by the average VIP scores. VIP scores for the 20-minute signaling metrics were 
omitted from the plot and the calculated average as they were uniformly uninformative (<< 1). In (B) and 
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(C), a line indicating the threshold value of 1 for informative VIP scores is shown for clarity. (D) Model 
fitness sensitivity to the removal of phosphoprotein signaling metrics. Model complexity was reduced by 
either (i) step-wise removal of the bottom average VIP phosphoprotein; (ii) from selection of four (p-
ERK1/2, p-Akt, p-p70 S6K, and p-HSP27) or six (those four plus p-MEK1 and p-p38) specific 
phosphoproteins from the highly informative MEK–ERK, Akt, p70 S6K, and p38–HSP27 signaling 
pathways; or (iii) using an equivalent number of signaling metrics as the four- and six-phosphoprotein 
models (24 and 36 metrics, respectively) but selected as the top VIP score metrics across all 17 
phosphoproteins. Model fitness is maintained under phosphoprotein removal until ~4 phosphoproteins 
remain. (E) A comparison of the cross-validated prediction from a full 17-phosphoprotein model and a 
reduced 4-phosphoprotein (p-ERK1/2, p-Akt, p-p70 S6K, and p-HSP27) model. Both models demonstrate 
good model fitness across all 66 conditions (R2 = 0.92 and 0.89 for 17- and 4-phosphoprotein models, 
respectively). A one-to-one correlation line demonstrating perfect model fitness (R2 = 1) is shown for 
clarity. 
 
 
 
Figure 4-6.  A cue-signal-response (CSR) drug- and cytokine-induced hepatotoxicity data compendium for 
model testing. Primary human hepatocytes (from donor #2) were cultured, treated, lysed, and assayed as 
described in Chapter 4.2. (A) Human hepatocytes were treated with 18 different combinations of nine 
“drug” conditions (three idiosyncratic hepatotoxins used in initial compendium, five idiosyncratic 
hepatotoxins not used in the initial compendium, and a DMSO control condition) and two “cytokine” 
conditions (no cytokine and the 3-cytokine/LPS mix) and were assayed for phosphoprotein signaling and 
LDH release. Idiosyncratic hepatotoxic drugs (listed in red font) were dosed at 100*Cmax concentrations, 
corresponding to the following molecular concentrations: 770 μM trovafloxacin (TRO), , 86 μM 
nefazodone (NEF), 334 μM clarithromycin (CLA), 111 μM chlorpromazine (CHL), 10 μM nortriptyline 
(NOR), 13 μM clomipramine (CLO), 88 μM mexiletine (MEX), and 107 μM riluzole (RIL).  
Phosphoproteins assays were focused on a reduced set of six highly informative signals (p-MEK1, p-
ERK1/2, p-Akt, p-70 S6K, p-p38, p-HSP27). These phosphoproteins and LDH release were assayed at both 
early (0 and 20 minutes) and delayed time-points (4, 24, and 48 hours) following drug and/or cytokine 
stimulation. A subset of drug/cytokine treatment conditions (all those containing the DMSO control, TRO, 
NEF, or CLA) were also assayed at 1 and 12 hours post-stimulation (see panel (B) and data not shown).  
Biological triplicates were used for both phosphoprotein and LDH assays. The total number of individual 
phosphoprotein signaling measurements in this CSR data compendium was 1296 (= 18 conditions × 6 
phosphoproteins × 4 time-points × 3 biological replicates). Phosphoprotein levels were fold-change 
normalized to untreated samples at 0 minutes and are plotted on a log2-scaled colormap to capture both up- 
and down-regulated signaling levels. LDH release data were fold-change normalized to untreated samples 
at 48 hours post-stimulation and are plotted on a linearly-scaled colormap. Note that the colormap scales 
are the same as in Figure 4-2. (B-C) Demonstration of drug-cytokine synergy in the sustained activation of 
p-HSP27 (B) and the induction of cell death (C) under conditions of trovafloxacin ± cytokine mix. Data are 
presented as the mean ± SEM of three biological replicates. 
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Figure 4-7.  (Previous page) A 6-phosphoprotein OPLSR model accurately predicts drug/cytokine 
responses across human hepatocyte donors, but only for drug/cytokine treatments present in the training 
data compendium. An OPLSR model of LDH release (t = 48 hr) was trained on the time-dependent 
signaling metrics from six phosphoproteins (p-MEK1, p-ERK1/2, p-Akt, p-70 S6K, p-p38, p-HSP27) using 
the drug/cytokine-induced hepatotoxicity data compendium from donor #1. This trained model was used to 
predict LDH release responses from the same six phosphoprotein signals collected in human hepatocytes 
from donor #2. The CSR data compendium from donor #2 contained 18 different combinations of nine 
“drug” conditions (three idiosyncratic hepatotoxins used in training compendium, five idiosyncratic 
hepatotoxins not used in the training compendium, and a DMSO control condition) and two “cytokine” 
conditions (no cytokine and the 3-cytokine/LPS mix). (A) A correlation plot relating the observed and 
predicted LDH release responses for all 66 drug/cytokine treatment conditions in the training (donor #1) 
CSR compendium (grey, R2 = 0.89), 8 drug/cytokine treatment conditions from the test (donor #2) CSR 
compendium that were also present in the training data (blue, R2 = -0.62), and 10 drug/cytokine treatment 
conditions from the test (donor #2) CSR compendium that were not present in the training data (red, R2 = -
0.26). Quantitatively accurate model predictions have positive R2 values, negative R2 values imply highly 
inaccurate model predictions, and an R2 value of 0 corresponds a model break-point [153]. A one-to-one 
correlation line demonstrating perfect model fitness (R2 = 1) is shown for clarity. Conditions (nefazodone 
[NEF] ± cytokine mix and mexiletine [MEX] + cytokine mix) with highly inaccurate predictions are noted. 
In (A) and (D), experimental data is presented as mean ± SEM of three biological replicates and the model-
predicted responses are presented as the mean prediction ± cross-validation standard error, calculated by 
jack-knifing [155]. Experimental and prediction uncertainties are not shown for the training data. (B-C) 
Closer inspection of the signaling time-course data reveals conditions with highly inaccurate predictions 
have outlying signaling data. (B) NEF ± cytokine mix conditions in donor #2 induced significant p-HSP27 
signal attenuation at late time-points, which was not observed in the training data or the other test data. (C) 
MEX + cytokine mix condition in donor #2 induced significant p-Akt signal activation at the 24 hour time-
point, which was not observed in the training data or the other test data. In (B) and (C), training and test 
data from non-outlier conditions are presented as mean values (of 1-3 biological replicates) only, test data 
from outlier conditions are presented as the mean ± SEM of three biological replicates, and phosphoprotein 
levels are plotted on a log2-scaled axis. (D) Removal of the outlier drug/cytokine treatment conditions from 
donor #2 demonstrates accurate model predictions. A correlation plot relating observed and predicted LDH 
release responses as in (A) but omitting the outlier drug/cytokine conditions from donor #2. After removal 
of outlier conditions, it is evident that the model demonstrates reasonable fitness in predicting cell death 
responses for test data from conditions present in the training compendium (R2 = 0.56), but is not as 
accurate for predictions of conditions not present in the training compendium (R2 = -0.86). Two test 
conditions (chlorpromazine [CHL] ± cytokine mix) not present in the training compendium but nonetheless 
predicted with quantitative accuracy are noted. 
 
data from donor #1 (R2 = -0.62) and the ten drug/cytokine co-treatment conditions not 
present in the training data (R2 = -0.26; Figure 4-7A).  Further inspection of these 
observation-prediction relationships from donor #2 identified that a small subset of 
treatment conditions (nefazodone ± cytokine mix and mexiletine + cytokine mix) resulted 
in substantially inaccurate predictions that skewed the model prediction fitness 
evaluations.  Inspection of individual phosphoprotein signaling time-courses for these 
conditions revealed signaling activities that were significantly outside of both the model 
training data from donor #1 and the remainder of the test data from donor #2 (Figure 4-
7B-C).  Specifically, the nefazodone ± cytokine mix conditions in donor #2 induced 
significant p-HSP27 signal attenuation at late time-points, which was not observed in the 
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training data or the other test data (Figure 4-7B).  A reduced level of sustained p-HSP27 
activation is interpreted by the model as a reduction in cell death due to late p-HSP27 
metrics having highly positive (pro-death) model loadings (Figure 4-4C).  Consequently, 
the model under-predicted cell death for the nefazodone ± cytokine mix conditions in 
donor #2.  The mexiletine + cytokine mix condition in donor #2 induced significant p-
Akt activation at the 24 hour time-point, which was not observed in the training data or 
the other test data (Figure 4-7C).  An increased level of p-Akt activation at t = 24 hr is 
interpreted by the model as a reduction in cell death due to late p-Akt metrics having 
highly negative (pro-survival) model loadings (Figure 4-4C).  Thus, the model under-
predicted cell death for the mexiletine + cytokine mix conditions in donor #2.  
After removal of these outlier drug/cytokine treatment conditions from donor #2, 
the 6-phosphoprotein OPLSR model trained on data from donor #1 demonstrated 
reasonably accurate predictions of cell death responses for test data from conditions 
present in the training compendium (R2 = 0.56; Figure 4-7D).  The model still generated 
inaccurate predictions of conditions not present in the training compendium (R2 = -0.86), 
although two of the test conditions (chlorpromazine ± cytokine mix) not present in the 
training compendium were nonetheless predicted with quantitative accuracy.  This 
demonstrated that the 6-phosphoprotein OPLSR model can accurately predict 
drug/cytokine responses across human hepatocyte donors, but only for non-outlier 
drug/cytokine treatment present in the training data.  It is possible that other signaling 
pathways, such as JNK, play a more substantial role in integrating hepatocellular 
responses drug-cytokine co-stimulation for some of the drugs, such as clomipramine and 
riluzole, not present in the training set.  Inclusion of these additional pathways in might 
enable more accurate cell death predictions for more varied set of drug/cytokine 
treatment conditions. 
The model’s ability to successfully predict hepatotoxicity signaling-response 
relationships across human hepatocyte donors for similar drug/cytokine conditions 
suggests that hepatocytes from multiple human donors share a “common effector” 
processing function [64].  In human hepatocytes from two different human donors, 
specific drug/cytokine treatment conditions (see clarithromycin + cytokine mix in donors 
#1 and 2; Figure 4-8) can elicit significantly different signaling network activation 
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profiles and induce different levels of cell death but the trained OPLSR model can 
accurately predict the cell death responses from both signaling network activity profiles 
by considering all the time-dependent signaling activity variables across the six measured 
phosphoproteins. 
 
 
 
Figure 4-8.  Common-effector processing mediates donor-specific responses to drug and/or cytokine 
stimulation. Signaling and response data from non-outlier conditions present in both human hepatocyte 
donors is shown as in Figures 4-2 and 4-6. An OPLSR model was trained on the 66-condition, 6-
phosphoprotein CSR data compendium from donor #1, as described in Figure 4-7. This OPLSR model 
generated quantitatively accurate predictions of cell death responses in donor #1 (for the conditions shown 
here, R2 = 0.89 and R [Pearson correlation coefficient] = 0.95) and donor #2 (for the conditions shown 
here, R2 = 0.56 and R = 0.96), even though donor-specific signaling network activation profiles and cell 
death responses were observed under the same drug/cytokine treatments. (Compare clarithromycin [CLA] 
± cytokine mix across the two donors.) The predictive accuracy of this OPLSR model suggests that a 
common-effector processing mechanism (f(x) = y) encompassing the integration of the survival and stress 
signaling network (x) yields quantitatively concerted cell death responses (y) to toxic drug/cytokine 
conditions exists and is shared between hepatocytes from different human donors. 
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Figure 4-9.  MEK–ERK and p38–HSP27 pathways at the confluence of drug/cytokine-induced signaling 
and drug efflux transporter regulation. Interpretations from the OPLSR model of hepatotoxicity suggest 
that the MEK–ERK and p38–HSP27 pathways are activated by drug- and/or cytokine treatments and 
positively regulate the resulting cell death response. Experimentally testing these model interpretations 
must be made with a complex cellular context in mind. Whereas the MEK–ERK pathway is generally 
considered pro-survival through its activation of anti-apoptotic effectors such as Bad [157], the p38–HSP27 
pathway is generally considered pro-apoptotic due to its transcription regulation of effector caspases [17]. 
Both pathways have been implicated in the regulation of the translocation of hepatocyte drug efflux 
transporters, including the bile salt export pump (BSEP) and the conjugate export pump (MRP2), to the bile 
canaliculi (BC). Consequently, inhibitors of the kinase activities of MEK [158] and p38 [159, 160] 
decrease drug efflux transporter translocation and activity, leading to cholestasis upon prolonged 
administration. Possibly due to their inhibition of drug efflux transporter activities or, more likely, in the 
case of MEK–ERK, due to their perturbation of apoptosis regulatory mechanisms, MEK [161, 162] and 
p38 [163] inhibitors elicit liver toxicity some cellular and animals models and clinical investigations. 
Moreover, some hepatotoxic drugs (either directly or through their reactive metabolites) such as 
nefazodone inhibit BSEP and/or MRP2 activities [138], which can induce transient activation of ERK and 
p38 signaling and consequently stimulate additional transporter protein translocation to the BC to enable 
recovery of drug efflux capacity. Additionally, ERK signaling has been associated with controlling the 
release of EGFR autocrine ligands such as TGF-α [107, 164]. Following TNF stimulation, autocrine TGF-α 
is contributes to the subsequent release and pro-apoptotic function of autocrine IL-1 in hepatocytes (see 
Chapter 2 and [77, 129]). Thus, the experimental perturbation of the MEK–ERK and p38–HSP27 pathways 
must be made with careful consideration to their complex, and possibly counter-acting, functions in 
response to drug and/or cytokine stimuli. 
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4.3.4. Kinase inhibition reveals pro-death control of drug- and cytokine-induced 
hepatotoxicity by the MEK–ERK and p38–HSP27 signaling pathways 
The initial 17-phosphoprotein OPLSR model suggested that sustained activation of the 
MEK–ERK and p38–HSP27 signaling pathways positively contributes to drug- and 
cytokine-induced hepatocellular death.  Whereas the p38–HSP27 pathway is generally 
considered pro-apoptotic, agreeing with the model predictions, due to its transcription 
regulation of effector caspases [17], the MEK–ERK pathway is generally considered pro-
survival, counter to the model predictions, in hepatocytes through its activation of anti-
apoptotic effectors such as Bad [157].  Moreover, the MEK–ERK and p38–HSP27 
pathways have complex functions as they are involved in not only apoptosis regulation 
but also are necessary signals for the proper maintenance of hepatocyte drug efflux 
transporters such as BSEP (see Figure 4-9 for additional details).  As such, inhibition of 
MEK or p38 kinase activity can perturb drug efflux transporter availability and function 
[158-160], leading to diminished drug efflux capability and a cholestatic hepatocellular 
phenotype.  And since some MEK [161, 162] and p38 [163] inhibitors elicit liver toxicity 
in cellular and animal models and clinical investigations, we selected MEK and p38 
inhibitors from panel of candidate small molecular inhibitors that were examined for their 
ability to potently inhibit phosphoprotein signaling and to induce minimal toxicity in 
human hepatocytes (from donor #3; Figure 4-10).  The MEK inhibitors U0126 (10 μM; 
Figure 4-10B) and PD325901 (1 μM; Figure 4-10D) potently inhibited TGF-α-induced p-
ERK1/2 activation, elicited minimal toxicity, and were selected for additional studies.  
The p38 inhibitors PHA-666859 (1 μM; Figure 4-10K) and PHA-818637 (1 nM; Figure 
4-10L) potently inhibited TNF-induced p-HSP27 activation, elicited minimal toxicity, 
and were selected for additional studies. 
 These selected MEK and p38 inhibitors were used to evaluate the control of 
MEK–ERK and p38–HSP27 signaling pathways in drug- and cytokine-induced 
hepatotoxicity.  In human hepatocytes (from donor #4) treated with the clomipramine + 
cytokine mix both p38 kinase inhibitors, but neither MEK inhibitors, attenuated the 
observed hepatotoxicity (LDH release measured at t = 24 hr; Figure 4-11B).  In human 
hepatocytes treated with nimesulide + cytokine mix (t = 24 hr; Figure 4-11C), cytokine 
mix alone (t = 48 hr; Figure 4-11D), and nortriptyline + cytokine mix (t = 48 hr; Figure 4- 
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Figure 4-10.  Selection of MEK and p38 kinase inhibitors based on potent signaling inhibition efficacy and 
minimal toxicity in human hepatocytes. MEK (A-D) and p38 (E-L) kinase inhibitors were evaluated for 
efficacy and toxicity in human hepatocytes (from donor #3) over a range of concentrations at seven 8× 
serial dilution concentrations from 20 μM (20 μM, 2.5 μM, 0.31 μM, 39 nM, 4.9 nM, 0.61 nM, 76 pM).   
SB202474 is an inactive control for SB202190 and SB203580.  PHA-460448 is an inactive control for the 
p38 inhibitors in (I) to (L). (A-L) To evaluate MEK and p38 kinase inhibitor toxicity, inhibitors were added 
at 1× final concentrations in fresh medium for 48 hours, then medium samples were assayed for LDH 
release. LDH results were normalized to wells from the same culture plate lysed in 1% Triton X for 10 
minutes, and values were reported as % cell death, with the lysed samples assumed to represent 100% cell 
death. (Note that only 20 μM MEKi-1 elicited significant toxicity.) (A-D) To evaluate MEK kinase 
inhibitor efficacy, human hepatocytes were pretreated with inhibitor for one hour before treatment with 100 
ng/ml TGF-α for 15 minutes and then were assayed for p-ERK1/2 activation. (E-L) To evaluate p38 kinase 
inhibitor efficacy, human hepatocytes were pretreated with inhibitor for one hour before treatment with 100 
ng/ml TNF for 15 minutes and then were assayed for p-HSP27 activation. (A-L) Signaling inhibition IC50 
values were manually estimated from the signaling down-regulation curves by identifying the inhibitor 
concentrations that elicited half-maximal phosphoprotein activation. The following kinase inhibitors/ 
concentrations were selected for their potent signaling inhibition and minimal toxicity and were used to 
perturb kinase activities in drug- and cytokine co-treatment experiments: 10 μM U0126, 1 μM PD325901, 
1 μM PHA-666859, and 1 nM PHA-818637. At these concentrations, these inhibitors yield the following 
reductions in phosphoprotein signaling: U0126, 70% reduction, and PD325901, 99%, for MEK–ERK 
inhibition; and PHA-666859, 93%, and PHA-818637, 99.5%, for p38–HSP27 inhibition. 
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Figure 4-11.  Kinase inhibitor perturbation of MEK and p38 signaling demonstrates their pro-death 
signaling control of drug/cytokine hepatotoxicity synergy. Human hepatocytes (from donor #4) were 
cultured as described in Chapter 4.2. Cells were treated with drugs (13 μM clomipramine [B], 2.1 mM 
nimesulide [C], 10 μM nortriptyline [E], or 0.25% DMSO control [A, D]) ± cytokine mix (20 ng/ml IL-1α, 
10 μg/ml LPS, 100 ng/ml TNF, and 20 ng/ml IL-6). After 24 or 48 hours, conditioned medium samples 
were assayed for LDH release. To inhibit MEK kinase activity, cells were pretreated with 10 μM U0126 or 
1 μM PD325901 one hour before drug/cytokine stimulation.  To inhibit p38 kinase activity, cells were 
pretreated with 1 μM PHA-666859 or 1 nM PHA-818637 one hour before drug/cytokine stimulation. Data 
are presented as the mean ± SEM of eight biological replicates. Drug-cytokine mix co-treatment conditions 
that elicited supra-additive hepatotoxicity synergy, evaluated as described in Chapter 4.2.11, are denoted as 
(*).  Differences between uninhibited and kinase inhibitor pretreatments are labeled as significant (‡) if P < 
0.05 by a Student’s t test. Kinase inhibitor pretreatments did not significantly perturb cell death responses 
in the absence of cytokine mix co-stimulation and thus are not shown. 
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11E), one or both of MEK and p38 kinase inhibitors attenuated the observed 
hepatotoxicities.  These results demonstrate that MEK and p38 signaling both contribute 
to the induction of hepatocellular death across multiple drug/cytokine mix and cytokine 
mix-only treatment conditions, confirming the OPLSR model suggestions. 
 
4.3.5. A multipathway OPLSR model predicts MEK and p38 kinase inhibition 
effects on drug- and cytokine-induced hepatotoxicity with qualitative accuracy 
To further test the utility of the reduced 6-phosphoprotein OPLSR model, we asked if it 
could make accurate a priori predictions of kinase inhibitor perturbations of drug- and/or 
cytokine-induced hepatocellular death.  To generate a test signaling data set, we  
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Figure 4-12.  (Previous page) OPLSR model makes qualitatively accurate predictions of the effects of 
MEK and p38 inhibitors in perturbing drug- and cytokine-induced hepatotoxicity. To make a priori 
predictions of a kinase inhibitor perturbation to a drug- and/or cytokine-induced hepatocellular death 
response, “computationally inhibited” signaling time-courses (based on uninhibited signaling data from 
donors #1 and/or #2) were generated by reducing the activation of the specific phosphoprotein signaling 
molecules targeted by a kinase inhibitor by an amount based on the inhibitor’s experimentally measurement 
signaling inhibition (in samples from donor #3; see Figure 4-10). Signaling proteins from pathways not 
targeted by the kinase inhibitor were left unchanged. These time courses were generated for the treatment 
conditions of DMSO ± cytokine mix and nortriptyline ± cytokine mix, in the presence or absence of 10 μM 
U0126, 1 μM PD325901, 1 μM PHA-666859, and 1 nM PHA-818637. After computationally inhibiting the 
time-point data, the integral and late average metrics were re-calculated, and the resultant computationally-
inhibited signaling metric compendium was used to predict cell death responses from trained OPLSR 
models. See Chapter 4.2.10 for additional details. Model fitness of the predicted inhibitor conditions was 
assessed by comparing to experimental measurements collected in human hepatocytes from donor #4 
(Figure 4-11). Two different 6-phosphoprotein OPLSR models were trained on a fused CSR data 
compendium from both donors #1 and #2.  (A) One model was trained using non-scaled cell death response 
data. Although this OPLSR model demonstrated good model fitness for the training data (R2 = 0.83), it 
poorly predicted the inhibitor test data (R2 = -0.19) and led to significantly under-predicted cell death 
responses. (B-D) A second OPLSR model was generated from the fused training compendium by 
regressing log-scaled cell death response data.  Logarithmic scaling of response data can provide a more 
accurate OPLSR model prediction of low response level observations, especially for non-uniformly 
distributed response data sets (B.D.C., unpublished observations). The log-scaled model demonstrated 
reasonable model fitness for the training data (R2 = 0.79) but only qualitatively accurate predictions of the 
test “computationally inhibited” data (R2 = 0.08). Using a less stringent Pearson correlation metric, the log-
scaled model yielded correlated prediction of the training (R = 0.90) and test inhibition (R = 0.63) data sets. 
In (A) to (D), experimental data are presented as mean ± SEM of eight biological replicates. In (A) and (B), 
model-predicted responses are presented as the mean prediction ± cross-validation standard error, 
calculated by jack-knifing [155], and experimental and prediction uncertainties are not shown for the 
training data. In (A) and (B), a one-to-one correlation line demonstrating perfect model fitness (R2 = 1) is 
shown for clarity. 
 
“computationally inhibited” signaling time-courses for the DMSO ± cytokine mix and 
nortriptyline ± cytokine mix conditions using uninhibited signaling data from donors #1 
and/or #2 and signaling inhibition data from donor #3.  See Chapter 4.2.10 and Figure 4-
12 for additional details.  Model fitness of the predicted inhibitor conditions was assessed 
by comparing to experimental measurements collected in human hepatocytes from donor 
#4 (Figure 4-11).  Two different 6-phosphoprotein OPLSR models were trained on a 
fused CSR data compendium from both donors #1 and #2.  One model was trained using 
non-scaled cell death response data (Figure 4-12A).  Although this OPLSR model 
demonstrated good model fitness for the training data (R2 = 0.83), it poorly predicted the 
inhibitor test data (R2 = -0.19) and led to significantly under-predicted cell death 
responses.  A second OPLSR model was generated from the fused training compendium 
by regressing log-scaled cell death response data (Figure 4-12B-D).  Logarithmic scaling 
of response data can provide a more accurate OPLSR model prediction of low response 
level observations, especially for non-uniformly distributed response data sets (B.D.C., 
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unpublished observations).  The log-scaled model demonstrated reasonable model fitness 
for the training data (R2 = 0.79) but only qualitatively accurate predictions of the test 
inhibitor data (R2 = 0.08).  Using a less stringent Pearson correlation metric, the log-
scaled model generated well-correlated predictions of the training (R = 0.90) and test 
inhibitor (R = 0.63) data sets.  This demonstrates that the reduced 6-phosphoprotein 
OPLSR model is capable of qualitatively accurate predictions of kinase inhibitor 
perturbations to drug- and cytokine-induced hepatotoxicity. 
 
4.4. Discussion 
4.4.1. Inflammatory cytokine-associated drug hepatotoxicity is governed by the 
integrated behavior of multiple intracellular signaling pathways 
Through a data-driven modeling approach, we demonstrated that synergistic induction of 
hepatocellular death by idiosyncratic hepatotoxins and physiologically-relevant 
inflammatory cytokine co-stimuli is governed by the integrated behaviors of multiple 
intracellular signaling pathways.  From an initial set of 17 phosphoproteins from 8 
signaling pathways (MEK–ERK, mTOR–p70 S6K, Akt, IKK–NF-κB, JNK, p38–HSP27, 
STAT3, and STAT6), cell cycle regulation, and DNA damage signaling, we identified a 
subset four key signaling pathways that were highly informative to an orthogonal least-
squares regression model calibrated on a drug/cytokine-induced data compendium 
consisting of combinations of 10 drug and 6 cytokine treatments.  This informative subset 
contained two pathways with model-assigned pro-survival  functions -- Akt and mTOR–
p70 S6K, in agreement with their well-documented survival signaling roles [149, 165] -- 
and two pathways with model-assigned pro-death functions -- MEK–ERK and p38–
HSP27, counter to ERK’s canonical role as contributing to survival signaling [157] but in 
agreement with p38’s apoptotic signaling role [17].  Together, these four signaling 
pathways represent a useful “network gauge” [68] capturing the balance between survival 
and death signaling in drug- and cytokine-treated hepatocytes.  Much effort has been 
focused on multivariate analyses of gene expression data to predict overt drug 
hepatotoxicity [166] and inflammation-associated idiosyncratic drug hepatotoxicity 
[167], but little attention has been focused on phosphoproteomic-based prediction models 
of liver toxicity.  This work demonstrates that quantitatively predictive models of drug- 
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and cytokine-induced toxicity in human hepatocyte cultures can be generated using as 
few as four phosphoprotein signals.  Furthermore, it shows that hepatotoxicity can be 
thought of in terms of a “network toxicity”, in which the integrated behavior of multiple 
hepatocellular signaling pathways should be considered in evaluating the hepatotoxicity 
of a given treatment condition (see Figure 4-13). 
 
 
 
Figure 4-13.  Inflammatory cytokine-associated idiosyncratic drug hepatotoxicity as a “network toxicity”.  
The multipathway modeling approach presented here suggests that an integration of multiple intracellular 
signaling pathway -- namely the MEK–ERK, mTOR–p70 S6K, Akt, and p38–HSP27 pathways -- activities 
is necessary for hepatocytes to specify death responses to hepatotoxic drug/cytokine co-treatment 
conditions. This provides motivation of the network-level consideration of multiple survival, stress, and 
apoptosis signaling pathways in evaluating the hepatotoxicity mechanisms of context-dependent 
hepatotoxic drugs.  
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4.4.2. MEK–ERK and p38–HSP27 as pro-death signaling pathways in hepatocytes 
Interpretations from the OPLSR model of hepatotoxicity suggested that the MEK–ERK 
and p38–HSP27 pathways are activated by drug- and/or cytokine treatments and 
positively regulate the resulting cell death response.  In follow up experiments, the 
model-suggested pro-death signaling contributions were confirmed using small molecule 
MEK and p38 kinase inhibitors for a select set of drug/cytokine mix synergy conditions.   
Both the MEK–ERK and p38–HSP27 pathways operate at the confluence of 
drug/cytokine-induced signaling and drug efflux transporter regulation (Figure 4-9).  
Both pathways have been implicated in the regulation of the translocation of hepatocyte 
drug efflux transporters, including the bile salt export pump (BSEP) and the conjugate 
export pump (MRP2), to the bile canaliculi (BC).  Consequently, inhibitors of the kinase 
activities of MEK [158] and p38 [159, 160] decrease drug efflux transporter translocation 
and activity, leading to cholestasis upon prolonged administration.   Possibly due to their 
inhibition of drug efflux transporter activities or more likely, in the case of MEK–ERK, 
due to their perturbation of apoptosis regulatory mechanisms, some MEK [161, 162] and 
p38 [163] inhibitors elicit liver toxicity some cellular and animals models and clinical 
investigations.  Moreover, some hepatotoxic drugs (either directly or through their 
reactive metabolites) such as nefazodone inhibit BSEP and/or MRP2 activities [138], 
which can induce transient activation of ERK and p38 signaling and consequently 
stimulate additional transporter protein translocation to the BC to enable recovery of drug 
efflux capacity. 
Still, it is unclear (and not demonstrated in this work), how ERK signaling might 
potentiate a death response to toxic drug and cytokine co-stimuli conditions.  One 
possibility is through ERK’s regulation of protein phosphatases [168] that may act to 
attenuate signaling in orthogonal, pro-survival pathways.  Although these protein 
phosphatases largely act to dephosphorylate ERK itself and the pro-stress/death kinases 
JNK and p38 [168], they operate within complex, multi-layered feedback loops [169] that 
may act, in net, to serve a pro-apoptotic function.  Additionally, ERK signaling has been 
associated with controlling the release of EGFR autocrine ligands such as TGF-α [107, 
164].  Following TNF stimulation, autocrine TGF-α is contributes to the subsequent 
release and pro-apoptotic function of autocrine IL-1 in hepatocytes (see Chapter 2 and 
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[77, 129]).  Thus, it is possible that drug- and/or cytokine-induced ERK activation leads 
to the release and pro-death activity of autocrine IL-1 ligands.  We preliminarily 
investigated this possible mechanism (see Appendix E), but did not observe any drug-
cytokine cell death synergies controlled by autocrine TGF-α or IL-1 activities.  
Additional investigations in the role of these autocrine ligands under a more well-selected 
set of drug/cytokine treatment conditions may prove fruitful. 
 
4.4.3. Hepatotoxicity predictions across human hepatocyte donors via OPLSR 
modeling 
An OPLSR model using data from six phosphoproteins from the four informative 
“network gauge” pathways demonstrated accurate predictions of hepatotoxicities induced 
by drug/cytokine treatments across two human donors, but only for non-outlier 
drug/cytokine treatments present in the training data.  The model’s ability to successfully 
predict hepatotoxicity signaling-response relationships across human hepatocyte donors 
for similar drug/cytokine conditions suggests that hepatocytes from multiple human 
donors share a “common effector” processing function [64].   This common effector 
processing function is captured in the model regression coefficients and allows for 
quantitatively accurate predictions of donor-specific cell death responses based on donor-
specific signaling network activation (see Figure 4-8).  To generate a model with more 
robust prediction accuracies in additional human hepatocyte donors, especially for 
hepatotoxicity conditions not present in the model training, it is likely that additional 
phosphoprotein signaling pathways, such as the stress- and cytokine-induced JNK 
pathway, will have to be included in the model and the model will have to be trained 
under an even more diverse set of drug/cytokine-conditions.  Increased model utility 
could also be demonstrated by showing that this “common effector” processing function 
is shared across hepatocytic cell systems, such as between primary rat hepatocytes and 
primary human hepatocytes.  If so, this would allow for robust model training in more 
readily available cell systems. 
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4.4.4. Implementation of multipathway modeling in more physiologically relevant 
hepatotoxicity models 
As discussed in Chapter 3.4.4, in vitro studies of drug-cytokine hepatotoxicity 
relationships will likely be benefited by the use of tissue-engineered hepatocyte cell 
culture systems that allow for prolonged maintenance of differentiated hepatocellular 
function and are assessable in reasonably high-throughput manner.  This work presents 
an example of the utility of large-scale cue-signal-response data compendia modeling to 
identify salient phosphoprotein signaling mechanisms governing drug- and cytokine-
induced hepatotoxicities in standard Matrigel-overlay cultures of primary human 
hepatocytes.  Considering the future directions of in vitro hepatotoxicity evaluations 
towards more physiologically relevant tissue-engineered culture systems, our work 
motivates additional efforts to bring the tools and techniques of “systems”-level biology 
to bare on the challenges of investigating physiologically-complex in vitro tissue models.  
This leads to a discussion in Chapter 5.2 how such systems biology approaches might be 
more fully implemented in microenvironmentally complex tissue-engineered culture 
systems.  
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CHAPTER 5 
 
Future directions 
 
5.1. Assaying autocrine signaling in in vivo biology 
In Chapter 2, we demonstrated that hepatocyte responses to TNF are regulated by an 
inducible, coupled, and self-antagonizing TGF-α–IL-1α/β–IL-1ra autocrine cascade that 
contributes to multiple intracellular signaling pathways that govern both hepatocyte 
proliferation and apoptosis.  This autocrine cascade promotes both TNF-induced 
apoptosis in hepatocytes infected with an adenoviral vector and TNF-induced 
proliferation in the absence of viral infection.  These and other recent findings illustrate 
the integral role of autocrine factors in hepatocyte proliferation, apoptosis, survival [114], 
and transformation [88] responses to exogenous cytokine stimuli and implicate diverse 
autocrine signaling connections between cytotoxic, inflammatory, and mitogenic ligands 
in hepatocytes.  Further development of animal models and quantitative in vivo signaling 
tools will be critical to parse the complex autocrine and paracrine signaling mechanisms 
regulating autocrine signaling in hepatocytes and other liver cell types in vivo and to 
validate any therapeutic interventions directed towards the autocrine control mechanisms.  
More generally, such tools would useful to interrogate aberrant autocrine signaling 
mechanisms related to human disease and cancer [170].  This section discusses the 
motivation for and application of non-invasive molecular imaging tools to the study of in 
vivo autocrine signal transduction. 
An increasing array of molecular imaging tools are available to interrogate the in 
vivo activities of specific signaling molecules.  These molecular imaging tools are useful 
not only for use in experimental animal models but also for improved diagnostics in 
human patients.  Ideally, the study of in vivo signal transduction would focus on 
informative signaling molecules governing the key cellular behaviors, such as the 
survival–death decision process.  Amongst these key signaling molecules are a series of 
intracellular kinases, such as Akt and ERK, that serve as signaling hubs that are activated 
by a variety of growth factor and matrix stimulatory cues and promote cell survival and 
migration (see Chapter 4).  A number of molecular imaging methods have been validated 
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to study the activities of these kinases in living cells and animals.  These include 
bioluminescence and fluorescence approaches requiring stably transfected constructs that 
are predominantly activated by the activity of a kinase enzyme of interest through its 
phosphorylation of a consensus peptide sequence present on the expressed peptide [171-
173].  Unfortunately, these methods require either the intracellular delivery of the kinase-
activated peptide sequence or transfection with a vector expressing this peptide; both 
having limited potential to serve as a noninvasive molecular imaging platform for 
imaging cellular signal transduction in human subjects.  Consequently, noninvasive 
molecular imaging approaches to assess in vivo signal transduction have, to date,  focused 
on probing cells via their expression of cell surface receptors of growth factor or adhesion 
ligands associated with disease or cancer.  Amongst these probed receptors are those of 
the ErbB family of receptor tyrosine kinases, whose dysregulated signaling are implicated 
in various mechanisms of cancer progression [174] and whose activities are implicitly 
involved in the TNF–TGF-α–IL-1–IL-1ra autocrine cascade examined in Chapter 2. 
The ligands for EGFR and other ErbB receptors are expressed as membrane-
bound peptides that are proteolytically cleaved for release and eventual receptor binding.  
EGFR ligands are cleaved and released by members of the ADAM family of proteases 
with EGF processed by ADAM10 and TGF-α, HB-EGF, and amphiregulin (and also the 
inflammatory cytokine TNF) processed by ADAM17.  These proteases recognize and 
cleave the transmembrane peptide precursors to the mature ligands at conserved ~15-20 
amino acid sequences in their ectodomain regions [175].  The activity of ADAM 
proteases is controlled by phosphorylation of their intracellular domains, which is 
mediated by ERK and p38 kinase signaling [176].  Consequently, ADAM proteases act in 
part of a positive feedback loop between EGFR stimulation, ERK/p38 activation, and 
EGFR ligand release [177].  As such, ADAM10/17 proteases can serve as extracellular 
readouts of EGFR activity and its downstream signaling.  The release and autocrine 
signaling of the EGFR ligands TGF-α and amphiregulin are activated by G-couple 
protein receptor signaling, the cytokines IL-6 and TNF, and also EGFR ligands 
themselves.  The development of molecular imaging tools to assay autocrine ligand 
production (namely for EGFR and IL-1R ligands) will be an important step for providing 
quantitative assessment of multiple signal transduction pathways in vivo.  Since autocrine 
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ligands are released into circulation in only negligible quantities and receptor expression 
levels do not accurately reflect their signaling activity, the most direct and tractable target 
of noninvasive molecular imaging probes of autocrine ligand production is the activity of 
the transmembrane proteases (such as ADAM17 and ICE) that regulate their release; 
moreover, the development of multiplexible probes will critical to investigate the 
complex, inter-related autocrine signaling mechanisms.   
Initial efforts to develop multiplexible autocrine ligand protease-dependent optical 
imaging probes could focus on the proteases ADAM10 (involved in release of EGF), 
ADAM17 (involved in release of TGF-α, amphiregulin, etc.), and ICE (as known as 
caspase-1; involved in release of IL-1β).  Numerous classes of extracellular proteases 
have been targeted for activity-based optical imaging probes including calpains [178], 
cathepsins [179], MMP’s [180], and caspases [181], but ICE is the only autocrine ligand 
protease that has been previously assayed by molecular imaging [182].  To 
simultaneously interrogate these three autocrine ligand proteases, three multiplexible 
optical imaging probes could be developed: two quenched near-IR peptide-based sensors, 
each containing an NIR emitter (Cy5.5 or AF750), a NIR absorber, and protease-selective 
sequence encoding the consensus cleavage sequence for ADAM10 or ADAM17, and one 
bioluminescence sensor, whose luciferase activity is dependent on peptide cleavage by 
ICE.  These three multiplexed probes could be imaged by multichannel NIRF and would 
have some ability to be imaged in deep tissues of small animals.  The multiplexing ability 
of these probes would have to be validated in vitro using recombinant proteases and cell 
lines expressing each of the proteases (e.g. the breast cancer cell line T4-2).  
Additionally, the specificity of these probes would have to be examined using scrambled 
protease-cleavage sequences and improved specificity from consensus cleavage 
sequences could be obtained by sequence evolution strategies.  Then, these multiplexed 
probes could be evaluated in xenograft models [183], in which they could be used to 
probe not only autocrine protease activity in various stages of cancer progression but also 
be used to directly assay the efficacy of proposed anti-cancer therapies such as autocrine 
ligand protease small molecule inhibitors (e.g. TAPI-2 for ADAM10/17 and Z-VAD-
FMK for ICE) or siRNA.  These studies could be used to parse the mechanistic 
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relationships between autocrine EGFR and IL-1R signaling and cancer progression in 
xenografts and models of liver, colon, and breast cancer. 
In general, molecular imaging probes of autocrine ligand protease activities offer 
the opportunity to assay cell signal transduction via extracellularly accessible proteases 
and could be implemented in a multiplexible and noninvasive manner.  In the future, 
these probes could provide early detection of aberrant autocrine signaling mechanisms 
related to cancer and thus improve disease diagnosis.  More immediately, they will serve 
as a much-needed tool set for interrogating the role of autocrine ligand signaling in 
experiment animal models and generate new insights to its roles in tissue homeostasis 
and pathophysiology.  The improvements to multiplex nature of these probes could bring 
systems biology approaches to noninvasive molecular imaging in whole animals through 
the simultaneous and repeatable quantitative assessment of multiple signal transduction 
pathways and its ability inform interpretive and predictive multivariate models of in vivo 
signal transduction. 
 
5.2. Systems biology approaches for tissue engineering 
As discussed in Chapters 3.4.4 and 4.4.4, in vitro studies of drug-cytokine hepatotoxicity 
relationships will likely be benefited by the use of tissue-engineered hepatocyte cell 
culture systems that allow for prolonged maintenance of differentiated hepatocellular 
function and are assessable in reasonably high-throughput manner.  The findings in 
Chapter 4 present an example of the utility of large-scale cue-signal-response data 
compendia modeling to identify salient phosphoprotein signaling mechanisms governing 
drug- and cytokine-induced hepatotoxicities in primary human hepatocytes.  Considering 
the future directions of in vitro hepatotoxicity evaluations (towards more physiologically 
relevant tissue-engineered culture systems), our work motivates additional efforts to 
bring the tools and techniques of “systems”-level biology to bare on the challenges of 
investigating physiologically-complex in vitro tissue models.  This section contains a 
discussion how such systems biology approaches might be more fully implemented in 
microenvironmentally complex tissue-engineered culture systems.  
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5.2.1. Tissue engineering 
Tissue engineering is a biotechnology centered on developing materials, scaffolds, or 
devices that provide biochemical and biophysical cues to facilitate cell survival, 
proliferation, differentiation, and organization into functional three-dimensional (3D) 
tissues [184].  The field of tissue engineering began decades ago with a focus on in vivo 
therapeutic constructs, but has progressed to now include a substantial emphasis on the 
likely greater impact of providing more effective experimental systems for studying 
complex human tissue physiology and pathophysiology in vitro [185].  This direction 
emerged in part because animal models fail to capture many crucial facets of human 
physiology, notably in the areas of tissue-specific transcriptional regulation [186], drug-
induced liver toxicity [8], pathogenic infection, host immune responses, and cancer [187, 
188].  Further, though human cells cultured in standard formats can be adapted to high-
throughput assays, most scalable cell cultures lack physiologically relevant 
microenvironmental stimuli of native tissues.  Engineered tissues built with human cells 
are thus being developed for a range of application areas, including hepatic drug 
metabolism and toxicity [8, 189, 190], mammary gland morphogenesis and oncogenesis 
[191, 192], lymphoid tissue neogenesis [193, 194], and stem cell differentiation [195], 
and offer promise for scaling to the data collection demands of high-throughput screening 
and systems biology. 
 In tissues, individual cells are stimulated by a diverse set of microenvironmental 
cues that arise from adhesion to extracellular matrix (ECM) components, mechanical 
forces, and soluble signaling factors from adjacent and distant cells [185].  Together, 
these cues activate a system of cell signaling pathways whose integrated operation 
regulates cell behavioral phenotypes [196].  Resultant cell behaviors are dependent not 
only on which microenvironmental cues are present, but also on their quantitative 
amounts, spatial arrangements, and temporal sequences.  A central challenge in tissue 
engineering is to elicit and maintain desired cell behaviors through externally-applied and 
-induced chemical signals and mechanical forces in a predictable fashion.  A tremendous 
diversity of tools – including biomaterials, bioreactors, and microfabricated devices – 
have been developed to manipulate tissue microenvironments [185, 197].  Design 
principles for deploying these tools are likewise emerging, but they are primarily aimed 
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at relating the magnitude of select external cues directly to cell phenotypic behaviors 
through quantitative analysis of molecular diffusion, convection, reaction, binding, and 
consumption [185, 198].  In increasingly complex engineered microenvironments, 
detailed understanding of how the multitude of cell signaling pathways process various 
microenvironmental cues to govern their behaviors will require application of systems-
level approaches.  To this end, systems biology offers a powerful new tool for the design 
and analysis of engineered tissues. 
This discussion focuses on molecular-level models that attempt to relate 
microenvironment stimuli to intracellular signal transduction pathways and their 
regulation of cellular behavioral responses.  (For discussion of systems-level modeling of 
transcription and metabolism, see references [45, 199].)  Although some promising 
systems-level studies [195, 200-202] have been examined in contexts that capture some 
of the physiological complexity of native tissues, systems-level cell signaling-response 
measurements and models, to date, have been largely implemented in simple, 
“prototypical” experimental contexts. Consequently, we focus on how systems biology 
might be more fully integrated into the design and analysis of engineered tissues. 
 
5.2.2. Fusing tissue engineering and multivariate measurement methods 
Systems-level models require experimental data of activities of multiple cell signaling 
molecules and behavioral phenotypes across a diverse combination of treatments, 
perturbations, and time points.  Accordingly, they require cell culture systems that are 
both addressable in a high-throughput manner and amenable to multivariate measurement 
methods.  Recent advances offer promise for parallelizing the culture of 
microenvironmentally complex engineered tissues (in so-called “multicellular arrays” or 
“tissue arrays”) sufficient to meet the data demands of systems biology.  Culture arrays 
have risen out of the desire to screen phenotypes of multicellular structures in a high-
throughput manner, and have been applied to drug discovery [203] and toxicology [190] 
and combinatorial approaches to directing and maintaining cell differentiation [202, 204-
206].  Such combinatorial screens of cell differentiation have provided unexpected 
insights into relationships between multiple microenvironmental cues [205] (e.g. printed 
ECM ligands) or intracellular signals [65, 202] and the maintenance of differentiated 
 141
phenotypes through multiparameter analyses.  (Note that we refer to culture arrays with 
~102-103 cells per spot or well as “tissue microarrays” and those with ~105-106 cells per 
sample well as “multiwell-format tissue arrays”.)   
 We emphasize that systems biology models to date have focused on responses to 
“acute”, bolus administration of cytokines and growth factors and thus have inferred 
substantial predictive significance to the transient signals and derived time course metrics 
immediately following receptor activation [50].  However, in tissue engineered constructs 
as in physiological contexts, most cell behaviors more likely are governed by longer 
time-scale stimuli, under more “chronic”, quasi-steady-state conditions.  There might 
indeed be significant differences in relationships between cues, signals, and responses for 
chronic as opposed to acute cue treatment, as in a recent report of important 
pathophysiological differences in 2D mammary epithelial migration by autocrine ligands 
or bolus stimulation from exogenously-added ligand [107]. 
  
5.2.3. Tissue microarrays 
Efforts in developing tissue microarrays have been focused on validating consistency of 
cellular phenotypes and assays such as drug-induced hepatocyte toxicity [190, 207], stem 
cell differentiation [204], and epithelial tissue organization [208, 209], and have not been 
used to systematically examine cue- or signal-response relationships.  A tissue microarray 
system well-suited for systems biology approaches is that of mammary epithelial cells in 
microprinted Matrigel cultures [209].  Matrigel culture of mammary epithelial cells 
fosters the establishment of 3D multicellular structures that resemble in vivo mammary 
gland acini, with the development epithelial cell structures that resemble either normal or 
cancerous mammary acini depending on a well-documented variety of both 
microenvironmental cues (such as matrix mechanical stiffness and composition and 
growth factor stimulation) and oncogenic perturbations [191, 192, 210, 211].  As of yet, 
tissue microarrays have not been adapted to allow inclusion of ECM components with a 
combinatorial complexity matching that used in the 2D microprinting methods [205] 
which will be necessary for systematic investigation of cellular cue-signal-response 
relationships. 
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 Although tissue microarrays could be scaled to be amenable to lysate-based 
measurements (requiring ~105 cells), they are nonetheless appropriate for systems 
biology approaches, such as Bayesian network inference, that are based on data from 
single cells or small populations of cells examined over a multitude of conditions.  
Critical will be the adaption of single-cell multivariate measurement techniques of flow 
and image cytometry for use in 3D engineered tissues.  Multicolor flow cytometry for 
quantifying multiple phosphoproteins has been carefully validated [55] and implemented 
[56, 212] for non-adherent cells but not adherent cells.  Multicolor flow cytometry in 
adherent cells, especially from intact 3D tissues, is a significant challenge as single-cell 
isolation methods can elicit stress-related signaling themselves and thus disturb signaling 
network states.  Further, prolonged isolation requirements could restrict the ability to 
measure the highly-informative phosphorylation events that follow within minutes of cell 
stimulation.  In contrast, image cytometry does not require isolation and permits for 
immediate cell fixation, allowing for sufficient temporal resolution to measure immediate 
phosphorylation events.  Instead, it is currently limited in its ability to include more than 
~4 simultaneous single-cell measurements due technical constraints [58].  Multicolor 3D 
imaging (so-called “tissue cytometry” [57]) using confocal microscopy is not yet 
sufficiently high-throughput to capture multivariate single-cell data across hundreds of 
tissue samples in an automated fashion.  Improvements in 3D imaging with respect to 
these limitations could make it a highly attractive approach for system-level, single-cell 
data acquisition, especially in the context of engineered tissues, such as immunological 
synapse arrays [213], whose cellular behaviors are dependent on microscale patterning of 
stimulatory cues thus necessitate spatially-resolved single-cell data. 
 Immunofluorescence methods, such as in-cell westerns, which are reasonably 
high-throughput but not strictly multiplexible, could be used to measure phosphoprotein 
levels or cell phenotypes in small populations of cells (~102-103) within tissue 
microarrays.  In-cell western measurements of arrayed tissues over a large combination 
of treatment conditions, assay targets, and, likely, sample replicates could yield a data set 
sufficient for Bayesian models.  As in-cell western measurements are not multiplexible, 
multivariate data sets will require assembly from multiple independent samples of cells, 
thus obscuring the single-cell covariations of signaling activities that are particularly 
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informative in Bayesian models [56].  Consequently, a substantial set of 
microenvironmental stimuli combinations (~100) might be required for accurate 
Bayesian network inference.  Moreover, care must be taken to insure that the biological 
heterogeneity, due to the small number of cells per sample, and measurement inaccuracy, 
which often arises due to the restrictive dynamic range of in-cell westerns, does not 
confound multivariate measurement fusion.   
  
5.2.4. Multiwell-format tissue arrays 
Multiwell-format tissue arrays [8, 10] are based on 12- or 24-well culture formats and can 
accommodate ~105-106 cells per sample well (sufficient for lysate-based measurements) 
and be scaled to a moderate number of sample conditions (i.e. treatments, time points) 
and thus are suitable for a greater diversity of systems-level modeling approaches than 
tissue microarrays.  A well-developed example of these multiwell-format tissue arrays 
that utilizes a 3D microenvironment is a perfused liver cell microreactor [8, 10].  
Perfused microreactors foster the maintenance of in vivo-like function of primary 
hepatocytes [8] and/or liver sinusoidal endothelial cells [94] over a prolonged culture 
duration (~14 days) in a physiologically-relevant 3D microenvironment.  And, as such, 
have been used examine hepatic drug metabolism and enzyme induction [8] and 
sinusoidal morphogenesis [94] over physiologically-relevant time scales. 
 The larger cell numbers per sample permit lysate methods such as bead-based 
arrays [52] and multiplexed kinase activity assays [48] to be utilized in addition to 
multicolor flow and image cytometry (given the aforementioned improvements) to 
measure cell signaling activities and phenotypes in a multivariate manner.  Bead-based 
phosphoprotein arrays allow for a greater number of measureable signaling molecules as 
they are benefited by an expansive set of validated, multiplexible reagents, while kinase 
activity assays have the advantage of measuring signal transduction activity directly, 
rather than inferred via phosphorylation state.  Consequently, activity data from kinases, 
especially of those thought to be at nodes of signaling networks that integrate multiple 
pathways, are often found to be highly informative signals in PLSR cell signaling-
response models trained on protein signaling data from heterogeneous assays [50, 62].  
Practical limitations on cell material and knowledge of which protein signaling assays 
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have been informative previously [50] together suggest that PLSR models using 
multiwell-format tissue arrays might be best constructed using ~2-3 kinase assays and 
~10 bead-based phosphoprotein measurements (all from a single lysate) of proteins 
distributed across multiple cell signaling pathways.  A challenge in multivariate 
measurement of engineered liver cell co-cultures (usually containing hepatocytes and 
second liver cell type) is the correct attribution of signaling profiles to each of the 
multiple cell types present.  Flow cytometry methods can simply employ one staining 
channel to a cell type marker, but lysate based methods require less straight-forward 
approaches such as those that rely on biomolecular mixture models [214] to infer cell 
type-specific phosphoprotein profiles. 
 
5.2.5. Implementing systems-level modeling for the design and analysis of 
engineered tissues 
In contrast to the fields of genomics and proteomics, a systems biology approach insists 
that knowledge and understanding about biology resides not in databases but instead in 
models – and that given the complexity of multivariate experimental measurements these 
models must be computational in nature.  Thus, the data generated in tissue engineering 
contexts as discussed in the previous section will be most gainfully employed by analysis 
in terms of one or more of the data-driven modeling methods described earlier. 
 Data-driven models of dynamic, multivariate cell signaling and response data can 
suggest hypotheses that relate activities of signaling molecules to behavioral phenotypes 
and can be implemented to generate a priori predictions of responses to new signaling 
network profiles.   Such models are most effectively constructed on the basis of training 
across a broad landscape of conditions, including conflicting or antagonizing cues, that 
stimulate a diversity of signaling network activities and cell responses that might be 
hypothesized to comprehend a range of physiological phenotypic behaviors (see Chapter 
4 and [62, 64, 66, 68]).   Prediction of cell behavior can then be effectively interpolative 
rather than extrapolative.  A priori prediction of cell phenotypes based on signaling 
network states could lead to the identification nonintuitive combinations to signaling 
activities (through computation searches, for example) that optimally produce a desired 
cell phenotype in an engineered tissue.  Design of novel engineered tissue micro-
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environments that generate the optimal signaling network state could be furthermore 
governed by physicochemical models of receptor activation and downstream signaling, 
thus integrating mechanistic and data-driven model approaches [72] to design features for 
fostering desired tissue phenotypes.  Moreover, models of cell behavior within a tissue 
engineered to mimic a particular physiology or pathophysiology could yield models 
capable of predictions of drug efficacy and toxicity in physiologically-relevant, tissue-
specific contexts.  In particular, such approaches could be used to select target pathways 
for interfering with 3D cell migration behaviors critical to cancer metastasis [215, 216] 
and matrix stiffness-induced mammary acinar oncogenesis [210].  For instance, 
successful a priori PLSR model prediction of cell phenotypic changes due to perturbation 
by one or more small molecular inhibitor(s) has been verified for compounds with 
specified kinase targets that lie upstream of protein signal(s) contained in the model and 
implemented by “computationally inhibiting” only the measured signals in a subset of the 
training data and then comparing the predicted results to new experiment observations 
(see [64, 66] and Chapter 4).  Perturbations that affect signaling networks more globally 
(therefore less predictably) such as growth factor receptor overexpression [68], disruption 
of autocrine ligand signaling [62], and RNA interference [67] have been evaluated using 
complete re-collection of signaling data rather than the straightforward estimation 
methods successful for small molecular inhibitors.  When measuring multiple diverse 
kinds of cell phenotypic behaviors, as is desired for understanding complex tissue 
physiology, constructing separate submodels for the various behaviors might allow for 
easier interpretation of the various respective signaling-response relationships.  
Decision tree and Bayesian network models can extend predictive capabilities to 
causality, more strongly indicating molecular mechanisms.  For example, a Bayesian 
network model for the signaling network regulating differentiation versus self-renewal 
processes of mouse embryonic stem cells permitted experimentally validated prediction 
of effects of Raf-1 independent of the canonical Raf–MEK–ERK pathway [217].  
Analogously, one can envision developing a similar predictive capability for signals 
governing lineage specification of mesenchymal stem cells cultured in complex 3D 
microenvironments containing varying adhesion ligands, matrix rigidities, and growth 
factors [217].  Likewise, predicted signaling network influences could suggest 
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microenvironmental cue and pharmacological intervention combinations for influencing 
osteoblast specification for implantable bone regeneration therapies [217].  
 Moreover, Bayesian network inference approaches could ask fundamental 
questions about the perhaps subtle differences in signaling network structure and function 
in cells of varying lineages and disease states and how those networks diverge from 
canonical models [212].  Such understanding could drive clinical therapies that are 
motivated by context-specific cell signaling networks.  Bayesian approaches could be 
employed in the challenging task of investigating the crosstalk between multiple cell 
types in healthy or diseased tissues.  By engineering tissue arrays that contain multiple 
interacting cell types, such as the immune system cells within a lymph node [193] or the 
varied cells within the liver [94], and measuring both cell type-specific phosphoprotein 
signaling and levels of soluble or matrix-related signaling factors, Bayesian network 
inference models can be constructed to provide mechanistic hypotheses for complex 
cellular crosstalk in tissues.  
 
 
 147
 
 
 
 
 
 
Figure 5-1. The scope of measurement and modeling in systems biology and tissue engineering. The 
present and future implementation of systems biology and tissue engineering are depicted with respect to: 
biological context (ranging from prototypical cell lines to engineered and native tissues to whole 
organisms); modeling detail (ranging from statistical models to influence models to mechanistic models); 
and molecular detail (ranging from a single protein to the entire proteome).  To date, tissue engineering has 
been focused on the recapitulation of the physiological complexity of native tissues but has not been 
studied in great molecular detail nor has been fused with systems-level computational modeling efforts.  In 
contrast, systems-level computational models, such as partial least-squares regression (PLSR), decision 
trees (DT), Bayesian networks (BN), and physicochemical (PC) models, can interpret a variety of 
molecular relationships governing cellular behavior but have been studied largely in a prototypical 
biological context (e.g. cell lines).  Future fusion of tissue engineering and system biology will require 
adaption of tissue engineering to the measurement demands systems-level computational models.  
Considering these demands, PLSR, DT, and Bayesian models provide attractive candidates for analysis of 
cell behaviors within engineered tissues in the near future.  More substantial progress in tissue engineering 
and multivariate measurement technologies will be required for implementation of models with more 
mechanistic and molecular detail. 
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Appendix A 
 
Abbreviations 
 
2D   two-dimensional 
3D   three-dimensional 
ADAM  a disintegrin and metalloproteinase protein 
Adv   adenoviral vector 
Akt   serine-threonine protein kinase B (PKB)/Akt  
ANOVA  analysis of variance 
AP-1   activator protein 1 
APAP   acetaminophen 
ASK1   apoptosis signal-regulating kinase 1 
ASP   aspirin 
BC   bile canaliculi 
BCA   bicinchonicic assay 
BID   BH3 interacting domain death agonist 
BN   Bayesian network 
BrdU   5-bromo-2’-deoxyuridine 
BSA   bovine serum albumin 
BSEP   bile salt export pump 
BUS   buspirone 
β-gal   β-galactosidase 
C/EBP   CCAAT-enhancer-binding protein 
CAR   coxsackie- and adenovirus-receptor 
CHL   chlorpromazine 
CIM   cimetidine 
CLA   clarithromycin 
CLO   clomipramine 
Cmax   average plasma maximum drug concentration 
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CM-H2DCDA  5-(and-6)-chloromethyl-2’7’-dichlorodihydrofluorescein diacetate 
    acetyl ester 
CREB   cAMP response element binding 
CSR   cue-signal-response 
DILI   drug-induced liver injury 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMSO   dimethyl sulfoxide 
DRAQ5  1,5-bis{[2-(di-methylamino)ethyl]amino}-4,8-   
    dihydroxyanthracene-9,10-dione 
DT   decision tree 
ECM   extracellular matrix 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
ELISA   enzyme-linked immunoabsorbant assay 
EMEM  Eagle’s minimum essential medium 
ERK   extracellular signal-regulated kinase 
FADD   Fas-associated death domain protein 
FBS   fetal bovine serum 
G2   HepG2 cells 
gp130   glycoprotein 130 
Grb-2   growth factor receptor-bound protein-2 
GSH   glutathione 
GSK-3α/β  glycogen synthase kinase-3α/β 
HB-EGF  heparin-binding EGF-like growth factor 
HBSS   Hank’s Balanced Salt Solution 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF   hepatocyte growth factor 
HGM   hepatocyte growth medium 
HH   primary human hepatocytes 
HNF   hepatocyte nuclear factor 
HSP27   heat shock protein 27 
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ICE   also known as caspase 1 
IFN-γ   interferon-γ 
IKK   inhibitor of nuclear factor-κB (IκB) kinase 
IL-10   interleukin-10 
IL-1R   interleukin-1 receptor 
IL-1ra   interleukin-1 receptor antagonist 
IL-1α/β  interleukin-1α/β 
IL-6   interleukin-6 
IL-6R   interleukin-6 receptor 
iNOS   inducible nitric oxide synthases 
IRS-1   insulin receptor substrate-1 
IκB-α   inhibitor of nuclear factor-κB-α 
JAK   Janus kinase 
JNK   c-Jun N-terminal kinase 
LDH   lactate dehydrogenase 
LEV   levofloxacin 
LPS   lipopolysaccharide 
mBCl   monochlorobimane 
MEK   MAPK-ERK kinase 
MEKK1  MAPK-ERK kinase kinase 1 
MEX   mexiletine 
MMP-3  matrix metalloproteinase-3 
MOI   multiplicity of infection 
MRP2   conjugate export pump 
MtMP   mitochondrial membrane potential 
mTOR   mammalian target of rapamycin 
NEF   nefazodone 
NF-κB   nuclear factor-κB 
NIM   nimesulide 
NIPALS  non-linear iterative partial least-squares 
NO   nitric oxide 
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NOR   nortriptyline 
NPC   non-parenchymal cell 
NSAID  non-steroidal anti-inflammatory drug 
OPLSR  orthogonal partial least-squares regression 
p38   p38 mitogen-activated protein kinase (MAPK) 
p70 S6K  p70 S6 protein kinase 
p90 RSK  p90 ribosomal S6 kinase 
PARP   poly(ADP-ribose) polymerase 
PBS   phosphate buffered saline 
PBS-T   PBS with 0.1% Tween-20 
PBS-TB  PBS with 0.1% Tween-20 and 1% BSA 
PC   principal component 
PDK1   phosphoinositide-dependent kinase-1 
PFA   paraformaldehyde 
PH   Pleckstrin homology 
PHx   partial hepatectomy 
PI3K   phosphoinositide 3-kinase 
PLSR   partial least-squares regression 
RAN   ranitidine 
RFU   relative fluorescence units 
RH   primary rat hepatocytes 
RIL   riluzole 
ROS   reactive oxygen species 
SEC   sinusoidal endothelial cell 
SEM   standard error of the mean 
SHP-2   SH2-domain-containing protein tyrosine phosphatase-2 
SOCS3  suppressor of cytokine signaling-3 
STAT3  signal transducer and activator of transcription-3 
TACE   tumor necrosis factor-α-converting enzyme 
TCPS   tissue culture polystyrene 
TEL   telithromycin 
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TGF-α   transforming growth factor-α 
TGF-β1  transforming growth factor-β1 
TMRM  tetramethyl rhodamine ester 
TNF   tumor necrosis factor-α 
TNFR   tumor necrosis factor receptor 
TRADD  TNFR1-associated death domain protein 
TRAF-2  TNFR-associated factor-2 
TRO   trovafloxacin 
v.p.   viral particle 
VIP   variable importance of projection 
WEM   William’s E medium 
XIAP   X-linked inhibitor of apoptosis protein 
 
 
 153
Appendix B 
 
Multiplexed bead-based phosphoprotein assays 
 
B.1. Lysis of primary rat hepatocytes in single-layer collagen gel cultures 
Rat hepatocytes were cultured on single-layer collagen gels and treated as described in 
Chapter 2.2.3.  At the desired time point, cells were placed on ice and culture medium 
was removed and centrifuged at 1000g for 4 minutes at 4°C to pellet non-adherent cells.  
Adherent cells and pelleted non-adherent cells were lysed with Phosphoprotein Lysis 
Buffer (Bio-Rad, Hercules, CA) for 20 minutes at 4°C.  Adherent cell lysates were 
collected by vigorous pipetting but without scrapping to avoid significant removal of the 
underlying collagen gel.  Lysates were clarified by centrifugation at 16,000g for 15 
minutes at 4°C.  Clarified lysates were analyzed using a bicinchonicic assay (Pierce, 
Rockford, IL) to determine the total protein concentration.  In each culture plate, a well 
without cells was maintained, lysed, and analyzed to calculate the protein contribution 
from the collagen gel alone and estimate the cellular protein concentration.  The gel-only 
protein concentration accounted for ~15-25% of the total protein concentration in wells 
containing cells and was subtracted from the protein concentrations from wells contains 
cells in a plate-specific manner to estimate the cellular protein concentration in each 
lysate sample. 
 
B.2. Lysis of primary human hepatocytes in Matrigel-overlay cultures 
Human hepatocytes were maintained in Matrigel-overlay cultures and treated as 
described in Chapter 3.2.3.  At the desired time point, cells were placed on ice and culture 
medium was removed.  Matrigel overlays were partially dissolved by adding ice cold 
PBS for 15 minutes at 4°C.  PBS was removed and cells were lysed with Phosphoprotein 
Lysis Buffer for 20 minutes at 4°C.  Lysates were collected by scrapping and vigorous 
pipetting.  Lysates were clarified by centrifugation at 16,000g for 15 minutes at 4°C.  
Clarified lysates were analyzed using a bicinchonicic assay to determine the total protein 
concentration.  In each culture plate, a well without cells was maintained, lysed, and 
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analyzed to calculate the protein contribution from the Matrigel overlay alone and 
estimate the cellular protein concentration.  The Matrigel-only protein concentration 
accounted for ~10-20% of the total protein concentration in cellular samples containing.  
An average of Matrigel-only protein concentrations from all plates in the same 
experiment was subtracted from the protein concentrations from wells contains cells to 
estimate the cellular protein concentration in each lysate sample.  (Compared to the lysis 
of rat hepatocytes on single-layer collagen gels, lysis of Matrigel-only wells showed less 
plate-to-plate correlation so the average across multiple plate in the same experiment was 
used to minimize error.) 
 
B.3. Lysis of HepG2 cells 
HepG2 cells were cultured and treated as described in Chapter 3.2.3.  At the desired time 
point, cells were placed on ice and culture medium was removed.  Cells were lysed with 
Phosphoprotein Lysis Buffer for 20 minutes at 4°C.  Lysates were collected by scrapping 
and vigorous pipetting.  Lysates were clarified by centrifugation at 16,000g for 15 
minutes at 4°C.  Clarified lysates were analyzed using a bicinchonicic assay to determine 
the total cellular protein concentration.  Adjustments for protein contributions from gel 
substrates (as in Chapters B.1 and B.2) were unnecessary. 
 
B.4. Bead-based phosphoprotein assays 
Bio-Plex bead-based assays (Bio-Rad) were used to quantify the following 
phosphoproteins: p-Akt (Ser473), p-CREB (Ser133), p-c-Jun (Ser63), p-GSK-3α/β 
(Ser21/Ser9), p-IκB-α (Ser32/Ser36), p-IRS-1 (Ser636/Ser639), p-ERK1/2 (Thr202/Tyr204, 
Thr185/Tyr187), p-Histone H3 (Ser10), p-HSP27 (Ser78), p-JNK (Thr183/Tyr185), p-MEK1 
(Ser217/Ser221), p-STAT3 (Ser727), p-STAT6 (Tyr641), p-p38 (Thr180/Tyr182), p-p53 (Ser15), 
p-p70 S6 kinase (Thr421/Ser424), and p-p90 RSK (Thr359/Ser363).  Bio-Plex assays were 
conducted per manufacturer’s recommendations on a Luminex 200 instrument (Luminex, 
Austin, TX) with protein lysates loaded in technical duplicate.  Cellular protein 
concentrations were adjusted by dilution of clarified protein lysates (following any 
necessary subtraction for estimated gel contributions to the total protein concentration) in 
Phosphoprotein Lysis Buffer.  Each phosphoprotein assay was individually validated for 
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each cell type using multiple positive control treatments over a range of cellular protein 
loading concentrations (0-20 μg cellular protein per assay well). 
Whereas some phosphoprotein assays demonstrated robust linearity across all 
protein loading concentrations (Figure B-1A), other assays showed problematic 
saturation effects.  One type of saturation effect was related to saturation of the 
instrument’s fluorescence detector, usually occurring for samples with >20,000 relative 
fluorescence units (RFU).  This detector saturation effect was observed for p-Akt (Figure 
B-1B) and p-HSP27 (data not shown) assays.  To avoid this saturation effect, assays were 
loaded at protein concentrations lower at <10 μg/well and/or under low PMT detector 
mode.   
A second type of saturation effect was related to saturation of the capture and/or 
detection antibody on the bead-based assay.  In this saturation effect, increasing protein 
loading amounts from a given sample biological resulted in a plateauing in assay 
fluorescence detection at fluorescence levels lower than detector saturation.  This 
antibody saturation effect was observed for p-IκB-α (Figure B-1C) and p-ERK1/2 (data 
not shown) assays.  To avoid this saturation effect, assays were loaded at consistent 
protein concentrations as relative phosphoprotein detection levels (i.e. fold-change versus 
the untreated samples) were well-maintained within a given protein loading concentration 
(data not shown). 
A final consideration made for phosphoprotein assay validation was to select a 
protein loading concentration that allowed for robust fold-change consistency and 
maximal assay dynamic range.  In considering this, we found that even for the same 
phosphoprotein assay, different cell types yielded distinctly different optimal loading 
concentrations.  For example, rat hepatocytes (optimal at 5 μg/well) versus HepG2 cells 
(optimal at 10 μg/well) for the p-Akt assay (see Figure B-1D-E).  Using these 
considerations to avoid assay saturation effects and to yield robust fold-change 
consistency and maximal assay dynamic range, we selected the following cellular protein 
loading concentrations: 10 μg/well for all phosphoprotein assays for rat hepatocyte, 
HepG2, and human hepatocyte lysates, except 5 μg/well for p-Akt, p-c-Jun, and p-
ERK1/2 assays for rat hepatocyte lysates. 
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To fuse raw fluorescence data from multiple technical assay plates, multiple (~3-
5) positive control treatments were loaded on each assay plate to scale raw fluorescence 
data to self-consistent relative values (Figure B-1F).  Positive control lysates were used 
from the same cell type as the sample lysates and were selected to contain at least one 
control condition that elicited roughly maximal phosphoprotein activation for every 
multiplexed phosphoprotein assayed simultaneously. 
 
 
 
Figure B-1.  Validation of multiplexed bead-based phosphoprotein assays. Cell lysates were prepared 
under various treatment conditions and assayed as described in Appendix B. (A) Linearity validation of 
bead-based p-GSK-3α/β assay using rat hepatocytes lysates loaded at 0 to 15 μg/well cellular protein. (B) 
Linearity validation of bead-based p-Akt assay using rat hepatocyte lysates loaded at 0 to 20 μg/well 
cellular protein. Note the detector saturation for samples with raw fluorescence values at >20,000 relative 
fluorescence units (RFU). (C) Linearity validation of bead-based p-IκB-α assay using HepG2 lysates 
loaded at 0 to 20 μg/well cellular protein. Note the antibody saturation for samples loaded at >10 μg/well 
cellular protein. (D-E) Linearity of bead-based p-Akt assay using rat hepatocyte (D) or HepG2 (E) lysates 
loaded at 0 to 20 μg/well cellular protein. Note discrepancy between cell types in the p-Akt level for the 
untreated samples and similar detector saturation effects at >15 μg/well for the EGF-treated samples. (F) 
Plate-to-plate normalization standards for bead-based p-JNK assay using rat hepatocyte lysates loaded at 10 
μg/well.  In panels (A) to (F), data is presented as the mean ± standard deviation of two technical replicates.  
In panel (F), the data on the y-axis represents mean ± standard deviation of four assay plates. 
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Appendix C 
 
Human hepatocyte donor information 
 
Table C-1.  Human hepatocyte donor information 
 
     
 
Donor information and history 
Donor 
ID Experiment 
Data 
in 
Culture 
start 
date 
Lot #1 
 
Gender, 
age Obesity
2 
Smoking, 
drug, 
alcohol 
use 
Disease, 
viral 
infection 
A 
Drug-cytokine 
compendium, 
sub-lethal 
imaging data 
Figs. 
3-3, 
3-7 
11/08/07 Hu0697 
 
Female, 
64 yrs old 
Not 
obese, 
BMI 24 
None 
known 
None 
known3 
B 90-drug study Fig. 3-9 04/23/08 Hu0793 
 
Female, 
33 yrs old 
Obese, 
BMI 37 
None 
known 
None 
known 
1 CSR training data set 
Fig. 
4-2 05/20/07 Hu4000 
 
Female, 
4 yrs old 
Not 
obese, 
BMI 
unknown 
None 
known 
None 
known 
2 CSR test data set 
Fig. 
4-6 10/18/08 Hu0921 
 
Male, 
38 yrs old 
Not 
obese, 
BMI 25 
None 
known 
None 
known 
3 
MEK and p38 
inhibitor IC50 
study 
Fig. 
4-10 10/17/08 Hu0920 
 
Female, 
52 yrs old 
Not 
obese, 
BMI 21 
None 
known 
None 
known 
4 
Kinase and 
autocrine 
inhibitor drug-
cytokine toxicity 
study 
Figs. 
4-11, 
E-1 
11/13/08 Hu0935 
 
Female, 
54 yrs old 
Not 
obese, 
BMI 20 
None 
known 
None 
known 
 
1Lot number assigned by CellzDirect, Inc. 
2BMI = body mass index. A BMI of 30 or greater is generally considered obese. 
3No known history of, or exposure to, Hepatitis B, Hepatitis C, cirrhosis, biliary disease or HIV. Not 
serology-tested. 
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Appendix D 
 
Generation of an orthogonal partial least-squares regression model 
 
 
 
 
Figure D-1.  Comparison of PLSR and OPLSR models. A partial least-squares regression (PLSR) model 
was generated from the CSR data compendium in Figure 4-2 using the NIPALS algorithm in SIMCA-P 
software (Umetrics, Inc., Kinnelon, NJ) following standard methods [62-64, 152, 153]. The PLSR model 
was generated using four principal components under standard optimization criteria [63], and its model 
scores (A), loadings (B), and cross-validated predictions (C) are plotted. The calibrated PLSR model was 
then subjected to a principal-component-space linear transformation by rotating the projection (in 4-
dimensionl principal-component-space, with only the first two PC’s shown in [A] and [B]) of the single cell 
death response variable completely into the first principal-component to allow for simplified interpretation 
of model loadings (E) and scores (B), thus yielding an “orthogonal” PLSR (OPLSR) model [154]. The 
signal (X) model loadings and model scores were similarly rotated. The OPLSR model demonstrated 
equivalent cross-validated model predictions and model fitness (F) as the original PLSR model (C). 
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Appendix E 
 
Role of autocrine signaling in drug- and cytokine-induced 
hepatotoxicity 
 
Based on the Adv/TNF-induced rat hepatocyte apoptosis findings in Chapter 2, it was 
speculated that autocrine TGF-α and IL-1 ligands may control drug/cytokine synergies.  
An initial examination in human hepatocytes (donor #4) did not show autocrine TGF-α or 
IL-1 ligand control of drug-cytokine hepatotoxicity synergy (Figure E-1).  It is possible 
that autocrine signaling control of drug/cytokine-induced hepatotoxicity can be perturbed 
only under: 
• sub-saturating TNF dosing concentrations (as in Figure 2-6J for Adv/TNF-
induced hepatocyte apoptosis); 
• drug/cytokine dosing conditions showing a greater synergy with TNF co-
treatment (such as trovafloxacin); and/or  
• other cytokine treatments such as TNF + IFN-γ (as in [77]) or TNF + LPS. 
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Figure E-1.  Autocrine ligand and kinase inhibitor perturbations of drug/cytokine hepatotoxicity synergy. 
Human hepatocytes (from donor #4) were cultured as described in Chapter 4.2. Cells were treated with 
drugs (13 μM clomipramine [B], 2.1 mM nimesulide [C], 10 μM nortriptyline [E], or 0.25% DMSO control 
[A, D]) ± 100 ng/ml TNF or a cytokine mix (20 ng/ml IL-1α, 10 μg/ml LPS, 100 ng/ml TNF, and 20 ng/ml 
IL-6). After 24 or 48 hours, conditioned medium samples were assayed for LDH release. To inhibit MEK 
kinase activity, cells were pretreated with 10 μM U0126 or 1 μM PD325901 one hour before drug/cytokine 
stimulation.  To inhibit p38 kinase activity, cells were pretreated with 1 μM PHA-666859 or 1 nM PHA-
818637 one hour before drug/cytokine stimulation. To inhibit autocrine EGFR ligand activity, cells were 
pretreated with 5 μg/ml anti-TGF-α neutralizing antibody (data not shown) or 10 μg/ml c225 monoclonal 
antibody one hour before drug/cytokine stimulation.  To inhibit autocrine IL-1 activity, cells were 
pretreated with 10 μg/ml recombinant human IL-1ra one hour before drug/cytokine stimulation. Data are 
presented as the mean ± SEM of eight biological replicates. Drug-cytokine co-treatment conditions that 
elicited supra-additive hepatotoxicity synergy, evaluated as described in Chapter 4.2.10, are denoted as (*).  
Differences between uninhibited and inhibitor pretreatments are labeled as significant (‡) if P < 0.05 by a 
Student’s t test. Autocrine ligand and kinase inhibitor pretreatments did not significantly perturb cell death 
responses in the absence of cytokine mix co-stimulation and thus are not shown. 
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